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ABSTRACT 
Hercules T Maguma. COMPARISON OF TOLERANCE CHARACTERISTICS IN THE 
GUINEA PIG FOLLOWING CHRONIC IN-VIVO EXPOSURE TO OPIOID VERSUS 
CANNABINOID RECEPTOR AGONISTS. (under the guidance of David A. Taylor)  
Chair: Dr. David A. Taylor Ph.D. 
Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina 
University. July 2010 
 
Few studies have compared the nature of tolerance that develops following chronic in 
vivo opioid treatment with that which develops after chronic cannabinoid exposure in the same 
tissue and species. Based on similarities in signaling and overlapping neuroanatomical receptor 
localization the candidate determined whether the tolerance that develops to hypothermic, 
analgesic and inhibitory action on neurogenic contractions of the longitudinal muscle-myenteric 
plexus (LM/MP) in the guinea pig is qualitatively similar regardless of the agonist employed. 
Since previous in vitro drug exposure studies using the LM/MP model have reported 
bidirectional heterologous tolerance, it was hypothesized: 1) that in vivo exposure to either 
agonist would result in heterologous tolerance 2) that the type of tolerance could be used to 
define the underlying cellular mechanisms; 3) that homologous tolerance would employ a 
mechanism that involved receptor regulation; 4) that co-localization of opioid and cannabinoid 
receptors may provide a basis for some cross-tolerance between agonists; and 5) that the 
mechanisms that underlie the development of tolerance can vary among different tissues or 
models. Specific aim 1 assessed the effect of chronic cannabinoid or opioid exposure on the 
sensitivity of the LM/MP to inhibitory agonists (WIN-55,212-2-2, CADO or morphine) or an 
  
excitatory agent (nicotine). Animals pretreated with morphine in vivo developed an increased 
responsiveness to nicotine and tolerance to all inhibitory agonists tested: the magnitude of 
rightward shift (i.e. ratio of mean IC50 values) or loss of sensitivity of the treated compared to the 
control group was 4.8-fold for DAMGO, 3.5-fold for CADO, and 5.2-fold for WIN-55,212-2. In 
contrast, in vivo WIN-55,212-2 pretreatment resulted in subsensitivity to WIN-55,212-2 only 
(factor of rightward shift of the IC50 values was 9.8) and reduced maximum responses to WIN-
55,212-2 and DAMGO; no shift was observed in the dose response curves for DAMGO, CADO 
and nicotine. Specific aim 2 sought to determine the effect of chronic WIN-55,212-2 or 
morphine exposure on the levels of both mu-opioid receptor (MOR) and cannabinoid receptor 1 
(CB1) protein in homogenates of the LM/MP. WIN-55,212-2 treatment resulted in a selective 
reduction in CB1 receptor protein levels by 35% while MOR levels remained unchanged whereas 
morphine exposure altered neither MOR nor CB1 receptor protein levels. Specific aim 3 sought 
to determine the qualitative nature of tolerance that develops in analgesic (thermal and 
mechanical) and hypothermic models. Chronic morphine treatment resulted in heterologous 
tolerance to the thermal analgesic effect of morphine and WIN-55,212-2 but did not alter the 
sensitivity to the hypothermic effect of WIN-55,212-2. The nature of tolerance observed in the 
hot plate test corresponds closely to that observed in the LM/MP studies where chronic morphine 
treatment produced heterologous tolerance and WIN-55,212-2 pretreatment resulted in 
homologous tolerance. In contrast to the results in the LM/MP studies, WIN-55,212-2 
pretreatment resulted in tolerance to the analgesic effect of morphine in the paw pressure model 
despite the fact that WIN-55,212-2 did not produce analgesia in this model. Unlike chronic 
treatment with WIN-55,212-2, chronic morphine treatment did not induce tolerance to the 
hypothermic effect of WIN-55,212-2. However, since only a very modest hypothermia was 
  
observed in response to a morphine challenge, tolerance to this effect was difficult to assess and 
may not be pharmacologically relevant. For specific aim 4 the candidate explored the distribution 
of MOR and CB1 receptor expressing neurons in the LM/MP and hypothalamus. 
Immunofluorescence assessment of the distribution of neurons expressing MOR and CB1 
receptors in the LM/MP revealed significant co-localization of receptors on myenteric plexus 
neurons thus raises the possibility of intracellular crosstalk between the two receptor systems. 
Furthermore, neither opioid nor cannabinoid treatment altered the density or distribution pattern 
of neurons expressing MOR or CB1 receptors. Assessment of neurons expressing MOR and CB1 
receptors in the preoptic anterior hypothalamus revealed extensive co-localization suggesting 
possible interaction of the two receptor systems in the regulation of body temperature. In 
conclusion, the variable tolerance expression observed in different models affirms the notion that 
nature and potential cellular mechanisms of tolerance can vary depending on the model system, 
the drug, the species, and regimen used to establish the phenomenon. The data also suggest that 
multiple cellular effects may play a role in the induction of functional tolerance in different 
model systems. 
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 CHAPTER ONE: INTRODUCTION 
I.  General Introduction 
The use of opioids, which dates back thousands of years, has evolved to its current state 
of conventional use in clinical settings over a long period of time, whereas the potential clinical 
uses of marijuana in clinical settings has only just begun to be realized in the past few decades. 
However, the recreational use of marijuana has been known for many years.  The United 
Nations’ World Drug Report of 2009 estimated that in 2007, between 143 and 190 million 
(~2.5% of the world population) worldwide used marijuana. Further evidence of the widespread 
use of this agent includes a 2007 National Survey on Drug Use and Health which revealed that 
14.4 million Americans over 12 years of age had used marijuana at least once in the month 
preceding the survey.  Regarding opioid use, a survey performed in 2008 by the National 
Institute on Drug Abuse (NIDA) estimated that 453,000 Americans over 12 years of age had 
used heroin once in the preceding year, proving that the illicit use of opioids is also relatively 
high. 
Extensive studies on the opioid system have discovered a number of endogenous and 
exogenous ligands targeting specific receptor subtypes that provide some diversity with respect 
to the clinical uses of the agents and the endogenous regulation of responses to external stimuli.  
Opioids and related agents are clinically indicated for the treatment of pain, acute pulmonary 
edema, cough and diarrhea.  Currently, cannabinoids are used clinically to treat muscle spasms in 
patients with multiple sclerosis, as anti-emetics in patients receiving chemotherapy for cancer, 
and to manage cachexia in HIV/AIDS patients. At least 66 phytocannabinoids have been isolated 
with ∆9- tetrahydrocannabinol (∆9-THC), the main psychoactive alkaloid, serving as the 
prototypical compound. Extensive research in the last twenty years has led to the discovery of an 
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endogenous cannabinoid system that utilizes a number of different “cannabinoid-like” 
compounds which include arachidonoyl-ethanolamine (anandamide or AEA), 2-arachidonoyl 
glycerol (2-AG), virodhamine (O-arachidonoyl-ethanolamine (OAE), noladin ether (2-
arachidonyl glyceryl ether) and N-arachidonoyl-dopamine (NADA) (Rodriguez de Fonseca et 
al., 2005). The discovery of two distinct cannabinoid receptors (i.e. CB1 and CB2), has spurred 
research into developing commercially viable agonists targeting these receptors e.g. dronabinol,  
nabilone and Sativex® (containing ∆9- tetrahydrocannabinol and cannabidiol). The selective CB1 
receptor antagonist Rimonabant (SR141716) indicated for obesity and smoking cessation, has 
recently been withdrawn from the European market due to concerns over adverse effects, namely 
depression and suicidal ideation.  
Chronic use of both cannabinoids and opioids is associated with the rapid development of 
tolerance which is defined by a progressive diminution of efficacy following prolonged drug 
exposure. This phenomenon results in the need for higher doses to achieve the same clinical 
benefit which increases the risk of adverse events including drug overdose, withdrawal effects 
and dependence. The extent of development of tolerance varies significantly depending on the 
pharmacological effect e.g. opioid tolerance develops quicker to its urinary retention and 
respiratory depression effects compared to its analgesic effects (Rang et al. 2007). In fact, 
tolerance to some effects of opioids e.g. constipation and miosis, does not occur in humans 
(Rang et al., 2007). Clinical studies evaluating tolerance to the analgesic effect of opioids have 
reported a reduction in tolerance by using agents like calcium channel blockers and the 
cholecystokinin antagonists (Santillan et al., 1994; Timar et al., 2005). In animal studies, calcium 
channel blockers (Smith et al., 1999), intrathecal magnesium and zinc (McCarthy et al., 1998; 
Larson et al., 2000), the phosphodiesterase inhibitor ibudilast (Ledeboer et al., 2007) or 
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cholecystokinin antagonists like proglumide (Watkins et al., 1984; Wong et al., 1996) have also 
been reported as promising remedies for analgesic tolerance observed following chronic opioid 
use. Tolerance to cannabinoids has not been widely reported in clinical settings and it has been 
suggested that extremely high doses may need to be consumed before tolerance can be observed 
(Flom et al., 1975; Jones et al., 1981).  
Simultaneous or successive use of both opioids and cannabinoids has escalated over the 
last few years especially in terminally ill patients (e.g. HIV and cancer patients).  Thus the 
potential interactions between these agents in terms of acute actions as well as the development 
of adverse effects should be of concern. Studies in animals have demonstrated rapid development 
of tolerance to these agents and possible cross-modulation of their pharmacological effects 
(Welch and Eads, 1999; Bass and Martin, 2000; Li et al., 2010). The interaction between opioids 
and cannabinoids stems from their similarities in cellular and physiological effects, and is likely 
influenced by the co-localization of their receptors (Salio et al., 2001). In spite of the large 
number of studies that have been performed, there are still conflicts, opposing data, and 
insufficient evidence to fully explain the tolerance phenomena observed following chronic 
treatment with these agents. This work described in this dissertation attempts to characterize the 
nature of the tolerance, look at the possible basis for the pharmacological interaction between 
these agents and describe the potential mechanisms associated with development of tolerance to 
the effects of these agents and to determine whether the mechanism is commonly shared or 
distinct. 
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II. Cannabinoid Pharmacology 
1. Cannabinoid Receptor Subtypes 
There are two major subtypes of cannabinoid receptors namely cannabinoid receptor 
subtype 1 (CB1) and CB2 receptor. The first CB1 receptor cDNA was cloned using the rat brain 
(Matsuda et al., 1990). The CB2 receptor which encodes fewer amino acids (360), displays a 
48% amino acid sequence homology to the CB1 receptor (Munro et al., 1993). The existence of a 
third cannabinoid receptor, the orphan receptor (GPR55), has been proposed based on its binding 
site sequence homology to classical cannabinoid receptors and the fact that it is activated by the 
cannabinoid receptor ligands  O-1602 and abnormal cannabidiol (Slowe et al., 1999; Johns et al., 
2007). In addition, the TRPV1 (transient receptor potential cation channel, subfamily V, member 
1) or vanilloid receptor 1, a ligand-gated non-selective cation channel activated by anandamide 
(AEA) and N-arachidonoyl-dopamine (NAPA) has also been proposed to represent another 
cannabinoid receptor subtype (Huang et al., 2002). 
2. Cannabinoid Receptor Distribution 
A. Central nervous system distribution. The extent and pattern of CB1 receptor 
distribution correlates with modulation of region-specific function associated with the effects of 
cannabinoids including alteration in memory, cognition, autonomic function and mood 
(Rodriguez de Fonseca et al., 2005). The hippocampus, cerebellum, caudate, substantia nigra, 
nucleus accumbens, globus pallidus and some olfactory regions demonstrate a high density of the 
CB1 receptor. The amygdala, medial hypothalamus and solitary nucleus display a moderate 
density of CB1 receptors whereas the thalamus and other parts of the brainstem e.g. nucleus of 
the solitary tract express low levels of CB1 receptors. The regulation of pain by cannabinoid 
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receptor agonists directly correlates with CB1 receptor expression in the periaquaductal gray, 
amygdala, raphe and the dorsal horn of the spinal cord where the receptor density is relatively 
low (Tsou et al., 1998; Farquhar-Smith et al., 2000). Although CB1 receptors are predominantly 
found on the presynaptic terminals where they appear to regulate transmitter release, they have 
also been identified on post-synaptic structures and glia (Rodriguez et al., 2001). Central CB2 
receptor distribution and density is comparatively sparse with receptor expression mainly 
localized in the following regions: neurons of the piriform, orbital, visual, motor and auditory 
cortex (Svizenska et al., 2008). In addition, the anterior olfactory nucleus, periaquaductal grey, 
substantia nigra pars reticulata and the pyramidal neurons on the hippocampal allocortex also 
express a low levels of CB2 receptors. 
B. Peripheral nervous system distribution. In the enteric nervous system, both 
cholinergic and non-cholinergic sensorimotor submucosal neurons including those in the 
myenteric plexus innervating the longitudinal muscle express CB1 receptors (Tyler et al., 2000; 
Adami et al., 2002). Activation of these enteric receptors attenuates the release of acetylcholine 
thus inhibiting smooth muscle contractility (Coutts and Pertwee, 1997). Intestinal contractility 
mediated through non-adrenergic non-cholinergic (NANC) neurons is also attenuated following 
CB1 receptor activation (Izzo et al., 1998). Furthermore, activation of CB1 receptors in the 
gastrointestinal tract inhibits intestinal and gastric fluid secretion (Pertwee, 2001). In the pelvic 
viscera, CB1 receptors are expressed in the vas deferens, bladder and the uterine wall where they 
regulate smooth muscle contraction (Pertwee et al., 1992). Peripheral expression of CB2 
receptors is mostly restricted to the immune system cells including β-cells, natural killer cells 
and monocytes which are suspected to play an immunomodulatory role (Walter et al., 2003). 
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CB2 receptor transcripts have also been found organs associated with the immune response 
including the spleen, thymus, tonsils and mast cells (Berdyshev, 2000; Sugiura and Waku, 2000). 
3. Ligands Targeting the Cannabinoid Receptors 
A. Endogenous ligands. Anandamide (AEA) was the first endogenous cannabinoid 
receptor ligand discovered and thereafter, 2-arachidonylglycerol (2-AG) was identified (Devane 
et al., 1992; Sugiura et al., 1995). 2-AG is a full agonist at both CB1 and CB2 receptors whereas 
anandamide acts as a partial agonist for both the CB1 and CB2 receptors although it has higher 
affinity for the latter (Hillard et al., 1999). The production of endocannabinoid neurotransmitters 
appears to be triggered by the stimulation of postjunctional neurotransmitter receptors (Giuffrida 
et al., 1999). Following release into the synaptic cleft, the ligand influxes back into the cells via 
an active and Na+-independent transport mechanism (Beltramo et al., 1997). The sequestered 2-
AG is eventually hydrolyzed by either monoacylglycerol lipase (MAGL) or fatty acid amide 
hydroxylase (FAAH) with the latter being the major player (Dinh et al., 2002).  
Other recently discovered endocannabinoids include virodhamine (O-
arachidonoyldopamine), which acts as a partial agonist at cannabinoid receptors (Porter et al., 
2002; Walker et al., 2002); noladin ether (2-arachydonoyl glyceryl ether) which targets both CB1 
and CB2 receptors but has higher affinity for the latter (Hanus et al., 2001); and N-
arachidonoyldopamine which acts as a ligand at CB1 and TRPV1 receptors and elicits 
pharmacological responses associated with cannabinoid receptor activation including analgesia 
(Huang et al., 2002).  
B. Exogenous ligands. The most widely used exogenous cannabinoids are the 
phytocannabinoids derived from Cannabis sativa (marijuana) with ∆9-THC (Fig 1.1) being the 
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most thoroughly studied. There are four major classes of naturally occurring and synthetic 
exogenous cannabinoid ligands namely classical cannabinoids (e.g. ∆9-THC, ∆8-THC and HU-
210), AC-bicyclic and ACD-tricyclic analogs (e.g. CP-55,940), aminoalkylindoles (e.g. WIN-
55,212-2) and the diarylpyrazole compounds (e.g. SR141716 and AM521) which act as inverse 
agonists and/or antagonists at the cannabinoid receptors (Rinaldi-Carmona et al., 1994).  In the 
current study we use WIN-55,212-2 which is highly lipid soluble and acts as a full agonist at 
both cannabinoid receptors though it has a two-fold higher affinity towards the CB2 receptor. 
4. Signal Transduction and Cellular Effects 
Cannabinoid receptors are G protein coupled therefore ligand binding induces a 
conformational change that results in the interaction of the serpentine receptor with its cognate 
heterotrimeric G protein located within the cytosol. Following agonist activation of the 
cannabinoid receptor and shifts in conformation of the G protein, the GTP conjugated Gi/o-
protein exchanges GTP for GDP then dissociates to form Gα–GTP and Gβγ subunits which act as 
primary messengers for intracellular signaling. 
Both CB1 and CB2 receptors are negatively coupled to adenylyl cyclase via the Gα 
subunit hence receptor activation reduces cytosolic cAMP levels in a pertussis toxin sensitive 
fashion (Howlett and Fleming, 1984; Howlett et al., 1986; Felder et al., 1992). The reduction in 
cAMP levels results in a decreased activation of cAMP dependent protein kinase A (PKA) 
activity hence attenuating PKA modulated downstream events. Ion channel activity is modulated 
either directly via the G protein βγ subunits or indirectly using other secondary messengers like 
protein kinase A (PKA) (Childers and Deadwyler, 1996). CB1 receptor agonists activate K+ 
channels resulting in K+ efflux thus hyperpolarization of the cell membrane potential.  This 
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action is accomplished by direct activation of the G protein-activated inwardly rectifying K+ 
channel (GIRK) via the Gβγ-protein subunit (Henry and Chavkin, 1995; Mackie et al., 1995). 
Activation of A-type-K+ channels is inhibited by cAMP-dependent PKA hence the cannabinoid 
induced reduction in cAMP-dependent PKA activity also results in greater A-type-K+ channel  
activity (Childers and Deadwyler, 1996). Cannabinoid receptor agonists indirectly inhibit L-type 
Ca2+ channels via the Gβγ subunit (Gebremedhin et al., 1999). Other Ca2+ channels inhibited by 
cannabinoid receptors agonists include the N- and Q-type Ca2+ channels (Caulfield and Brown, 
1992; Felder et al., 1993; Mackie et al., 1995). In a paradoxical fashion, calcium currents can 
also be activated following CB1 receptor activation in a pertussis toxin and phospholipase C 
sensitive manner (Sugiura et al., 1996).  
CB1 receptor agonists have been reported to activate mitogen activated protein kinases 
(p38 and p42/p44) which results in increased early gene expression (Bouaboula et al., 1995; 
Reche et al., 1998; Liu et al., 2000).  Anandamide has also been demonstrated to activate 
production of nitric oxide in the rat median eminence fragments and in human arterial 
endothelial cells (Prevot et al., 1998). Focal adhesion kinase (FAK), responsible for signal 
transduction events and integrating cytoskeleton changes like synaptic plasticity (neutric 
retraction), is also regulated by cannabinoid receptor agonists (Derkinderen et al., 1996). 
5. Summary of Cannabinoid Actions 
Endogenous cannabinoids are distributed throughout the body and cannabinoid receptors 
exist in tissues where endogenous cannabinoid innervations occurs as well as in tissues without 
any cognate cannabinoid innervations.  The effects appear to be mediated by primarily 2 receptor 
subtypes (CB1 and CB2) with the majority of the pharmacological responses in the central and 
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peripheral nervous systems being mediated through the CB1 receptor.  The effects mediated by 
CB2 receptors appear to focus more on the inflammatory processes and the immune system 
(Newton et al., 2009).  The effects that are important from a clinical point of view include 
regulation of gastrointestinal motility, ataxia, appetite, reward, learning and memory, analgesia 
and body temperature. 
The central nervous system effects of CB1 receptor agonists include analgesia, appetite 
enhancement, modulation of muscle activity, and regulation of hormone and neurotransmitter 
release (Di Marzo et al., 2001; Fride and Shohami, 2002; Fride et al., 2003). Endocannabinoids 
in the brain regulate the release of acetylcholine, dopamine, GABA, histamine, serotonin, 
glutamate, prostaglandins, norepinephrine and opioid peptides thus indirectly affecting the 
physiological function of the organism. Cannabinoid-induced reduction of dopamine activity in 
brain areas involved in motor control and reward may explain its effect on motor co-ordination 
and addiction, respectively (Giuffrida et al., 2001; Gardner, 2002). Cannabinoids demonstrate 
effective analgesic activity in models of neuropathic pain and have also been shown to work 
synergistically with opioids in acute pain models (Welch and Eads, 1999). Neuropathic pain in 
humans generally responds poorly to opioid agents but cannabinoids have been shown to be 
effective in alleviating pain associated spinal cord injury, peripheral neuropathy, and nerve injury 
(Wilsey et al., 2008). A neuroprotective role for endocannabinoids in the traumatic brain injury 
animal model (Mechoulam et al., 2002) may be due to inhibition of metabotropic glutamate 
signaling that results in toxic Ca2+ influx or through an antioxidant effect that scavenges reactive 
oxygen species (Hampson et al., 2000; Grundy, 2002). 
The cardiovascular effects of cannabinoids include tachycardia, increased cardiac output 
and elevated oxygen demand (Tashkin et al., 1977; Szabo et al., 2001). Other pharmacological 
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effects of cannabinoids include peripheral vasodilation, orthostatic hypotension, and reduced 
platelet aggregation (Lake et al., 1997). In the gastrointestinal tract, CB1 receptor activation 
attenuates vagal drive leading to reduced gastric emptying and secretion, and decreased 
peristaltic activity (Coruzzi et al., 1999; McCallum et al., 1999). Coutts and Pertwee (1997) 
demonstrated that activation of presynaptic CB1 receptors, predominantly located on cholinergic 
neurons in the myenteric plexus, results in the inhibition of release of acetylcholine from the 
myenteric ‘S’ neurons thus inhibiting peristaltic activity. Other pharmacological effects of 
cannabinoids mediated through CB2 receptors include a reduction in sperm count (Hembree et 
al., 1978) and an interaction with the hypothalamic–pituitary-adrenal axis which influences a 
number of hormonal processes including hypothermia (Rawls et al., 2002).  
III. Opioid Pharmacology 
1. Opioid Receptor Subtypes 
Several classes of opioid receptors have been identified that include the mu- (MOR), 
kappa- (KOR), delta- (DOR) opioid and nociceptin receptors (opioid like receptor [ORL-1]). 
Two MOR subtypes, MOR1 and MOR2, have been identified and characterized based upon 
variable biphasic binding characteristics and differential blockade of opioid effects by 
naloxonazine (Pasternak, 2005). Two delta receptor subtypes, DOR1 and DOR2, have been 
characterized by DOR-selective agonists and antagonists which display variable patterns of 
supraspinal analgesia (Traynor and Elliott, 1993). Another delta receptor classification postulates 
the existence of deltacx and deltancx subtypes based on the hypothesis that the deltacx subtype is 
complexed with MOR (or perhaps KOR) whereas the deltancx subtype exists independently 
(Traynor and Elliott, 1993). The existence of three subtypes of the kappa opioid receptor (KOR1, 
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KOR2 and KOR3) has been proposed based on radioligand binding studies, but currently there is 
no categorical functional pharmacological evidence to fully support this idea (Devi, 2001). 
cDNA library screening has identified the opioid like receptor 1 (ORL1) which has a high degree 
of homology to the classical receptor subtypes. The existence of other opioid receptor subtypes 
namely sigma (σ) and epsilon (ε) receptors has been proposed but there is either contradictory 
data or insufficient evidence to support the claims of physiological existence and function of 
these receptor subtypes (Contet et al., 2004). 
2. Opioid Receptor Distribution 
A. Central Distribution. The CNS comparatively expresses higher levels of opioid 
receptors than the peripheral nervous system. One or more of the mu-opioid receptor (MOR) 
subtypes are expressed to the highest levels in brain regions that include the cerebral cortex 
(especially laminae II and IV), thalamus, striosomes (striatum), periaquaductal gray and the 
substantia gelatinosa of the spinal cord whereas kappa opioid receptor subtypes (KOR) are 
highly expressed in the hypothalamus, periaquaductal gray, claustrum and the substantia 
gelatinosa of the spinal cord (Anand et al., 2010). The delta opioid receptor subtypes are 
distributed in the pontine nuclei, amygdala, the olfactory bulbs and deep cortex whereas ORL1 
expression has been identified in the cerebral cortex, amygdala, hippocampus, septal nuclei, 
habenula and the spinal cord. Regardless of the distribution, the cellular transduction pathway 
that mediates the effects of receptor activation is similar for all the receptors (Connor and 
Christie, 1999).  
B. Peripheral Distribution. Expression of MOR and KOR in the myenteric plexus of the 
gut is well documented (Bagnol et al., 1997); activation of these receptors results in a reduction 
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of acetylcholine release from the myenteric ‘S’ neurons (Paton, 1957). Mu-opioid receptors 
(MOR) are located on the soma and reduce transmitter release by hyperpolarization-mediated 
reduction in excitability while kappa opioid receptors, located on the axon terminals, decrease 
acetylcholine release by inhibiting calcium influx into the nerve terminal (Kojima et al., 1994; 
Coutts and Pertwee, 1997). In addition, the small and large intestines also express DOR. Delta- 
and mu- opioid receptors have also been identified in the vas deferens (Marshall et al., 1979; 
Sheehan et al., 1986).  Evaluation of testes, ovary, uterus, kidney and adrenal tissue suggests the 
presence of MOR in these tissues. Sparse populations of the DOR and KOR have also been 
reported to exist in these peripheral tissues as indicated in Table 1 (Wittert et al., 1996). 
3. Opioid Receptor Ligands 
A. Endogenous Ligands. Endogenous opioid ligands are derived from long-chained 
peptide precursor molecules. Pro-opiomelanocortin (POMC) is a precursor for opioid peptides 
like β-endorphin and the enkephalins, as well as non-opioid peptides like beta-melanocyte 
stimulating hormone (MSH) and adrenocorticotropin (ACTH). β-endorphin displays high 
affinity for delta- and mu- opioid receptors but has weak affinity for the kappa opioid receptors 
(Corbett et al., 2006). Proenkephalin acts as a precursor for both Met- and Leu-enkephalin which 
are MOR agonists (Corbett et al., 2006). The derivative peptides cleaved from prodynorphin 
include dynorphin-A and dynorphin-B, α- and β-neoendorphin (Goldstein et al., 1981). 
Dynorphin A and B have a high affinity for KOR but also bind to MOR and DOR (Corbett et al., 
2006). Pronociceptin acts as a precursor molecule for endomorphin-1 and -2, and 
nociceptin/orphanin-FQ, a ligand at ORL-1. Other active endogenous derivatives like 
dermorphin, and deltorphin I and II, have multiple precursors namely prodermorphin and 
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prodeltorphin. Dermophin is highly potent and selective for MOR whereas deltorphins are highly 
selective for DOR (Erspamer et al., 1989).  
B. Exogenous Ligands. Opioids are naturally derived from the opium poppy plant 
(Papaver somniferum) and the structure of most synthetic analogs is derived from these naturally 
occurring ligands. The chemical classification groups the opioid ligands into four major classes 
namely phenanthrenes (e.g. morphine [Fig 1.2], codeine, hydromorphone, levorphanol, 
oxycodone, nalbuphine and hydrocodone), benzomorphans (e.g. pentazocine), phenylpiperidines 
(e.g. fentanyl, alfentanil, sulfentanil, and mepiridine) and diphenylheptanes (e.g. propoxyphene 
and methadone) (Trescot et al., 2008). Tramadol does not fit into any of the four groups stated 
above hence is classified as an atypical opioid. 
The pharmacological classification of opioid ligands is based on the pharmacodynamic 
properties and defines the compounds as agonists, antagonists, and partial agonists or agonists-
antagonists. Opioid receptor agonists include morphine, codeine, fentanyl, methadone and 
oxycodone. The partial agonist buprenorphine has a high affinity but low efficacy at the MOR 
and also acts as an antagonist at the KOR (Trescot et al., 2008). Most antagonists have high 
receptor affinity but are devoid of efficacy e.g. naloxone, naltrexone and nalmefene. Opioid 
agonist-antagonist agents e.g. pentazocine, nalbuphine and butopharnol, exhibit antagonistic 
effects on the MOR but also show agonist activity on the KOR.  
4. Signal Transduction and Cellular Effects 
As illustrated in Fig 1.3, opioid receptors are part of the GPCR superfamily which couple 
to pertussis toxin sensitive heterotrimeric Gi/o proteins. Upon receptor activation the GTP 
conjugated heterotrimeric G protein exchanges GTP for GDP then dissociates to form Gα-GDP 
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and Gβγ subunit complexes that are ultimately responsible for initiation of the downstream 
intracellular signaling. Opioid receptors are negatively coupled to adenylyl cyclase therefore 
activation lowers cytosolic cAMP concentrations resulting in the inhibition of a 
hyperpolarization-activated cation channel (Ih) also known as the pacemaker current thus 
decreasing neuronal excitability (Childers, 1991; Ingram and Williams, 1994). Inhibition of 
adenylyl cyclase activity is also associated with direct inhibition of neurotransmitter release in a 
PKA-dependent manner. Other pathways regulated by cAMP-dependent PKA including cell 
differentiation, ion channel conductivity and metabolism are also negatively regulated by opioid 
receptor activation (Krebs and Beavo, 1979; Schwartz and Rubin, 1983).  
All opioid receptor subtypes have been shown to activate a variety of potassium channels, 
including the G protein-activated inwardly rectifying K+ channel (GIRK) and BK calcium-
sensitive potassium (Twitchell and Rane, 1993; Jan and Jan, 1997). Activation of opioid 
receptors has also been shown to inhibit voltage dependent conductance by dendrotoxin-sensitive 
and M-type channels (Madamba et al., 1999). Calcium channels inhibited following opioid 
receptor activation include L-, N-, P- and Q- type voltage dependent calcium channels (Samways 
and Henderson, 2006). In some cell types, receptor activation can also result in a paradoxical 
increase in calcium levels by releasing calcium from intracellular stores or enhancing its entry 
via a dihydropyridine-sensitive mechanism (Samways and Henderson, 2006). 
Opioid receptor activation has been shown to attenuate neurotransmitter release. 
Activation of the MOR in the vas deferens and the LM/MP preparation results in the inhibition 
of ATP and acetylcholine release, respectively (Henderson et al., 1972; Kosterlitz and 
Waterfield, 1972; Coutts and Pertwee, 1997). Inhibition of neurotransmitter release has been 
attributed to the activation of potassium conductance and/or inhibition of calcium currents, or 
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inhibition of hyperpolarization-activated cation channel (Ih) (Ingram and Williams, 1994). In 
myenteric ‘S’ neurons, acetylcholine release is inhibited by both MOR and KOR activation; 
MOR-induced  inhibition occurs via activation of K+ currents at the level of the cell soma, while 
KOR activation inhibits the release through inhibition of Ca2+ currents. Other effects of opioid 
receptor activation include potentiation of NMDA currents via activation of PKC (Koyama and 
Akaike, 2008). 
Opioid agonists have been shown to stimulate mitogen-activated protein kinase (MAPK) 
activity via different routes: one pathway involves Gβγ subunit activation of phophatidyl-inositol 
3-kinase (PI3K) that eventually results in MAPK activation via a series of phosphorylation steps 
(Polakiewicz et al., 1998); a second method involves beta-arrestin which acts as an adaptor 
protein to bind both c-Src and the agonist-occupied receptor to form a mitogen signaling 
complex that is internalized (Ignatova et al., 1999). The internalized complex activates an 
extracellular signal regulated kinase (ERK), which is translocated into the nucleus and thus 
affects gene regulation through regulation of transcription factors such as cAMP response 
element binding (CREB) (Khokhlatchev et al., 1998). 
5. Summary of Opioid Actions 
The pharmacological effects of opioids are defined by the receptor type and its location. 
There is however, combined overlap of the effects amongst the receptors. Like MOR agonists, 
DOR ligands also stimulate supraspinal and spinal analgesia, and modulate release of hormone 
and neurotransmitter but lack some of the other pharmacological effects. Similarly, KOR 
activation results in supraspinal and spinal analgesia, as well as some of the psychosomatic 
effects and slowed gastrointestinal transit.  
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The central effects of opioid include regulation of sensory and affective components of 
pain. Euphoria that presents as a pleasant floating sensation is precipitated by opioid use. The 
sedative effect of opioids is employed clinically to supplement the action of hypnotic agents. At 
standard doses, morphine disrupts normal rapid eye movement and non-rapid eye movement 
(NREM) sleep patterns. Stimulation of MOR in the brainstem causes respiratory depression thus 
elevating alveolar pCO2 levels. Opioids also have antitussive and miotic properties. Direct 
stimulation of the chemoreceptor trigger zone results in nausea and vomiting especially with 
apormorphine. Other central effects of opioids include regulation of body temperature; the 
resultant effect depends on the receptor subtype activated e.g. selective activation of MOR in the 
anterior hypothalamus results in hyperthermia whereas KOR agonist activation induces 
hypothermia (Adler and Geller, 1987; Spencer et al., 1988). Central activation of MOR1 results 
in supraspinal analgesia and physical dependence whereas the effects of MOR2 activation 
include respiratory depression, miosis, euphoria, reduced gastrointestinal motility and physical 
dependence.  Kappa opioid receptor activation results in spinal analgesia, sedation, miosis and 
inhibition of anti-diuretic hormone (ADH) release. The pharmacological effects observed 
following activation of the DOR include analgesia, antidepressant effects and physical 
dependence. 
The cardiovascular effects of opioids are complex and ligand dependent. Most opioid 
agonists do not have a direct effect on the heart with meperidine being an exception since it 
causes tachycardia through its antimuscarinic action. Opioid-induced hypotension is probably 
due to peripheral and venous dilation attributed to central depression of vasomotor-stabilizing 
mechanisms and the release of histamine. Opioids also regulate gastrointestinal processes; in the 
myenteric plexus, activation of the MOR found on the soma of the ‘S’-type neurons results in 
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activation of a hyperpolarizing potassium current that leads to inhibition of acetylcholine release 
whereas activation of the KOR located on the axon terminal results in inhibition of calcium 
currents thus depress neuronal excitability (Cherubini and North, 1985; Kojima et al., 1994). 
Other gastrointestinal effects include contraction of the biliary smooth muscle. The sphincter of 
Oddi may contract resulting in biliary reflux (Rang et al. 2007). The renal effects of opioids 
include an increase in urethral, bladder, and sphincter smooth muscle tone, and a reduction in 
renal plasma flow. Other peripheral effects of opioids include uterine wall relaxation and 
histamine-induced pruritis. 
Clinically, opioids are indicated for pain, congestive heart failure associated with 
pulmonary edema, elevated intracranial pressure, diarrhea, cough, shivering (meperidine) and in 
combination with other drugs for anesthesia. In spite of the large number of clinical uses, there 
are still forms of chronic pain that respond poorly to opioids.  The development of alternative 
agents and protocols to the management of these types of pain has been somewhat of a shotgun 
approach with the selection of agents based upon speculation rather than evidence.  Nevertheless, 
there are a number of agents that have been used either in place of or in conjunction with opioids 
to manage certain types of pain refractory to opioids e.g. valproate or carbamazepine or 
cannabinoids for neuropathic pain (Rang at al. 2007).  
IV. The Phenomenon of Drug Tolerance 
1. General Introduction 
Tolerance occurs in response to chronic treatment when the pharmacological effects of a 
drug decrease such that larger doses are required to achieve the same response. Dosage 
adjustment potentially results in a greater incidence of adverse effects including drug overdose, 
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development of withdrawal and enhanced drug dependence. Tolerance and dependence to 
cannabinoids and opioids has been extensively studied and several animal models have been 
developed to test both phenomena. Multiple forms of tolerance, mediated via different sets of 
adaptation, are characterized by variable time courses for development (Bass and Martin, 2000; 
Li et al., 2010) and have been associated with reduced responsiveness of the test system to 
different agonists that is either homologous or heterologous. Homologous tolerance presents as 
limited alteration in responsiveness to specific agents using the same receptor or signaling 
pathway whereas heterologous tolerance exhibits as an altered responsiveness that extends to 
agents that do not utilize the same receptor or signaling pathways (Taylor and Fleming, 2001).  
The homologous form of diminished sensitivity has been shown to occur through a series of 
desensitization events that are precipitated by prolonged exposure to usually very high 
concentrations of an agonist. The latency to induce homologous desensitization varies from a 
few seconds to as long as days or weeks depending on the agonist, dose, species, and model used 
e.g. opioid induced homologous desensitization resulting from G protein uncoupling occurs 
within minutes (Law and Loh, 1999) whereas adenylyl cyclase (AC) upregulation as a form of 
adaptation may take hours to manifest (Nestler, 1993).  In contrast, heterologous tolerance is 
usually associated with adaptive changes in responsiveness that develop over a longer time frame 
and decay over an even longer time course e.g. a reduction in the electrogenic function of the 
Na+K+ATPase (Fleming, 1999; Taylor and Fleming, 2001). While heterologous tolerance is 
certainly triggered by receptor-mediated events, the cellular impact extends to functions that are 
not tied to that receptor or signaling pathway.   
It is generally believed that homologous tolerance is expressed faster than heterologous 
tolerance since it is associated with immediate receptor dependent changes (e.g. uncoupling of 
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the receptor from its cognate G protein, phosphorylation by GRKs, mobilization of beta-arrestins 
or changes in the adenylyl cyclase pathway) whereas heterologous tolerance is produced by non-
receptor dependent changes like protein expression which can take days to weeks (Taylor and 
Fleming, 2001). The reversal of desensitization occurs relatively quickly following cessation of 
the drug exposure and depends on the length of agonist exposure, agonist used and the 
physiological/cellular effect being assessed.  The time frame for recovery from heterologous 
tolerance is much longer and may last for weeks (Li et al., 2010).  
2. Role of Phosphorylation in Desensitization 
Early studies proposed the major mechanism implicated in desensitization to involve 
phosphorylation of the receptor (Stadel et al., 1983; Pitcher et al., 1998) by second messenger 
kinases like protein kinase C or protein kinase A (Benovic et al., 1985). However, later studies 
using PKC and PKA knockout animals identified beta-adrenergic receptor kinase (β-ARK), 
subsequently termed G protein-coupled receptor kinase subtype 2 (GRK2), as another kinase 
capable of phosphorylating the β2-adrenergic receptor (Benovic et al., 1986). β2-adrenergic 
receptor (β2-AR) phosphorylation has been shown to occur through phosphorylation at two 
different regions; on serine residues (Ser262) in the 3rd intracellular loop by PKA and on the 
serine residues (Ser355 and Ser356) in the proximal COOH terminus by GRKs (Tran et al., 
2004). The site of phosphorylation is dependent on the concentration of the agonist, with PKA 
activity triggered at low agonist concentrations and the GRK effect observed at higher agonist 
concentration (Tran et al., 2004). In addition, studies have shown that PKC can phosphorylate 
GRK2 thus enhancing the ability of the latter kinase to phosphorylate agonist activated GPCRs 
(Chuang et al., 1995; Krasel et al., 2001). PKA has also been implicated in the phosphorylation 
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of GRK-2 thus enhancing the latter’s ability to phosphorylate the β2-AR (Cong et al., 2001; Li et 
al., 2006).  
In line with the concept of functional efficacy, the ability of a ligand to induce receptor 
phosphorylation appears to be ligand dependent. This could result from subtle variability in 
signaling between different ligands targeting the same receptor e.g. DAMGO to induces greater 
MOR internalization compared with morphine (Schulz et al., 2004).  In human embryonic kidney 
(HEK) 293 cells expressing rat MOR1 as well G protein-coupled inwardly rectifying potassium 
(GIRK) channel subunits, DAMGO was shown to induce greater MOR internalization in a 
GRK2-dependent fashion whereas morphine confers negligible internalization that is PKC 
dependent (Johnson et al., 2006). In the latter study, the desensitization by DAMGO was blocked 
by expression of a dominant negative mutant GRK2 whereas that induced by morphine was 
attenuated by PKC inhibitors. 
3. The Role of Beta-Arrestins in Downregulation 
Beta-arrestins have been demonstrated to be key players facilitating receptor 
desensitization (Lohse et al., 1990; Pitcher et al., 1992). Beta-arrestins have high affinity for the 
phosphorylated GPCRs and function by sterically hindering and uncoupling the receptor from its 
cognate G protein thus blocking the receptor-generated response (Gurevich and Gurevich, 2004). 
Fluorescence resonance energy transfer (FRET) analysis has illustrated beta-arrestin dissociation 
from the receptor upon agonist removal, even though the GPCR is still phosphorylated (Krasel et 
al., 2005). Beta-arrestin also directs the phosphorylated receptor as a GPCR/arrestin complex 
into clathrin coated pits. Upon internalization, the GPCR can either be dephosphorylated and 
recycled or degraded by lysosomes (Krupnick and Benovic, 1998). GRKs and arrestins also act 
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as multiprotein intracellular scaffolds, responsible for downstream activation of MAPK and other 
long-term cellular signaling pathways which may contribute to plasticity (DeWire et al., 2007; 
Ribas et al., 2007).  
4. The Role of Changes in Protein Levels in Adaptive Heterologous Tolerance 
Cellular tolerance may be associated with a decrease in receptor protein levels due to 
internalization that ultimately results in receptor degradation (Chavkin and Goldstein, 1984; 
Bohn et al., 2004). However, levels of other cellular proteins may also change as part of the key 
elements of adaptation that play a role in the development and maintenance of heterologous 
tolerance. The proteins that may be engaged in this process would likely be proteins that play a 
role in regulating general cell excitability since changes in responsiveness occur to agents that 
employ very different signaling pathways. Chronic morphine exposure has been reported to 
decrease the levels of the functional alpha3 subunit isoform of the Na+/K+ ATPase responsible 
for the regulation of membrane potential (Biser et al., 2002).  This has been proposed to account 
for a partial depolarization which results in increased supersensitivity to stimulatory agents and 
subsensitivity to multiple inhibitory agents (Meng et al., 1997; Taylor and Fleming, 2001; Li et 
al., 2010). Development of tolerance has also been associated with the alteration of specific AC 
isoforms involved in the long term adaptive phenomenon of cAMP superactivation (Rhee et al., 
2000). 
5. Functional Efficacy and Tolerance 
The ability of different agonists targeting the same receptor to stimulate different 
signaling pathways has been explained by the concept of functional efficacy (Urban et al., 2007). 
The concept ascribes the ligand-specific effects to variable conformations of the GPCR conferred 
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by the agonist that results in activation of different sets of responses including the cellular 
processes responsible for desensitization (Perez and Karnik, 2005). Studies on the MOR 
demonstrate that DAMGO and etorphine both induce beta arrestin-GPCR interactions that lead 
to MOR internalization whereas exposure to morphine does not induce significant internalization 
(Keith et al., 1996; Zhang et al., 1998). It has been hypothesized that if the method of 
desensitization is agonist dependent, then resensitization and downregulation could also be 
agonist dependent. This potential was illustrated by Schulz et al. (2004) who discovered that 
morphine-induced phosphorylation and subsequent dephosphorylation and resensitization of the 
MOR occurs over a much slower timeframe than that associated with DAMGO exposure. 
However, the concept of the role of agonist efficacy in the development of functional tolerance is 
not universally accepted since studies with both opioids and cannabinoids have shown a lack of 
correlation between efficacy and the ability to induce desensitization (Clark et al., 1999). Other 
GPCRs that exhibit desensitization related functional selectivity include β2-adrenergic receptor 
and 5-HT2C receptors (Urban et al., 2007).  
V. Development of Opioid Tolerance  
1. The Role of Receptor Uncoupling and Phosphorylation in Tolerance 
As with most G protein-coupled receptors (GPCR), opioid receptor function is regulated 
by several processes including phosphorylation primarily by GPCR kinase (GRK) (Appleyard et 
al., 1999) and secondary kinases like PKA and PKC (Smith et al., 2006). Upon agonist 
activation, the GPCR assumes a conformation that is receptive for phosphorylation by GRK, 
PKA or PKC (Smith et al., 2006).  The PKC inhibitor, H7, and the PKA inhibitor, KT-5720, 
have been shown to reverse tolerance to the antinociceptive action of opioids (Narita et al., 1996; 
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Bernstein and Welch, 1997). Moreover, intrathecal administration of an anti-sense 
oligodeoxynucleotide to PKCα mRNA inhibited the development of tolerance to morphine (Hua 
et al., 2002). GRK phosphorylation of agonist-activated receptors results in beta-arrestin-induced 
uncoupling of the phosphorylated receptor thus resulting in receptor specific desensitization. 
Experiments assaying the coupling efficacy of MORs following chronic opioid exposure have 
illustrated functional uncoupling of the receptor that results in reduced GTPase activity, 
attenuated ability of opioids to stimulate G  protein-activated  inwardly rectifying K+ channels 
(GIRK) and diminished regulation of calcium currents (Christie et al., 1987; Sim et al., 1996; 
Selley et al., 1997). The reduced coupling efficiency has also been attributed to beta-arrestin 
induced functional uncoupling of the receptors from their cognate G proteins or the loss of cell 
surface receptors (Chakrabarti et al., 1995a; Bohn et al., 2004). 
2. The Role of Beta-Arrestins and Receptor Internalization in Tolerance 
Beta-arrestin has been demonstrated to sterically hinder the interaction of an activated 
receptor with its cognate G protein.  In addition, this protein also directs movement of the 
receptor to clathrin-coated pits in the cytosol thus initiating internalization, sequestration and 
trafficking of receptors (Gurevich and Gurevich, 2004). Phosphorylation of the opioid receptor 
has been shown to increase its affinity for beta-arrestin. The phosphorylated receptor/beta-
arrestin complex is targeted for internalization through clathrin-coated pits and subsequently 
undergoes intracellular trafficking to subcellular compartments (e.g. lysosomes) where 
degradation or dephosphorylation occurs (Schulz et al., 2004). Receptor downregulation 
inevitably results in the loss of downstream signal transduction and is a key facet in the 
development of homologous tolerance (Chavkin and Goldstein, 1984; Chakrabarti et al., 1995a). 
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The extent of internalization and downregulation of MOR is ligand-dependent as DAMGO 
appears to have greater capacity to induce receptor downregulation when compared to morphine 
(Schulz et al., 2004; Johnson et al., 2006). Direct assessment of the density of the MOR on the 
cell surface has also shown downregulation in the brainstem following chronic treatment with 
morphine (Bernstein and Welch, 1998; Tao et al., 1998; Law and Loh, 1999). The involvement 
of beta-arrestin in the desensitization of opioid signaling is further supported by a study in which 
beta-arrestin 2 knockout mice exhibited enhanced, prolonged analgesia to morphine following 
chronic opioid exposure (Bohn et al., 1999). Although beta-arrestins are implicated in receptor 
internalization, they also act as scaffolding proteins for a wide spectrum of signaling molecules 
thus facilitating downstream signal transduction (DeWire et al., 2007). 
3. Duality of G protein Signaling and Effect on AC in Tolerance 
Previous studies have reported that adenylyl cyclase can be differentially regulated by the 
Gα and Gβγ subunits, derived from the heterotrimeric Gi protein, with the latter enhancing and the 
former attenuating adenylyl cyclase activity (Wang and Gintzler, 1995; Sunahara et al., 1996; 
Wang and Gintzler, 1997). In acute opioid exposure, Giα activity dominates whereas chronic 
exposure shifts the balance towards Gβγ. The shift in signaling from Gα inhibitory to Gβγ 
excitatory induced following sustained opioid exposure is further augmented by an increase in 
the synthesis of those AC isoforms (AC IV) stimulated by Gβγ (Rivera and Gintzler, 1998). 
Furthermore phosphorylation of Giβ subunit by PKC results in an increased potency of Gβγ to 
stimulate AC II thus augments AC activity (Chakrabarti et al., 1998; Chakrabarti and Gintzler, 
2003). This two pronged effect favoring activation of AC is triggered by prolonged opioid 
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exposure and results in a synergistic stimulation of AC thus shifting from Gα inhibitory to Gβγ 
excitatory. 
4. Pleiotropy of Opioid Receptors in Tolerance 
As with most GPCR, opioid receptors interact with multiple G proteins including Giα3, 
Giα2, Goα2 and also Gq (Chakrabarti et al., 1995b; Ho et al., 2003). Opioid receptor signaling has 
been reported to occur through both Giα (inhibitory) and Gsα (excitatory), depending on the length 
of agonist exposure. Acute action of opioids is mediated through Giα whereas chronic exposure 
to morphine and other opioid agonists appears to shift the signaling towards Gs resulting in 
increased production of cyclic AMP (Sunahara et al., 1996).  Gs induced adenylyl cyclase 
activity raises cyclic AMP levels thus activating intracellular signaling pathways which affect 
neurotransmitter release and other intracellular pathways (Gintzler et al., 1987; Gintzler and Xu, 
1991). Immunoprecipitation studies have also demonstrated an interaction of opioid receptors 
with Gsα whereas the interaction between the receptor and Giα decreases following chronic 
exposure to opioids (Chakrabarti et al., 2005). Other data supporting opioid receptor coupling to 
Gs include the increased ability of opioids to enhance neurotransmitter release and AC activity in 
a cholera toxin sensitive manner following chronic morphine exposure (Wang and Gintzler, 
1997). This Gs signaling combined with previously mentioned switch to Giβγ- signaling following 
chronic opioid exposure contributes toward adenylyl cyclase superactivation which has been 
proposed to be a key facet in the development of opioid tolerance. These adaptations enable 
opioid tolerance mechanisms to be pliable and represent part of a much broader spectrum of 
adaptational events that may surround and play an integral role in the development of tolerance. 
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5. Changes in Membrane Potential in Opioid Tolerance 
Electrophysiological assessment of LM/MP neurons from morphine tolerant animals 
have demonstrated a partial depolarization of the cell membrane potential (Leedham et al., 1992; 
Meng et al., 1997) that may account not only for the increased sensitivity to excitatory agents 
like K+ ions, 5-hydroxytryptamine and nicotine but also the reduced responsiveness to inhibitory 
agents like morphine, CADO and clonidine (Schulz and Goldstein, 1973; Johnson et al., 1978; 
Taylor et al., 1988). Additional studies associated the partial depolarization to a reduced 
abundance of the Na+/K+-ATPase caused by decreased expression of its functional alpha3 subunit 
isoform (Kong et al., 1997; Biser et al., 2002). The time course for reduction and recovery of 
alpha3 subunit isoform protein has also been shown to parallel the time course for the 
development and recovery of heterologous tolerance following chronic morphine exposure (Li et 
al., 2010). 
VI. Development of Cannabinoid Tolerance  
1. Receptor Phosphorylation and Desensitization in Tolerance 
As with most GPCR, desensitization of cannabinoid receptors involves GPCR kinase 
(GRK) induced phosphorylation and beta-arrestin initiated receptor decoupling and 
internalization (Jin et al., 1999; Kouznetsova et al., 2002). PKA and Src tyrosine kinase have 
also been implicated in the desensitization process since PKA or Src kinase inhibitors have been 
demonstrated to reverse the development of analgesic tolerance to cannabinoids following 
chronic WIN-55,212-2 exposure (Lee et al., 2003). Specific intracellular domains including 
S317, S426 and S430 have been identified to be critical for receptor desensitization since their 
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disruption results in decreased tolerance development (Garcia et al., 1998; Jin et al., 1999; Roche 
et al., 1999).  
2. Involvement of Beta-Arrestins, Receptor Internalization and Downregulation 
Cannabinoid receptor downregulation in the CNS is well documented, although the 
extent of the downregulation appears to be region dependent. The internalization of the receptors 
has been demonstrated in receptor-transfected cells (Hsieh et al., 1999) and, like the opioid 
receptors, it has been hypothesized that the agonist-activated cannabinoid receptor is targeted by 
beta-arrestin which directs the phosphorylated receptor as a GPCR/arrestin complex into clathrin 
coated pits. Upon internalization, the GPCR can either be dephosphorylated and recycled or 
degraded by lysosomes (Krupnick and Benovic, 1998; Schulz et al., 2004). Chronic treatment 
with the cannabinoid receptor agonists ∆9-THC, CP-55,940 has also been shown to reduce CB1 
receptor levels (Bmax) in the caudate putamen (Oviedo et al., 1993), striatum but not in the ventral 
mesencephalon (Rodriguez de Fonseca et al., 1994). As with opioid agonists, the ability of 
cannabinoids to desensitize receptors appears to be ligand dependent since anandamide, a poorly 
stable endocannabinoid, failed to elicit downregulation/desensitization whereas R-
methanandamide, a more stable analog, induced it (Romero et al., 1999). Brain regions that show 
the highest magnitude of cannabinoid receptor downregulation include the cerebellum, caudate 
putamen, globus pallidus, substantia nigra, nucleus accumbens, amygdala, hypothalamus, 
thalamus and PAG: the basal ganglia output nuclei show a modest change in receptor number 
following chronic cannabinoid exposure (Sim-Selley and Martin, 2002).  
A reduction in CB1 receptor mRNA transcription has also been demonstrated in the 
caudate putamen following ∆9-THC or CP-55940 exposure (Caberlotto et al., 2004). Importantly, 
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cannabinoid receptors appear to be more sensitive to downregulation in the brain compared to 
other Gi/o-coupled receptors, such as the MOR and 5-HT1A receptors (Sim et al., 1996; Sim-
Selley et al., 2000). Resensitization of an internalized receptor requires dephosphorylation by 
phosphatases and it has been proposed that endosomal acidification occurs for the internalized 
receptor to assume a conformation conducive for receptor dephosphorylation thus allowing 
receptor recycling (Hsieh et al., 1999).  
3.  Duality and Pleiotropy of Cannabinoid Signaling and AC Superactivation in Tolerance 
As with chronic opioid exposure, persistent cannabinoid exposure has been demonstrated 
to result in increased adenylyl cyclase activity following antagonist-precipitated withdrawal (Fan 
et al., 1996; Rubino et al., 2000). Studies in CB1-transfected cell lines have demonstrated the AC 
superactivation phenomenon. The cellular basis for the superactivation has not been fully 
defined, but it is suspected to be due to increased activation of Gs and decreased activation of the 
Gi-family of G proteins (Rhee et al., 2000).  Moreover, studies in COS-7 cells transfected with 
CB1 receptors show concentration-dependent selective superactivation of AC types I, III, V, VI, 
and VIII which increase cAMP levels. The cAMP increase is stimulated in part, by free Gβγ 
subunit (Rhee et al., 2000). 
4. Role of Protein Kinases in Tolerance 
The cannabinoid induced reduction in cAMP-dependent PKA activity has been proposed 
to result in  disinhibition of focal adhesion kinase (FAK) which in turn activates Src tyrosine 
kinase that ultimately results in the development of tolerance (Martin et al., 2004). In support of 
this idea is the data that shows inhibitors of Src tyrosine kinase to reverse analgesic tolerance 
induced following chronic ∆9-THC exposure (Lee et al., 2003).  Chronic cannabinoid exposure 
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also results in the uncoupling of Gi/o-proteins from the receptor resulting in disinhibition of AC 
and increased activity of c-AMP-dependent PKA (Martin et al., 2004). PKA activity has been 
proposed to be involved in the development of tolerance since inhibition of PKA results in 
attenuation of tolerance development (Lee et al., 2003). In contrast, inhibitors of PKC, PKG and 
phosphoinositide 3-kinase (PI3K) where shown to be ineffective in reversing ∆9-THC induced 
tolerance to analgesia assessed using the tail flick assay (Lee et al., 2003). The onset, extent and 
duration of the development of cannabinoid tolerance has also been shown to be ligand 
dependent thus suggesting the existence of potentially distinct mechanisms of receptor regulation 
(Bass and Martin, 2000; Sim-Selley, 2003).  
VI. Interaction of the Opioid and Cannabinoid Systems 
1. Common Cellular Effects/Signaling Pathways 
Significant similarities in the signal transduction events have been observed between 
opioid and cannabinoid systems. Both receptor families’ systems are coupled to pertussis toxin 
sensitive heterotrimeric Gi/o protein thus activation results in comparable downstream signaling 
pathways instigated by the Giα and Giβγ subunits. The Giα subunit attenuates adenylyl cyclase 
activity thereby reducing cAMP production (Howlett et al., 1986; Childers, 1991). Other 
common cellular effects include inactivation of N, P/Q, and R-type Ca2+ channels (Rhim and 
Miller, 1994; Howlett et al., 2002); activation of the MAPK pathway (Bouaboula et al., 1995) 
and activation of G protein-activated inwardly rectifying potassium (GIRK) channels (McAllister 
et al., 1999). As with most GPCRs, chronic activation of both receptor systems results in 
phosphorylation of the receptor by GPCR kinases (GRK) and PKA (Kelly et al., 2008). 
Interaction between the phosphorylated receptor and beta-arrestins induces assembly of adapter 
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proteins responsible for internalization of the receptors through clathrin-coated pits (Krupnick 
and Benovic, 1998; Hsieh et al., 1999).  
2. Shared Pharmacological Effects 
The comparable anatomical distribution patterns between opioid and cannabinoid 
receptors may represent the basis for the similar pharmacological effects observed with agents 
targeting the receptors. Activation of KOR, MOR and CB1 receptors in the gastrointestinal tract 
has been shown to reduce acetylcholine release thus attenuating intestinal peristalsis and 
increasing ileum transit time (Paton, 1957; Coutts and Pertwee, 1997).  In the vas deferens, both 
MOR and CB1 receptors have also been shown to reduce smooth muscle contractility (Hughes et 
al., 1975; Pertwee et al., 1992). Analgesic activity seen following CB1 and opioid receptor 
activation is directly related to the presence of the cannabinoid and opioid receptors in the 
amygdala, dorsal horn, periaquaductal gray and raphe. Other common pharmacological effects 
include precipitation of hypothermia, sedation and euphoria, and the development of 
dependence. 
3. Common Pharmacodynamic Substrates Underlying Tolerance Development 
A. General overview. Like most GPCRs, both opioid and cannabinoid receptors’ signal 
transduction are negatively regulated by receptor uncoupling, phosphorylation, internalization 
and degradation (Bailey and Connor, 2005). Upon activation, both receptor families are 
phosphorylated by G protein-coupled receptor kinases (GRKs) and subsequently bind to beta-
arrestin proteins which inhibit additional signaling by impeding further coupling between the 
receptor and its cognate G protein (Ferguson, 2001; Connor et al., 2004). The nature of tolerance, 
whether homologous (i.e. reduced responsiveness limited to agonists employing the same 
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receptor or signaling pathway) or heterologous (i.e. alterations in responsiveness that extend to 
innate cellular properties that regulate global function such as cell excitability), is determined by 
the specific adaptive cellular changes that occur within the cell in response to chronic alterations 
in the environment such as chronic drug exposure.  Homologous tolerance is mainly associated 
with receptor dependent modifications like receptor uncoupling from G proteins, receptor 
internalization or changes in cell signaling pathway and mostly occurs within hours/days after 
exposure whereas heterologous tolerance is often characterized by non-receptor dependent 
modifications that are non-specific in nature and expansive in character (e.g. membrane 
depolarization or changes in protein expression that regulate general cell function  (Taylor and 
Fleming, 2001)).  As outlined in previous sections, the adenylyl cyclase superactivation and 
reversal of response that is associated with tolerance is also observed with both receptor systems 
following chronic agonist exposure (Sunahara et al., 1996; Wang and Gintzler, 1997; Rhee et al., 
2000).  A number of other components of the cell have been proposed as being engaged in the 
adaptive process which has led to considerable controversy as no clear responsible cellular 
modification has been identified (Taylor and Fleming, 2001; Williams et al., 2001; Mizutani et 
al., 2005; Gintzler and Chakrabarti, 2008). 
B. In vitro studies to define the cellular basis of tolerance. It should be pointed out at 
the onset that many of the in vitro studies employ expression systems or relatively acute 
exposure to high concentrations to effect the adaptive change.  Therefore, it is not surprising that 
many of these studies have been evaluating the cellular mechanisms of desensitization as 
opposed to long term post-adaptive change that might occur as a result of extended exposure. In 
vitro studies using N18TG2 neuroblastoma cells co-expressing delta opioid and CB1 receptors 
demonstrate that the opioid and cannabinoid receptors present in these cells are coupled to 
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different isoforms of Gi proteins or isoforms and that their signaling pathways converge only at 
the level of adenylyl cyclase as evidenced by the additive effect on the [35S] GTPγS binding 
(Shapira et al., 1998). 
Studies using cultured cells have reported conflicting data on whether heterologous or 
homologous tolerance is expressed following chronic exposure to these agents. Studies in HEK-
293 cells co-transfected with DOR and CB1 receptors demonstrate the development of 
heterologous tolerance following exposure to an opioid agonist (etorphine) whereas chronic 
cannabinoid agonist (desacetyllevonantradol [DALN]) exposure precipitates homologous 
desensitization (Shapira et al., 2003). The asymmetric expression of heterologous desensitization 
was also accompanied by asymmetric heterologous receptor downregulation expressed as an 
etorphine induced a reduction in cannabinoid receptor abundance; DALN on the other hand 
failed to reduce the level of DOR.  In contrast, studies using the COS-7 cell line also transfected 
with DOR and CB1 receptors resulted in heterologous desensitization and heterologous receptor 
downregulation following chronic exposure to either desacetyllevonantradol (DALN) or 
etorphine (Shapira et al., 2003). Moreover, studies using cultured splenocytes also showed 
heterologous desensitization to cAMP inhibition following chronic exposure to either opioids or 
cannabinoids (Massi et al., 2003). These interactions between opioids and cannabinoids suggest 
that the diverse interplay between the two receptor systems might be influenced by the 
cell/tissue/model system employed and the parameter(s) assessed. The differential results may be 
due to different levels of enzymes or isoforms involved in the adaptive desensitization; namely 
beta-arrestin, G protein-coupled receptor kinase (GRK), PKA, PKC and other kinases. A number 
of investigators have suggested various components of the cell signaling pathways as candidates 
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for the cellular locus of tolerance, including the protein kinases, adenylyl cyclases, transcription 
factors and tyrosine kinases (Shapira et al., 1998; Shapira et al., 2003).   
5 hour exposure of excised guinea pig ileum to either an opioid or a cannabinoid ex vivo 
followed by assessment of the ability of various agents to inhibit neurogenic contractions in the 
longitudinal muscle/myenteric plexus (LM/MP) preparation, demonstrated the development of 
symmetrical heterologous tolerance (Basilico et al., 1999). However, no studies have been 
performed to determine whether the heterologous tolerance observed following in vitro opioid 
exposure in this LM/MP model can be extrapolated to an in vivo exposure model.  Other studies 
using a similar approach have demonstrated that chronic in vitro exposure to cannabinoid 
agonists leads to a reduction in cannabinoid responsiveness (Pertwee et al., 1993; Guagnini et al., 
2006).  However, it should be noted that the effects of cannabinoid receptor agonists in the 
LM/MP model system do not reverse so the loss of responsiveness to opioids after exposure 
could reflect a general reduction in responsiveness of the system.  
C. In vivo studies investigating the cellular basis of tolerance. Studies using intact 
animals have often reported conflicting results on the development of heterologous tolerance or 
changes in receptor population following chronic opioid or cannabinoid exposure. Heterologous 
tolerance, as evidenced by reduced responsiveness to the analgesic effect of ∆9-THC, was 
observed in morphine tolerant mice (Thorat and Bhargava, 1994). On the other hand, studies 
using rats observed an opposite effect i.e. analgesic hypersensitivity to ∆9-THC in morphine 
tolerant animals (Rubino et al., 1997). Furthermore, the effect of chronic opioid exposure on 
cannabinoid receptor population has provided varying results. Chronic morphine exposure has 
been reported to decrease CB1 receptor levels in the rat hippocampus (Vigano et al., 2003). In 
contrast, other investigators have observed an increase in receptor number in the caudate 
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putamen and limbic structures (Gonzalez et al., 2002). These discordant results may have been 
influenced by differences in the species used, the use of different doses and the different brain 
regions assessed. Interestingly, Cichewicz and Welch (2003) demonstrated that co-
administration of low doses of ∆9-THC and opioid agonist morphine does not result in the 
development of analgesic tolerance but in fact maintains high antinociception to both agonists 
without changing the level of MOR, KOR and DOR. Synergistic analgesia following concurrent 
use of cannabinoid and opioid agonists has also been reported (Welch and Eads, 1999; 
Cichewicz, 2004). In contrast, Smith et al. (1994) reported symmetrical heterologous tolerance 
between ∆9-THC and the KOR agonists U-50,488H and CI-977 in the mouse tail flick test 
following chronic treatment with a selective KOR (U-50,488H) agonist or ∆9-THC. 
The development of heterologous tolerance in the isolated LM/MP following chronic 
morphine exposure in vivo has been known for decades and was demonstrated to extend to both 
inhibitory agents and excitatory agents that did not employ the same signaling pathways 
(Goldstein and Schulz, 1973; Johnson et al., 1978; Taylor et al., 1988). The LM/MP neurons of 
morphine tolerant animals show a partial depolarization of the cell membrane potential 
(Leedham et al., 1991; Meng et al 1997) that has been proposed to account for the increased 
sensitivity to excitatory agents like K+ ions, 5-hydroxytryptamine and nicotine and reduced 
responsiveness to inhibitory agents like morphine, CADO and clonidine (Johnson et al, 1978; 
Schulz and Goldstein, 1973). It was further suggested that the partial depolarization may be 
associated with the observed reduced function of the Na+/K+-ATPase caused by a decreased 
expression of the alpha3 subunit isoform of the sodium pump (Kong et al., 1997; Biser et al., 
2001). However, no data have been published to date on the effect of chronic in vivo cannabinoid 
exposure on the sensitivity of the LM/MP to excitatory agents like nicotine, K+ and 5-
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hydroxytryptamine.  Such studies might be helpful in identifying the specific cellular 
mechanisms that need to be explored to define the cellular basis for tolerance.  
D. Effect on the endogenous system. Cannabinoid agonists have been shown to 
independently influence the levels of endogenous opioid receptor ligands. ∆9-THC and other 
endocannabinoids (except anandamide) have been shown to increase extracellular levels of 
dynorphin in the spinal cord thus enhancing KOR stimulation and analgesia (Mason et al., 1999; 
Welch and Eads, 1999). It has been proposed that cannabinoids may induce the release of 
endogenous opioids (Pugh et al., 1997; Welch and Eads, 1999; Houser et al., 2000).  This notion 
is supported by studies which have demonstrated that opioid receptor antagonists can block 
cannabinoid-induced antinociception in the tail-flick, hot plate and paw pressure tests 
(Manzanares et al., 1999). Furthermore, chronic ∆9-THC exposure has been shown to increase 
prodynorphin and proenkephalin gene expression in the rat spinal cord, and preopiomelanocortin 
gene expression in the arcuate nucleus (Corchero et al., 1997). An increase in proenkephalin 
mRNA in the rat ventro-medial nucleus of the hypothalamus and periaquaductal gray (PAG) has 
also been observed following chronic treatment  with ∆9-THC or methanandamide (Manzanares 
et al., 1998). Opioid exposure has also been reported to alter the levels of endocannabinoids; 
chronic morphine exposure reduced 2-arachidonoyl-glycerol (2-AG) levels without altering 
anandamide levels in several brain regions e.g. striatum, cortex, hippocampus, limbic area and 
hypothalamus (Vigano et al., 2003).  These data point to a complex interplay between the opioid 
and cannabinoid systems which poses a challenge for dissecting specific pathways involved in 
the development of tolerance to these agents. 
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VII. Methods of Assessing Cannabinoid and Opioid Tolerance 
1. Behavioral and Physiological Tests 
The development of tolerance to cannabinoids and opioids has been evaluated by 
measuring the following physiological effects: blood pressure depression, miotic effect and 
respiratory depression efficacy.  However, none of these systems have provided results as robust 
and reproducible as those that have been developed using the nociceptive, thermal regulatory and 
locomotor activities that are associated with the acute administration of both opioids and 
cannabinoids.  These three systems have been utilized substantially in the assessment of not only 
the acute actions but also as models against which to detect the development of tolerance 
following chronic treatment. 
A. Antinociception. This method assesses change in threshold required to elicit a 
response to noxious stimuli following a challenge dose of an analgesic agent. Several 
antinociceptive methods have been used e.g. tail flick, hot plate, paw pressure and radiant heat 
assays (Spina et al., 1998; McQuay, 1999). The tail flick test is generally regarded as a measure 
of spinal antinociception whereas the hot plate is thought to assess supraspinal analgesia 
(Manzanares, Corchero et al. 1999). The analgesic effect of opioids and cannabinoids is well 
documented in both acute and chronic models and the development of tolerance to the analgesic 
effect has been extensively studied using these model systems of antinociception (Spina et al., 
1998; McQuay, 1999). Pain transmission appears to be regulated by opioid and cannabinoid 
receptor activation in the following regions: periaquaductal grey, amygdala, raphe and the dorsal 
horn (Rang et al., 2007).   
B. Hypothermia. The hypothermic effect of opioids is receptor dependent and is affected 
by a variety of factors including ambient temperature, drug dose, level of restraint, and the 
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species or strain used (Baker and Meert, 2002).  Morphine exposure generally results in 
hyperthermia at warmer ambient temperatures and hypothermia at cooler ambient temperatures 
(Rosow et al., 1980; Handler et al., 1994). The hypothermic efficacy of opioids is also agonist 
dependent with morphine exhibiting a very shallow dose-response relationship compared to that 
of loperamide (Baker and Meert, 2002). The nature of the response also appears to be receptor 
dependent since MOR stimulation appears to induce hyperthermia whereas KOR precipitates 
hypothermia (Xin L et al., 1997). Opioid receptors located in the preoptic hypothalamus and 
nucleus accumbens (Baldino et al., 1980; Tseng et al., 1980) have been implicated in the 
development of the hypothermia, though peripheral MOR stimulation by loperamide, a selective 
agonist with limited blood brain barrier penetration, also produces substantial hypothermia 
(Smith et al., 2006).  
The hypothermic effect of cannabinoids has, in part, been attributed to the activation of 
CB1 in the preoptic anterior hypothalamus (Sim-Selley, 2003). Stereotaxic injection of the 
selective CB1 antagonist SR141617A into the preoptic anterior hypothalamus attenuates the 
hypothermic effect of WIN-55,212-2 in this brain region (Rawls et al., 2002). The development 
of tolerance to the hypothermic effect in cannabinoids is well documented in mice and rats and 
was one component of the cannabinoid tetrad that was originally proposed (Little et al., 1988; 
Rawls et al., 2002) to compare cannabinoid agonists.  However, few studies have been 
performed characterizing the temperature regulation impact of cannabinoids and opioids using 
the guinea pig.  Furthermore, the hypothermic response to cannabinoids appears to be much 
more robust and less variable than the hypothermic responses observed to opioids. 
C. Catalepsy and hypomotility. The cataleptic effect of cannabinoid and opioids is dose 
dependent and is mostly observed at higher doses. Catalepsy can be assessed using the ring test 
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described by Pertwee (1972) which measures the ability of an animal to remain motionless after 
being placed on “the ring” which consists of horizontal wire ring of 5.5 cm diameter that is 
attached at a point on its circumference to the top of a 16 cm stainless steel tube held vertically. 
The development of tolerance to this cataleptic effect of cannabinoid agonists has been reported 
to occur within 9 days after chronic exposure in mice (Bass and Martin, 2000). Reduced 
locomotor activity following acute administration of both cannabinoids and opioids is well 
documented; the hypomotility response to a drug can be assessed by placing an animal into 
activity cages where animal movement is measured by recording the total number of photocell 
beam interruptions (Wise et al., 2007). The latency for the development of tolerance to the 
hypomotility effect of cannabinoids is 1.5 days after initiation of drug exposure (Bass and 
Martin, 2000). Tolerance to the hypomotility effect morphine (10mg/kg) has also been reported 
following prolonged opioid exposure (Timar et al., 2005). 
2. Isolated Tissue and in vitro Tests 
A. Longitudinal muscle/myenteric plexus (LM/MP) preparation. The guinea pig 
LM/MP model system has been shown to be reliable and robust for the assessment of tolerance 
and dependence to a number of agents following chronic drug treatment (Rezvani et al., 1983; 
Taylor et al., 1988; Johnson and Fleming, 1989; Taylor and Fleming, 2001). The model was first 
characterized as a useful method to assess the acute actions of opioids by Paton et al. (1965) and 
was then later used by Goldstein and his associates (Schulz and Goldstein, 1973) as a model 
system to assess the development of tolerance following chronic opioid treatment. The LM/MP 
preparation assesses the impact of chronic treatment on the ability of an agonist to inhibit 
electrically induced neurogenic contractions of the smooth muscle.  In addition, this model 
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system is also easily employed to determine the ability of excitatory agents to induce a 
contraction and has been used to illustrate the development of supersensitivity to excitatory 
agents following chronic opioid treatment (Goldstein and Schulz, 1973; Johnson et al., 1978). 
Both cannabinoid and opioid agonists reduce intestinal peristaltic activity through activation of 
cannabinoid (CB1) or opioid receptors (KOR and MOR), respectively. Studies have shown that 
activation of these receptors results in the inhibition of acetylcholine release from the myenteric 
‘S’ neurons thus attenuating peristaltic activity (Coutts and Pertwee, 1997). The MOR and CB1 
receptors are found on the soma and reduce acetylcholine release by hyperpolarization and 
reduction in excitability while the KOR are located on the axon terminals and decrease 
acetylcholine release through inhibition of N-type voltage-sensitive calcium channels (Kojima et 
al., 1994).  To date, few studies have been conducted using this model system to assess the 
impact of chronic cannabinoid treatment on the sensitivity to excitatory agents or to characterize 
the nature of the tolerance that develops following chronic cannabinoid treatment 
B. Vas deferens model. The presence of MOR and CB1 receptors in the mouse vas 
deferens has been used effectively to assess the acute effects of opioid and cannabinoid agonists 
(Christopoulos et al., 2001; Pertwee et al., 2002). Activation of these receptors inhibits the 
excitability of the noradrenergic neurons in the tissue that are responsible for the production of 
smooth muscle contraction (Hughes et al., 1975; Pertwee et al., 1992). MOR and CB1 receptor 
agonists dose-dependently inhibit electrically induced neurogenic contractions of smooth 
muscles in these tissues (James et al., 1991). Thus, the mouse vas deferens has been employed as 
a model to assess the development of tolerance following chronic treatment by comparing the 
potency of agents to inhibit neurogenic contractions in a manner similar to that described for the 
ileum LM/MP preparation. 
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C. Cell line and expression system. HEK-293, COS-7 cell lines and Xenopus oocytes 
have been used to assess the development of tolerance to cannabinoids and opioids (Shapira et 
al., 2003). It should be pointed out that these systems require the transfection of receptors and/or 
the appropriate signaling partners in order to develop acute responsiveness to agonists which 
makes the system less realistic so that data generated from these studies needs to be interpreted 
carefully.  Tolerance can be assessed by comparing the ability of agonists to open GIRK 
channels, activate Ca2+ channels or reduce cAMP levels before and following opioid and 
cannabinoid agonist exposure. Since the expression systems are usually exposed to agonists over 
shorter periods of time using higher concentrations, these chronic exposure studies may be more 
utilitarian in evaluating the mechanisms underlying the development of desensitization rather 
than “tolerance”. 
VIII. Purpose of Current Study 
Data generated from studies investigating the characteristics and mechanisms of the 
development of opioid and cannabinoid tolerance have often been contradictory and ambiguous. 
This may be due, in part, to differences in the models used (tissues versus animal), the dosage 
regimen employed, and/or whether drug exposure is accomplished in vivo or in vitro. Therefore, 
in spite of the extensive investigation that has been done in this area, the precise nature and 
mechanism of the interactions between the opioid and cannabinoid systems and how those 
interactions impact upon the modifications in responsiveness following chronic treatment 
remains elusive. A clear consensus is yet to emerge regarding the mechanism(s) underlying the 
development of tolerance to opioids and cannabinoids individually and very few studies have 
evaluated how chronic exposure to agonists targeting one system affects sensitivity to agonists 
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targeting the other. Relatively few studies have compared the development of tolerance to the 
hypothermic, analgesic (antinociceptive) and ileum longitudinal muscle inhibitory effects of 
cannabinoids and opioids in the guinea pig. Advantages of the guinea pig include the fact that it 
exhibits closer anatomical, physiological, neurological and developmental similarities to the 
humans (Mansour et al., 1988; Bot et al., 1992). The guinea pig has also been used extensively as 
a model for studying gastro-intestinal and respiratory physiology, and assessment of opioid 
tolerance (Chavkin and Goldstein, 1984; Hunter et al., 1997; Gray et al., 2001).  
Based on the overlapping neuroanatomical localization of receptors and the comparable 
cellular signal transduction pathways that are involved in the acute actions, the candidate 
hypothesized that bidirectional heterologous tolerance to the hypothermic, analgesic and 
gastrointestinal inhibitory effects of these agents will develop following chronic exposure to 
cannabinoid or opioid receptor agonists. The candidate developed an experimental plan to 
address the hypothesis that tolerance may overlap between opioids and cannabinoids.  The 
experimental plan was based upon the following specific aims: (1) To compare and contrast the 
effect of chronic in vivo cannabinoid or opioid exposure on the sensitivity of the LM/MP to 
excitatory agents like nicotine; (2) To determine if chronic cannabinoid/opioid  exposure results 
in changes in the MOR and CB1 receptor abundance; (3) To evaluate the distribution of MOR 
and CB1 receptor expressing neurons in the terminal LM/MP and pre-optic hypothalamic area,; 
(4)To evaluate effect of chronic drug exposure on the development of tolerance to the analgesic 
and hypothermic effects of opioids and cannabinoids.  
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Table 1.1 Peripheral and central distribution of mu-, delta, and kappa-opioid receptor  
The table below shows the respective relative distribution of mu-, delta, and kappa-opioid 
receptor transcripts in peripheral and central tissues (Mansour et al., 1994; Wittert et al., 1996). 
. 
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 Mu-opioid receptor 
(µ) 
Kappa-opioid receptor 
(κ) 
Delta- opioid receptor 
(∆) 
CNS 
   
Spinal cord high high moderate 
Cerebral Cortex high high high 
Hypothalamus high high high 
Cerebellum moderate low - 
Thalamus high high - 
Raphe high high low 
PAG high high low 
Amygdala high low high 
 
   
PERIPHERY 
   
Stomach low   
Small intestine moderate moderate moderate 
Large intestine low low moderate 
Liver low - low 
Adrenal moderate low moderate 
Kidney  moderate low low 
Lung low low low 
Heart - Low/moderate low 
Endothelium - - - 
Spleen high Low/moderate low 
Synovium - - - 
Testis moderate low moderate 
Ovary  moderate low low 
Uterus moderate low low 
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Table 1.2 Peripheral and central distribution of CB1 and CB2 receptors  
The table below shows the respective relative distribution of CB1 and CB2 receptors in peripheral 
and central tissues (Mansour et al., 1994). 
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 Cannabinoid receptor 1 
(CB1) 
Cannabinoid receptor 1 
(CB2) 
CNS 
  
Hippocampus  high low 
Cerebellum high - 
Substantia nigra high low 
Nucleus accumbens high - 
Caudate high - 
Globus pallidus high - 
Olfactory regions high low 
Amygdala moderate - 
Medial hypothalamus moderate - 
Nucleus of the solitary tract low - 
Thalamus low - 
Brainstem low - 
Amygdala low - 
Raphe low - 
Dorsal horn of the spinal cord low - 
PAG moderate low 
 
  
PERIPHERY 
  
Gastrointestinal tract high - 
Vas deferens, bladder present - 
Uterine wall present - 
Spleen - present 
Thymus - present 
Tonsils - present 
Mast cells - Present 
Β-cells, natural killer cells 
monocytes 
- present 
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Figure1.1 Chemical structures of the cannabinoid receptor ligands ∆9-THC and WIN-55,212-2 
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Figure 1.2 Chemical structure of the opioid receptor ligand: Morphine  
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Figure 1.3 Common Signal Transduction Pathways Employed by Opioid and Cannabinoid 
Receptor Agonists 
Common cellular signal transduction pathways activated following opioid (mu- kappa- and 
delta) or cannabinoid (CB1 and CB2) receptor activation. 
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CHAPTER TWO: MATERIALS AND METHODS 
I. Chemicals and Drugs 
DAMGO ([D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate), WIN-55,212-2 [(R)-(+)-
[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
napthalenylmethanone], morphine (morphine sulfate pentahydrate salt), nicotine (nicotine 
hydrogen tartrate) and CADO (2-chloroadenosine) were procured from Sigma-Aldrich Co. (St. 
Louis, MO). For organ bath studies, solutions of DAMGO, morphine and CADO were made by 
dissolving their respective salts in distilled water while the lipid soluble agent, WIN-55,212-2, 
was first dissolved in a vehicle containing DMSO/normal saline (1:9) from which serial dilutions 
were made using normal saline. Parenterally administered morphine was dissolved in normal 
saline whereas WIN-55,212-2 was dissolved in a vehicle consisting of normal saline and 10% 
DMSO (v:v).  
II. Animals  
Dunkin-Hartley guinea pigs (Charles-River labs; Raleigh, NC) of either sex weighing 
200-450g were used in the study. The animals were housed two per cage with access to food and 
water ad libitum.  The guinea pigs were kept in the animal facility for one week to permit 
acclimation prior to initiation of the treatment.  All experimental procedures employing animals 
were reviewed and approved by the Institutional Animal Care and Use Committee of the Brody 
School of Medicine at East Carolina University and were conducted in accordance with the 
guidelines for the humane use of animals in research (NIH “Public Health Service Policy on 
Humane Care and Use of Laboratory Animals” [revised 2002]).  Every effort was made to 
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reduce the use of animals to the minimum number required to achieve sufficient statistical 
power. 
III. Drug Exposure/Administration Schedules.   
1. Morphine 7-day s.c. Administration Schedule 
Previous studies have demonstrated that chronic exposure to morphine via pellet 
implantation and s.c. injection produces tolerance to opioids and other agents that is qualitatively 
and quantitatively similar (Li et al., 2010).  The following dosing regimen was used for the 
morphine s.c 7-day exposure: day 1, 10mg/kg b.i.d.; day 2 and 3, 20mg/kg b.i.d.; days 4, 5 and 6, 
40mg/kg b.i.d; and day 7, 80mg/kg b.i.d. The drug was injected 12-hourly (10:00 a.m. and 10:00 
p.m.) and the animals were euthanized between 9 and 10 a.m. the following day after the last 
dose.  This protocol was based on one previously employed in guinea pigs to produce 
dependence (Mizutani et al., 2005) and has been employed in previous studies in this laboratory 
(Li et al., 2010). The animals were weighed daily prior to dosing and the appropriate dose given 
subcutaneously. The animals were also examined daily for signs of discomfort. The control 
animals were injected with the drug-free vehicle in a similar fashion. 
2. WIN-55,212-2 5-day i.p. Administration Schedule 
WIN-55,212-2 was administered intraperitoneally at a dose of 6mg per 100g body weight 
once daily for 5 consecutive days. The drug was injected at 10:00 a.m. and the animals were 
euthanized between 9 and 10 a.m. the following day after the last dose. The drug regimen was 
adapted from a previously used regimen (Spina et al., 1998) and was modified based upon 
preliminary experiments which determined that this time period of treatment was necessary for 
tolerance to be induced. The animals were weighed prior to dosing and examined daily for signs 
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discomfort. The control animals were injected with the drug-free vehicle in a similar dosing 
schedule.  
IV. Longitudinal Smooth Muscle-Myenteric Plexus (LM/MP) Model 
1. Longitudinal Smooth Muscle-Myenteric Plexus (LM/MP) Preparations  
The LM/MP from treated animals was removed and isolated as previously described by 
Taylor et al. (Taylor et al., 1988). Segments of the ileum were obtained from animals sacrificed 
by decapitation following isoflurane anesthesia. The abdomen was opened to expose the cecum. 
The 10 cm section of ileum closest to the cecum was removed and discarded, and 2-4 cm 
segments of ilea from the adjacent 10 cm of ileum were used to set the LM/MP preparations. The 
segments of ilea were threaded onto a glass rod and, using a cotton swab moistened with Krebs 
solution, the LM/MP carefully stripped tangentially from the point of mesenteric attachment 
until the muscle-nerve preparation was detached from the total area of the ileum (Fig 2.1).  
The resulting sheet of LM/MP was tied at each end with a fine thread, passed through 
platinum-ring electrodes and placed in a 10 ml organ bath containing Krebs buffer solution. One 
thread was tied to a PowerLab force transducer and the other fixed to a tissue holder. A basal 
tension of 1.0 g was set and isometric tension generated by the muscle was recorded using the 
PowerLab/Chart 5 computer program (AD Instruments, Colorado Springs, CO) through a 4 
channel power lab system using a 4 channel Quad bridge converter interface (AD instruments, 
Colorado Springs, CO).  
The tissues were maintained at 37oC in a physiological Krebs buffer solution bubbled 
continuously with a mixture of 95% O2/5% CO2 consisting of the following (in mM): NaCl 
(117), KCl (4.7), CaCl2 (2.5), KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 (25) and Dextrose (11.5). 
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Neurogenic contractions were elicited via electrical stimulation using supramaximal voltage 
delivered to the tissue through platinum-ring electrodes using a stimulation system consisting of 
a Grass S48 stimulator connected to the electrodes by a Med Lab Attenuator and Stimu-splitter. 
To ensure only nerve endings were stimulated, the following parameters were used: voltage 
(50V); impulse duration (<1msec); delay setting (zero); and frequency (0.1 Hz). Fig 2.2 shows a 
typical cumulative concentration response curve for 2-chloroadenosine on neurogenic 
contractions of the LM/MP. 
2. Measurement of LM/MP Sensitivity to Inhibitory Agents 
Following the equilibration period, the tissues were exposed to cumulatively increasing 
concentrations of the inhibitory drugs (final concentrations in the organ bath ranging between 1 
nM and 10 µM). Three 5 min washes followed by three 15 min washes with drug free Kreb’s 
solution were performed between concentration-response curves of different drugs permitted full 
recovery of the amplitude of neurogenic contractions. In each experiment, two LM/MP 
preparations from each test group of animals (i.e. placebo and drug-treated groups) were studied 
simultaneously and the responses of the tissues from the same animal averaged. The effect of 
each agonist on the amplitude of the neurogenic contractions was determined and calculated as 
percent inhibition from the original amplitude (Fig 2.3). Due to the highly lipophilic nature of the 
cannabinoid agonist, WIN-55,212-2, concentration-response curves for this agonist were always 
constructed last as neurogenic contractions following exposure to this agent did not recover in 
spite of numerous washes.  Each of the other agonists was alternated in sequence to reduce the 
impact of the sequence upon the calculated IC50 value. Geometric mean IC50 values are 
calculated and used for comparison among treatment groups for each agonist as previously 
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described (Taylor et al., 1988). Computer assisted analysis of each concentration-response curve 
using Sigmaplot® software (SPSS Inc.) was employed to determine the IC50. 
3. Measurement of LM/MP Sensitivity to a Stimulatory Agent 
The procedure outlined above was also used for experiments using nicotine with the only 
difference being the absence of electrical stimulation since nicotine elicited contractions by 
ganglionic stimulation of acetylcholine release. Nicotine (final bath concentrations ranging 
between 0.3 µM and 100 µM) was added in a non-cumulative manner with at least three 5 min 
washes performed before the next drug concentration was added. Responses were calculated in 
grams of tension or percent of the maximum contraction for that tissue. The values were used to 
determine the EC50 (i.e. concentration required to produce 50% of the maximum response) and to 
calculate the maximum tension produced by nicotine. Computer assisted analysis of each 
concentration-response curve using Sigmaplot® software (SPSS Inc.) was employed to 
determine the EC50. 
V. Receptor Protein Analysis  
1. Tissue Homogenization 
Western blotting was used to determine the MOR and CB1 receptor protein levels in the 
LM/MP. The LM/MP tissue prepared as outlined earlier was immediately snap frozen in liquid 
nitrogen then stored at -80oC pending homogenization at which time the tissue was thawed, 
weighed and placed in ice-cold protease inhibitor buffer (0.25 M sucrose, 10.0 mM EDTA, 4.08 
mM phenylmethylsulfonyl fluoride, 1mM 4-aminobenzamidine and 1 mg/ml bacitracin) and 
homogenized using a glass homogenizer (PowerGen 125; Fisher Scientific, Pittsburgh, PA). The 
homogenate was centrifuged at 14,000 rpm for 5 seconds and the supernatant used for analysis. 
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2. Protein Concentration Determination 
 Spectrophotometric protein determination was performed using a Pierce® BCA protein 
assay kit (Pierce Biotechnology, Rockford, Illinois).  Tissue homogenates or standard samples 
were mixed with Pierce® BCA reagent A/B solution and absorbance was measured in triplicate 
using the Synergy HT spectrophotometer (BiTek®, South Coast Metro, CA) at a wavelength of 
562 nm. The sample absorbance was calculated and protein concentrations extrapolated from a 
standard curve generated with data from serially diluted pre-determined standard samples of 
bovine serum albumin. 
3. Western Blotting 
For each protein of interest, preliminary immunoblot experiments were performed to 
verify the specificity of the primary antibodies employed and to optimize conditions of the 
appropriate range of protein, the optimal primary and secondary antibody concentrations for the 
immunoblot procedure. The Western blotting procedure is similar to that previously described 
(Biser et al., 2002). Homogenates containing 10 µg total protein were loaded on 10% precast 
Tris-HCl Ready gels (Bio-Rad Laboratories, Inc., Hercules, CA) and size fractionated via 
electrophoresis at 110 V using a Mini-PROTEAN II Cell (Bio-Rad Laboratories, Inc., Hercules, 
CA). The proteins were then transferred to nitrocellulose membranes presoaked in transfer buffer 
using a Trans-Blot SD semi-dry transfer cell (Bio-Rad Laboratories, Inc., Hercules, CA). After 
allowing the membrane to completely dry, it was prehybridized in pre-made Odyssey® blocking 
buffer (Li-Cor Biosciences, Lincoln, NE) for 3 h. The membrane was washed with phosphate 
buffered saline (PBS:  137 mM NaCl; 2.7 mM KCl; 10.1 mM Na2HPO4 and 1.8 mM KH2PO4) 
containing Tween 20 (0.1%) three times for 15 min, and incubated overnight with the primary 
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antibody. The following primary antibodies were used; mouse anti-glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (1:60,000 – Millipore, Burlington, MA), rabbit anti-MOR (1:2000 – 
Millipore, Burlington, MA) and rabbit anti-CB1 (1:200 – Cayman, Ann Arbor, MI). Following 
incubation, the blots were washed three times with PBS-T and incubated for 1 h with the 
appropriate secondary antibody obtained from Li-Cor® Biosciences (Lincoln, NE). The final 
blot was washed an additional three times in PBS to remove any excess secondary antibody 
before detection using the Odyssey® near-infrared imaging system (Li-Cor® Biosciences).  
VI. Immunofluorescence Assessment 
1. Tissue preparation 
A. Longitudinal muscle/myenteric plexus preparation. Ileum segments (1 cm) excised 
from the terminal ileum were placed in cold PBS solution and cut longitudinally along the 
mesenteric border. The sheet of tissue was then pinned on a dissecting plate containing Sylgard® 
with the mucosal side facing up. The tissues were incubated and fixed overnight in 4% 
paraformaldehyde. Following the overnight incubation, the paraformaldehyde was removed by 
rinsing the tissue with PBS. The mucosal and circular layers were removed using fine forceps 
under a microscope and the LM/MP immersed and stored in PBS containing 0.1% sodium azide 
at 4oC pending immunofluorescence probing. 
B. Preparation of brain sections for near-infrared and immunofluorescence 
imaging.  
Animal Perfusion and Tissue Fixing 
Guinea pigs were first weighed then anesthetized with Ketamine (85 mg/ml)/Xyalazine 
(15 mg/ml) administered via intraperitoneal injection (0.10 ml/100 g) body weight. The 
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anesthetic effect was checked after 3 – 5 min to determine whether the animal was non-
responsive to toe pinch. The procedure was performed by two people; one person held the animal 
in position and the other performed the dissection and perfusion. Once the animal had been 
positioned, an incision was made in the lower abdominal area then cut longitudinally along the 
midline towards the thoracic cavity to expose the heart. Once the thoracic cavity had been 
opened and heart exposed, an incision was made on the right atrium where the perfusate would 
exit. Cold PBS buffer was then transcardially perfused via the left ventricle using a 50 ml syringe 
with a 23G needle, until a clear perfusate exited of the right atrium. Once the PBS infusion was 
complete, a cold solution of 4% paraformaldehyde in PBS was injected into the left ventricle 
until the animal’s extremities became stiff. Thereafter, the head was decapitated and the brain 
carefully extracted from the skull. The brain was then immersed in 4% paraformaldehyde and 
stored overnight at 4oC. On the following day, the brain was transferred and stored in PBS 
containing 25% sucrose for at least 48 h pending sectioning. 
Brain Sectioning 
The sectioning of brain tissue was performed using the Leica VT1000S vibratome brain 
slicer (Leica Microsystems, Bannockburn, IL). First the brain was placed and aligned in the 
guinea pig brain matrix (Kent Scientific, Torrington, CT) where it was sliced in a coronal fashion 
at the -12.5 mm plane away from bregma to divide the cerebellum and the cerebrum (Fig 5.3). 
The cerebrum was further sliced into two sections by making a coronal section at the bregma as 
shown in Fig 5.3 The brain segments were then attached to the sample tray using super-glue and 
aligned to allow minimal movement of the blade during each sectioning pass. Sectioning of the 
brain was executed with the brain fully immersed in cold PBS. The resulting sections of 
approximately 40 µm thickness were immersed and stored in cold PBS containing 0.1% sodium 
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azide at 4oC pending immunofluorescence probing. A total of 13 distinct regions of the cerebrum 
were sectioned (Fig 5.6). 
2. Immunostaining Procedure 
A. LM/MP preparation for immunofluorescence imaging. The CB1 receptor was 
localized using a rabbit primary polyclonal antibody (Cayman, Ann Arbor, MI) directed against 
the C-terminus (1:50) and the secondary antibody was a donkey anti-rabbit FITC-conjugate 
(1:100 – Jackson Immunoresearch, Westgrove, PA). MOR was detected using a goat primary 
polyclonal antibody (Santa Cruz, Santa Cruz, CA) directed against the C-terminus (1:50) and the 
secondary antibody was a donkey anti-goat Cy5-conjugate (1:100 – Jackson Immunoresearch, 
Westgrove, PA). Prior to primary antibody incubation, the LM/MP tissues were blocked with 
donkey serum (10%) for 45 min. Dual-labeling experiments were performed with simultaneous 
incubation of antibodies targeting both MOR and CB1 receptors. The tissues were incubated 
overnight using the primary antibodies at 4°C. Following the overnight incubation, the tissues 
were washed with phosphate buffered saline (PBS) and then incubated for 4 h at room 
temperature in a mixture containing both FITC- and Cy5- conjugated secondary antibodies.  
Negative control experiments excluded the primary antibodies and these revealed negligible faint 
labeling due to non-specific binding of the secondary antibodies (Fig. 2.2).  
B. Coronal brain sections. 
Coronal sections for near-infrared imaging 
Initial studies involved attempting to outline general MOR and CB1 receptor distribution 
and visualize the anatomical landmark structures in the 13 coronal sections of the cerebrum (Fig. 
5.4). This was accomplished by tagging MOR and CB1 receptors with near-infrared secondary 
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antibodies. Following coronal sectioning of the guinea pig brain at the forementioned coronal 
planar co-ordinates (Table 5.1); the brain slices were incubated with near-infrared antibodies 
targeting the MOR and CB1 receptors. The CB1 receptor was localized using a rabbit primary 
polyclonal antibody directed against the C-terminus (1:50 – Cayman, Ann Arbor, MI) and the 
secondary antibody used was a goat anti-rabbit (1:5000 – Li-Cor Biosciences. Lincoln, NE). 
MOR was detected using a goat primary polyclonal antibody directed against the C-terminus 
(1:50 – Santa Cruz Biotechnology, Santa Cruz, CA) and the secondary antibody used was a 
donkey anti-goat (1:15000 – Li-Cor Biosciences. Lincoln, NE). The brain sections were first 
incubated in 0.1% Triton X-100 in PBS for 25 min followed by three 10 min washes with PBS. 
Prior to primary antibody incubation, the LM/MP tissues were blocked with donkey serum 
(10%) for 45 min and rinsed using PBS. Thereafter, the tissues were incubated overnight in a 
cocktail of anti-CB1 and anti-MOR primary antibodies in 2% BSA in PBS at 4°C. Following the 
overnight incubation, the tissues were washed with PBS and then incubated for 4 h in a mixture 
containing both secondary antibodies targeting MOR and CB1 receptors. Following incubation 
with the respective secondary antibodies, the LM/MP tissues were mounted on slides, allowed to 
dry in total darkness, and then coverslipped pending imaging. Near infra-red imaging of these 
slices was performed using the Odyssey imaging system (Li-Cor Biosciences. Lincoln, NE.  
Coronal section for immunofluorescence imaging 
The method used to localize the MOR, CB1 receptors and gonadotropin releasing 
hormone (GnRH) is identical to the one outlined above for the LM/MP. The concentrations of 
primary and secondary antibodies used for MOR and CB1 receptors are identical to those used 
for the LM/MP (see APPENDIX F). In addition, GnRH was used as a marker protein for the 
preoptic anterior hypothalamic neurons where the hormone is exclusively expressed. GnRH was 
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localized using a mouse primary polyclonal antibody directed against the C-terminus (1:500 
Santa Cruz Biotechnology, Santa Cruz, CA) and the secondary antibody used was a donkey anti-
mouse Cy3-conjugate (1:500 – Jackson Immunoresearch, West Grove, PA). The experiment 
assessed GnRH distribution in coronal sections 7, 8, 9, 10, 11 and 12 since these are 
anatomically relevant sections based on the location of the hypothalamus. Only the brain slices 
that displayed GnRH immunofluorescence were used for later triple labeling studies targeting the 
MOR, CB1 receptors and GnRH. Triple-labeling experiments were performed with simultaneous 
incubation of antibodies targeting GnRH (gonadotropin releasing hormone), MOR and CB1 
receptor populations. The tissues were incubated overnight using the primary antibodies at 4°C. 
Following the overnight incubation, the tissues are washed with phosphate buffered saline (PBS) 
and then incubated for 4 h at room temperature in a mixture containing FITC-, Cy5- and Cy3- 
conjugate secondary antibodies.   
3. Image Acquisition and Processing 
A. LM/MP preparation. A Zeiss® LSM 510 laser scanning confocal microscope and 
imaging system was used for image acquisition and processing. The donkey anti-rabbit Cy5-
conjugated antibody was excited at 633 nm, whereas the donkey anti-goat FITC-conjugated 
antibody was excited at 488 nm. In dual-labeling experiments, a composite image targeting both 
the FITC- and Cy5- conjugates was scanned so that the image could be merged or separated and 
analyzed offline. Fig 2.2 shows prototypical immunofluorescence images of the LM/MP. 
B. Coronal brain sections. Confocal imaging was performed as outlined above targeting 
FITC- (CB1), Cy5- (MOR) and Cy3-conjugated secondary antibodies. The donkey-anti-rabbit 
Cy5-conjugate was excited at wavelength 633 nm, whereas the donkey anti-goat FITC- and 
63 
 
donkey anti-mouse Cy3-conjugates were excited at wavelengths 488 nm and 550 nm 
respectively. In triple labeling experiments, a composite image targeting the FITC-, Cy3- and 
Cy5-conjugates was scanned simultaneously and could be separately analyzed offline. Co-
localization of MOR and CB1 receptors was analyzed in the hypothalamic neurons where GnRH 
was observed. 
4. Assessment of MOR and CB1 Receptor-Immunopositive Cells 
Qualitative analysis was used to determine the distribution pattern and extent of co-
localization of MOR and CB1 receptor positive neurons. Cells were considered to be 
immunopositive if they expressed visually detectable labeling. Immunopositive neurons with 
bright to faint labeling were analyzed, because the faint labeling could represent low protein 
expression in positively labeled cells. Zeiss® LSM software was used to capture the images and 
Image J® software was used to analyze the distribution and possible co-localization of MOR and 
CB1 receptor-immunopositive neurons, and was also employed to determine the density of 
immunopositive neurons. The density of immunopositive neurons was assessed by counting the 
number of immunopositive neurons in a manually circumscribed region of the myenteric ganglia 
(i.e. number of neurons/area of circumscribed region). The area of the circumscribed region was 
computed using Image J® software whereas the number of visually detectable immunopositive 
neurons was counted manually. Neurons expressing both receptor proteins were counted 
individually and converted to a density based upon the circumscribed area evaluated. The 
relative expression of co-localized was expressed as a percentage of the total population of 
neurons possessing both receptor proteins versus those neurons expressing either MOR or CB1 
receptor proteins only. 
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VII. Behavioral Tests 
1. Paw Withdrawal Test 
All animals were acclimated to the observation room for 1 h prior to assessment. Baseline 
paw pressure on both hind paws was measured prior to injecting the vehicle or drug. The paw 
pressure test consisted of gently holding the body of the guinea pig while the hind paw was 
exposed to increasing mechanical pressure (Fig 2.4) using the Randall-Selitto analgesimeter 
model 2500 (IITC Life Science, Woodland Hills, CA) . The digital paw pressure applicator tip 
was used to exert a force on the paw in a related fashion to the Randall and Selitto test of 
mechanical nociception (Randall and Selitto, 1957). The pressure was manually applied to the 
plantar surface of the hind paw using a cone-shaped pusher with a rounded tip as illustrated in 
Fig. 2.4. The force (measured in grams) at which the guinea pig withdrew its hind paw was 
defined as the paw pressure threshold. A cut-off was set at 600 g to prevent tissue damage. 
Antinociception was then assessed using the minimum pressure values required to elicit a 
withdrawal at a specific time period after vehicle or test drug administration. The mean pressure 
(in grams) required to elicit the withdrawal response was determined (+standard error of the 
mean (S.E.M.)) at the following time intervals following drug or vehicle administration: 0 
(baseline), 15, 30, 45, 60, 90 and 120 min. Antinociceptive activity was defined as an increase in 
the pressure required to elicit the withdrawal response.  Tolerance to the antinociceptive effect of 
an agonist was defined as a reduction in the antinociceptive effect of the challenge dose such that 
the maximum amount of pressure required to elicit a paw withdrawal was decreased. Challenge 
doses used were determined based on preliminary studies done to assess the optimum dose 
required to produce an adequate and quantifiable analgesic response.  The assessment intervals 
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were based on the latent time required to observe an effect, the approximate time of the 
maximum effect and the maximum duration of the effect. 
2. Hot Plate Analgesia Test 
The procedure used is similar to that previously described (Bannon and Malmberg, 
2007). Guinea pigs were brought to the testing room and allowed to acclimatize for 1 h prior to 
testing. The response to a thermal stimulus was measured using a hot plate analgesia meter (IITC 
Life Science, Woodland Hills, CA). Based on preliminary studies, it was determined that 
optimum results would be achieved if surface of the hot plate was heated to a constant 
temperature of 50oC. Once the animal was placed on the hot plate which is surrounded by a clear 
acrylic cage, a timer was activated and the latency to respond with either a paw lick or paw flick 
was measured by deactivating the timer when the response was observed. To prevent tissue 
damage, a cut-off point of 40 seconds was used if the guinea pig did not respond. Each animal 
was tested only once. 
3. Hypothermic Testing 
Assessment of rectal body temperature has been extensively used to monitor the acute 
actions of many drugs including the cannabinoids which produce a robust reduction in core 
temperature (Rawls et al., 2002).  The method employed was adapted that used by Spina et al. 
(1998). All measurements were made in a quiet room at an ambient temperature of 25oC. After a 
1 h period of acclimatization in the test room, body temperature was measured with a digital 
rectal thermometer inserted to a constant depth of 2.5 cm. Following thermometer insertion, a 15 
sec equilibration period was allowed to lapse before the temperature was recorded. The animal 
was gently held during temperature measurement but was unrestrained and allowed to move 
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freely at all other times. The rectal temperature was measured at the following time intervals post 
drug administration: 0 (baseline), 15, 30, 45, 60, 90 and 120 min. A baseline temperature was 
assessed twice prior to drug challenge. Though rectal temperature was measured in oF, these 
values were converted to oC in and results were expressed as the means + S.E.M of the ºC change 
from baseline temperature. 
VII. Data Analysis 
1. LM/MP Studies 
For the LM/MP organ bath experiments, the sensitivity of a group of tissues to an 
inhibitory agonist was determined by calculating the mean negative log of the concentration 
producing 50% inhibition of the electrically induced contraction (IC50 + SEM). Percent 
inhibition was calculated using the mean contraction height at the maximum inhibition following 
addition of a given concentration of agonist, divided by the average contraction height 1 min 
before exposure to the initial dose of that agonist. Differences in sensitivity to a given agonist 
between two groups of tissues (drug-treated vs. vehicle treated groups) were determined by 
comparing the geometric mean IC50 values and the mean ratio of geometric mean IC50 values 
(calculated as the mean antilog of the difference in IC50 values between the two groups). For 
nicotine stimulation experiments, the EC50 (i.e. the concentration of drug required to produce a 
contraction magnitude equal to 50% of the maximum contraction obtained in that tissue) and the 
maximal isometric tension developed were determined and compared. Analysis of the 
immunoblotting results was performed by comparing the receptor protein to GAPDH protein 
intensity ratios (i.e. MOR or CB1 receptor/GAPDH densitometric units) between the control and 
the test groups. Immunofluorescence images were analyzed to quantitatively determine the 
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density of neurons expressing MOR or CB1 receptor protein. The density of immunopositive 
neuron co-expressing both MOR and CB1 receptors was also assessed and further computed as a 
percent of MOR or CB1 receptor expressing neurons Significant differences between the test and 
control groups were determined using unpaired Student’s “t” test. Comparison of mean values 
between three or more groups was performed using one-way ANOVA followed by the 
appropriate post hoc test, usually Tukey’s test, with the probability level of ≤ 0.05 accepted as 
significantly different. 
2. Hypothermia and Analgesia Studies 
Student’s t-test for unpaired samples was used to analyze the maximum rectal 
temperature change and maximum analgesia thresholds.  Statistical analysis was performed for 
each time point. p value ≤ 0.05 considered as a statistically significant difference. 
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Figure 2.1 Anatomy of the different layers of the ileum 
Illustration depicting the layers of the ileum (Berne and Levi, 1988). The inner layer consists of 
the mucosal layer followed by the submucosal plexus and circular muscles. The outer layer 
comprises of the myenteric plexus and the longitudinal muscle. 
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Figure 2.2 Typical immunofluorescence images depicting MOR or CB1 receptor expressing 
neurons of the LM/MP stretch preparation: 
A: MOR-immunopositive neurons B: CB1 receptor-immunopositive neurons. C: negative control 
(primary antibodies excluded from the exposure) 
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Figure 2.3 Typical LM/MP tracing illustrating concentration dependent reduction in neurogenic 
contractions following cumulative exposure to 2-chloroadenosine 
Representative tracing showing the intrinsic efficacy of CADO on electrically-induced 
neurogenic contractions of the LM/MP preparation from the guinea pig ileum. The LM/MP 
tissue was exposed to cumulatively increasing concentrations of the inhibitory drug, 2-
chloroadenosine (final organ bath concentrations ranging between 1nM and 10µM). The effect of 
2-chloroadenosine on the amplitude of the neurogenic contractions was determined and 
calculated as percent inhibition from the original amplitude. The IC50 value was the 
concentration at which the tissue contraction falls to 50% of the initial amplitude. 
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Figure 2.4 Method for mechanical analgesia assessment (paw pressure test) 
A Randall-Selitto analgesimeter model 2500 (IITC Life Science, Woodland Hills, CA) used to 
assess the analgesic effects of agonists and the development of tolerance following chronic drug 
exposure. The digital paw pressure applicator tip is used to exert a force on the plantar surface of 
the hind paw in a fashion related to the Randall and Selitto test of mechanical nociception 
(Randall and Selitto, 1957). 
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CHAPTER THREE: COMPARISON OF THE CHARACTERISTICS OF TOLERANCE 
IN THE GUINEA PIG LONGITUDINAL MUSCLE/MYENTERIC PLEXUS 
PREPARATION AFTER CHRONIC IN VIVO EXPOSURE TO OPIOID VERSUS 
CANNABINOID RECEPTOR AGONISTS. 
I. Abstract 
Few studies have compared the nature of tolerance that develops following chronic 
opioid treatment with that which develops after chronic cannabinoid exposure in the same tissue 
and species. The degree and character of tolerance induced by 7 day exposure to morphine or 5 
day exposure to the cannabinoid receptor agonist, WIN-55,212-2, was examined by comparing 
the ability of DAMGO (MOR selective agonist), CADO (non-selective adenosine receptor 
agonist) and WIN-55,212-2 (non-selective cannabinoid receptor agonist) to inhibit neurogenic 
contractions of the longitudinal muscle/myenteric plexus (LM/MP) preparation and the ability of 
nicotine to elicit contractions in the LM/MP.  Chronic morphine treatment resulted in tolerance 
to all inhibitory agonists (rightward shift in IC50 values of 4-5-fold) and an increase in the 
responsiveness to the excitatory effect of nicotine while chronic WIN-55,212-2 exposure resulted 
in subsensitivity only to WIN-55,212-2. Chronic WIN-55,212-2 treatment significantly reduced 
CB1 receptor but not MOR protein abundance while chronic morphine treatment did not change 
either receptor protein level. Thus, in contrast to the heterologous tolerance that develops after 
opioid treatment, tolerance in the LM/MP following chronic in vivo WIN-55,212-2 exposure is 
associated with the development of homologous tolerance that is accompanied by a decrease in 
CB1 receptor abundance.  The heterologous tolerance observed following chronic morphine 
exposure suggests that the two receptor systems share a number of sites for convergence of 
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action that could serve as the cellular basis of tolerance. The data also suggests that the cellular 
basis of tolerance differs between the two systems. 
I. Introduction 
While opioids have been used as analgesics, anti-diarrheals, antitussives and in palliative 
care for many years, the conventional therapeutic use of cannabinoids and related agents in the 
treatment of glaucoma, muscle spasticity, obesity, cachexia, nausea and possibly as 
immunomodulatory agents has only just begun to emerge. The use of both cannabinoids and 
opioids has been associated with the rapid emergence of tolerance (Bass and Martin, 2000; 
Alvarez et al., 2002) resulting in a need for higher doses to achieve the same pharmacological 
effects. Tolerance to common pharmacological effects like analgesia, hypomotility, hypothermia 
and inhibition of gastrointestinal motility is well documented with these two agents (Martin et 
al., 2004; Bailey and Connor, 2005).  However, unlike the development of tolerance to the acute 
intestinal effects of opioids, there is little information from animal models regarding the 
development of tolerance to the acute gastrointestinal effects of cannabinoids in vivo (Pertwee et 
al., 1992; Basilico et al., 1999). Guagnini et al. (2006) have reported the development of 
tolerance in human intestinal tissue following ex vivo exposure to cannabinoids.  
There is a growing body of evidence pointing toward convergence and commonality of 
activity and cell signaling pathways between the two receptor systems that may act in concert to 
alter many of the pharmacological effects of each including the development of tolerance. 
Common cellular effects include: coupling through Gi/o proteins leading to inhibition of adenylyl 
cyclase (Howlett and Fleming, 1984); inactivation of N, P/Q, and R-type Ca2+ channels (Rhim 
and Miller, 1994; Howlett et al., 2002); activation of the MAPK pathway (Bouaboula et al., 
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1995); and activation of G protein-activated inwardly rectifying potassium (GIRK) channels 
(McAllister et al., 1999). There is also evidence of comparable distribution of cannabinoid and 
opioid receptors within the ileum, vas deferens, caudate-putamen, dorsal hippocampus, 
substantia nigra and hypothalamus (Rosow et al., 1980; Ross et al., 1998; Rawls et al., 2002). 
Cellular co-localization of cannabinoid and opioid receptors in both the central nervous system 
and peripheral neurons (Salio et al., 2001)may contribute to the closely related physiological and 
clinical effects (Manzanares et al., 1999) including dependence and tolerance (Lichtman and 
Martin, 2005). The nature of tolerance, whether homologous (i.e. reduced responsiveness limited 
to agonists employing the same receptor or signaling pathway) or heterologous (i.e. adaptive 
alterations in responsiveness that extend to agents using different receptor and/or signaling 
pathways), can be characterized by the specificity of changes in responsiveness. The character of 
the tolerance also provides information regarding the most likely cellular and molecular adaptive 
changes that occur to account for the altered responsiveness. Homologous tolerance is mainly 
associated with receptor-dependent modifications such as receptor uncoupling from G proteins, 
receptor downregulation through internalization and degradation, or changes in the common 
components of the cell signaling pathway.  In contrast to this type of tolerance that develops 
mostly within hours/days, the heterologous form of tolerance develops over much longer time 
periods (days/weeks) and is often characterized by non-receptor dependent modifications in cell 
function (Taylor and Fleming 2001). 
Chronic exposure to opioids and cannabinoids has been shown to result in adaptive 
alterations in adenylyl cyclase and the enzyme’s coupling to G proteins which may alter the 
responsiveness of agonists for other receptors coupled through Gi/o proteins such as cannabinoids 
(Nestler, 1993; Rhee et al., 2000; Gintzler and Chakrabarti, 2006). Cannabinoid tolerance has 
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been suggested to be dependent on protein kinase A (PKA), Src kinase (Lee et al., 2003) and also 
nitric oxide (Spina et al., 1998) whereas development of opioid tolerance has been suggested to 
be dependent on protein kinase A (Nestler, 2001; Gintzler and Chakrabarti, 2008), protein kinase 
C, and is associated with a decrease in the abundance of the alpha3 subunit of the sodium pump 
(Taylor and Fleming, 2001). Several laboratories have demonstrated development of 
heterologous tolerance in the LM/MP following chronic exposure to morphine  (Johnson et al., 
1978; Taylor et al., 1988). Electrophysiological assessment of the LM/MP neurons of morphine 
tolerant animals shows a partial depolarization of the cell membrane potential (Leedham et al., 
1992; Meng et al., 1997) that accounts for the increased sensitivity to excitatory agents like K+ 
ions, 5-hydroxytryptamine and nicotine and reduced responsiveness to inhibitory agents like 
morphine, CADO and clonidine (Schulz and Goldstein, 1973; Johnson et al., 1978). Later studies 
tied the partial depolarization to a reduction in the function of the Na+/K+-ATPase caused by 
decreased expression of its alpha3 subunit isoform (Biser et al., 2002; Li et al., 2010). However, 
despite extensive research, no data have been published on the effect of chronic in vivo 
cannabinoid exposure on the sensitivity to excitatory agents like nicotine, K+ and 5-
hydroxytryptamine. Homologous tolerance among cannabinoid receptor agonists, namely ∆9-
THC, CP-55,940 and WIN-55,212-2 has been reported in the guinea pig ileum (Fan et al., 1994). 
Studies using in vitro exposure of the LM/MP preparation to opioid and cannabinoid agonists 
have reported the development of heterologous tolerance extending to both cannabinoid and 
opioid agonists (Pertwee et al., 1992; Guagnini et al., 2006) but no studies have assessed whether 
this type of change in response also occurs following in vivo exposure. Investigations using 
intact animals have reported conflicting and often discordant results on changes in receptor 
abundance following chronic opioid or cannabinoid exposure. Chronic opioid exposure has been 
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illustrated to decrease CB1 receptor levels in the rat hippocampus (Vigano et al., 2003) or evoke 
an increase in the caudate putamen and limbic structures, whereas other labs have reported no 
significant change (Thorat and Bhargava, 1994). The varying results may have been influenced 
by differences in the species used, doses and brain regions assessed. However, no studies have 
assessed the effect of chronic in vivo exposure to either opioids or cannabinoids on both MOR 
and CB1 receptor protein in the LM/MP. 
The guinea pig LM/MP model is a reliable, robust in vitro model for evaluating the 
development of both tolerance and dependence (Rezvani et al., 1983; Johnson and Fleming, 
1989). Activation of both cannabinoid (CB1) and opioid (kappa- and mu-) receptors attenuates 
ileal intestinal peristaltic activity. CB1 and mu-opioid receptors (MOR) are located on the soma 
and reduce transmitter release by hyperpolarization-mediated reduction in excitability while 
kappa opioid receptors, located on the axon terminals, decrease acetylcholine release by 
inhibiting calcium influx into the nerve terminal (Kojima et al., 1994; Coutts and Pertwee, 1997). 
The present study investigated the changes in LM/MP sensitivity to inhibitory agents (WIN-
55,212-2 [non-selective cannabinoid receptor agonist], DAMGO [selective MOR agonist] and 2-
chloroadenosine (CADO) [adenosine receptor agonist]) and an excitatory agent (nicotine) 
following chronic in vivo treatment with morphine or WIN-55,212-2. CADO was included 
because previous studies suggested that it hyperpolarized ‘S’ neurons and produced inhibition of 
neurogenic contractions through a mechanism different from that of morphine (Meng et al., 
1997). Assessment and comparison of the effect of chronic in-vivo opioid versus cannabinoid 
exposure on LM/MP sensitivity to nicotine and CADO would also provide insight into the 
possible mechanisms that may contribute to the development of tolerance.  
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Studies using in vitro exposure of the LM/MP preparation to opioid and cannabinoid 
agonists have reported the development of heterologous tolerance extending to both cannabinoid 
and opioid agonists (Pertwee et al., 1992; Basilico et al., 1999; Guagnini et al., 2006) but no 
studies have assessed whether this type of change in response occurs following in vivo exposure 
or whether in vivo exposure to either agonist alters CB1 receptor and/or MOR protein abundance 
in the LM/MP. Based upon previous reports on the development of symmetrical heterologous 
tolerance in the LM/MP ex vitro exposure model (Basilico et al., 1999), it was hypothesized that 
qualitatively similar tolerance will develop following in vivo drug exposure. Since previous 
studies have demonstrated that CB1 receptor activation results in a significant degree of  CB1 
receptor internalization (Sim et al., 1996; Sim-Selley et al., 2000) whereas morphine displays 
cellular desensitization with low MOR internalization (Johnson et al., 2006), we further 
hypothesize that the tolerance induced by CB1 receptor activation will be associated with 
receptor level changes whereas chronic morphine exposure will not induce changes in receptor 
protein levels. In light of the controversies, conflicts and limited data comparing the 
development of tolerance following chronic in vivo opioid or cannabinoid exposure, the 
candidate set out to determine whether chronic in vivo exposure to opioids or cannabinoids 
would: (1) result in the development of heterologous tolerance; (2) lead to an increase in 
responsiveness to nicotine; (3) produce changes in CB1 receptor or MOR protein abundance. 
The candidate predicts the development of symmetrical heterologous tolerance following chronic 
exposure to either opioid or cannabinoid receptor agonists. The tolerance induced by 
cannabinoid exposure is anticipated to involve changes in receptor abundance whereas opioid 
exposure will result in non-specific subsensitivity with no changes in receptor protein. 
82 
 
II. Experimental Protocol 
1. Longitudinal smooth muscle/myenteric plexus (LM/MP) preparations  
In the present study, guinea pigs were subjected chronic exposure to morphine or WIN-
55,212-2 in an effort to induce the development of tolerance. The WIN-55,212-2 drug regimen 
was adopted from previously used regimens (Spina, Trovati et al. 1998) and was modified 
following preliminary experiments performed to determine when tolerance is induced The 
following dosing regimen was used for the morphine s.c 7-day exposure: day 1, 10mg/kg b.i.d.; 
day 2 and 3, 20mg/kg b.i.d.; days 4-6, 40mg/kg b.i.d; and day 7, 80mg/kg b.i.d (Table 3.1). This 
protocol was based on one previously employed in the guinea pig to produce dependence 
(Mizutani, Arvidsson et al. 2005).  Morphine was injected 12-hourly (10:00 a.m. and 10:00 p.m.) 
and WIN -55,212-2 was administered intraperitoneally once daily (10:00 a.m.) for 5 days. The 
drugs were administered in the animal housing facility where guinea pigs were given free access 
to food and water. On the day of the experiment, following the chronic drug exposure, the guinea 
pigs were euthanized and the terminal ileum excised.   
The organ bath assays were performed following chronic drug exposure (in vivo or in 
vitro).  Assessment of tolerance to inhibitory agents (WIN-55,212-2, CADO and morphine) in 
the LM/MP preparation involved determination of cumulative doses of the drug required to 
inhibit neurogenic contraction by 50%. In addition the experiments also assessed the effect of 
chronic WIN-55,212-2 or morphine treatment on the sensitivity of the LM/MP preparation to 
nicotine. The values were used to determine the EC50 (i.e. concentration required to produce 50% 
of the maximum response) and to calculate the maximum tension produced by nicotine. 
Statistical analysis of the data was done using the student t-test on the IC50 (concentration 
required to inhibit neurogenic twitches to 50% of initial) and EC50 (concentration required to 
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induce 50% of maximum LM/MP tissue contraction) values. Significant differences between the 
test and control groups were determined using unpaired Student’s “t” test. Comparison of mean 
values between three or more groups was performed using one-way ANOVA followed by the 
appropriate post hoc test, usually Tukey’s test, with the probability level of ≤ 0.05 accepted as 
significantly different.. 
2. Receptor Protein Analysis  
The Western blotting procedure is similar to that previously described (Biser et al., 2002).  
Homogenates were loaded on 10% precast Tris-HCl Ready gels (Bio-Rad Laboratories, Inc., 
Hercules, CA) and size fractionated via electrophoresis at 110 V using a Mini-PROTEAN II Cell 
(Bio-Rad Laboratories, Inc., Hercules, CA). The proteins were then transferred to nitrocellulose 
membranes presoaked in transfer buffer using a Trans-Blot SD semi-dry transfer cell (Bio-Rad 
Laboratories, Inc., Hercules, CA).  After allowing the membrane to completely dry, it was 
prehybridized in pre-made Odyssey® blocking buffer (Li-Cor Biosciences, Lincoln, NE) for 3 h. 
The membrane was washed with phosphate buffered saline (PBS) containing Tween 20 (0.1%) 
three times (15 min/wash) and incubated overnight with the primary antibody. The following 
primary antibodies were used; mouse anti-GAPDH (1:60,000), rabbit anti-MOR (1:2000) and 
rabbit anti-CB1 (1:200). Following incubation, the blots were washed three times with PBS-T 
and incubated for 1 h with the appropriate secondary antibody obtained from Li-Cor® 
Biosciences (Lincoln, NE).  The final blot was washed an additional three times in PBS to 
remove any excess secondary antibody before detection using the Odyssey® near-infrared 
imaging system (Li-Cor® Biosciences).  
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IV. Results 
1. LM/MP organ bath assay 
Treatment for 7-days with morphine resulted in the development of subsensitivity to 2-
chloroadenosine (CADO), DAMGO and WIN-55,212-2, suggesting that the heterologous 
tolerance previously reported extends to cannabinoid agonists as well. As illustrated in Fig 3.2, 
concentration-response curves showed a significant rightward shift for all agonists and 
comparison of the calculated IC50 values of the morphine and vehicle treated groups revealed a 
significant reduction in responsiveness as indicated by the significantly lower IC50 values: 
DAMGO, 6.8 vs. 7.5 (p < 0.05); CADO, 6.6 vs. 7.1 (p < 0.05); WIN-55,212-2, 7.5 vs. 8.2 (p < 
0.05). The calculated magnitude of rightward shift (i.e. ratio of mean IC50 values) or loss of 
sensitivity of the treated compared to the control group was 4.8-fold for DAMGO, 3.5-fold for 
CADO, and 5.2-fold for WIN-55,212-2. The calculated mean ratio of IC50 values (based on the 
determined geometric mean IC50 values for each group) for tissues obtained from animals that 
received morphine compared to the control group was not significantly different among the three 
agonists hence the degree of tolerance development was quantitatively comparable (F (2, 5) = 
1.07, p = 0.37). In addition, analysis of the maximum inhibitory effect for each of the agonists 
between the control and morphine-treated groups did not show any statistically significant 
difference in the magnitude of the maximum inhibitory response for DAMGO and CADO. 
However, chronic treatment with morphine did lead to a significant reduction (23%; p < 0.05) in 
the maximum response to WIN-55,212-2. 
As illustrated in the concentration-response curves presented in Fig 3.1, 5-day treatment 
with WIN-55,212-2 resulted in a reduction in sensitivity to WIN-55,212-2 only as shown by the 
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IC50 values for the WIN-55,212-2 and vehicle groups: DAMGO, 7.67 vs. 7.73 (p > 0.05); 
CADO, 7.2 vs. 7.3 (p > 0.05); WIN-55,212-2, 7.3 vs. 8.3 (p < 0.05). Data calculated from Fig 2 
revealed that the magnitude of rightward shift in the concentration-response curve (i.e. ratio of 
mean IC50 values) was 1.3-fold for CADO, 1.1-fold for DAMGO and 9.8-fold for WIN-55,212-
2. The rightward shift of the IC50 values was only significantly different for WIN-55,212-2, 
suggesting that homologous tolerance had developed in the LM/MP preparation following 
chronic in vivo cannabinoid treatment. Analysis of the maximum inhibitory effect revealed a 
statistically significant reduction (25%; p < 0.05) in the maximum inhibition of neurogenic 
contractions produced by WIN-55,212-2 in tissues obtained from animals chronically treated 
with WIN-55,212-2. Interestingly, a small but significant reduction (11%; p < 0.05) in the 
maximum inhibitory response to DAMGO was also observed in those same tissues obtained 
from animals chronically treated with cannabinoid agonist. In contrast, chronic cannabinoid 
treatment produced no significant change in the maximum inhibitory response obtained to 
CADO in the same tissues. The impact of chronic drug treatment on the response of the LM/MP 
to nicotine, illustrated in Fig 3.3, revealed no statistically significant difference in the nicotine 
EC50 values following either chronic morphine  (treated, 5.32 vs. vehicle, 5.45; p > 0.05) or 
WIN-55,212-2 treatment (treated, 4.98 vs. vehicle, 5.34; p > 0.05). However, chronic morphine 
treatment (treated, 3.7 g vs. vehicle, 2.44 g; p < 0.05) but not WIN-55,212-2 treatment (treated, 
2.73 g vs. vehicle, 2.68 g; p > 0.05) produced a significant increase the magnitude of the 
maximum contractions produced by nicotine (Table 3.2). 
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2. MOR and CB1 receptor protein abundance assessment 
In light of the fact that chronic agonist exposure often results in receptor downregulation, 
we assessed whether the treatments had any effect on receptor protein levels. Fig 3.4 shows 
results of Western blot analyses performed to assess possible changes in the MOR and CB1 
receptor protein abundance following chronic opioid or cannabinoid exposure. Quantitative 
analysis involved comparison of the specific receptor protein to GAPDH intensity ratios (MOR 
or CB1 receptor/GAPDH densitometric units) between the control and the test groups. CB1 
receptor protein analysis showed a statistically significant reduction in receptor protein 
abundance in homogenates from tissues obtained from the WIN-55,212-2 treated group 
compared to the control (Fig 3.4A) as indicated by a 32% (p < 0.05) lower CB1 receptor/GAPDH 
intensity ratio. In contrast, no statistically significant difference was observed in the 
MOR/GAPDH intensity ratios between the control and WIN-55,212-2 treated groups. As 
illustrated in Fig 3.4B, 7-day morphine treatment did not alter either MOR or CB1 receptor 
protein abundance. For both treatments, no statistically significant difference was observed in the 
GAPDH levels between control and drug-treated tissue homogenates thus implying that the total 
cellular protein levels remained relatively constant. 
V. Discussion 
Based upon the similarity of cellular, physiological and pharmacological effects of cannabinoids 
and opioids, and the conflicting results regarding the character of tolerance that develops 
following chronic exposure, experiments were conducted to determine whether parenteral in vivo 
exposure to either opioids or cannabinoids results in the development of tolerance that is 
qualitatively similar. In order to assess potential cellular mechanisms, the candidate also sought 
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to determine the LM/MP sensitivity and responsiveness to excitatory agents like nicotine 
following chronic drug treatment. Since we hypothesized that chronic treatment with 
cannabinoids or opioids could evoke receptor-dependent changes in cells, we investigated the 
impact of chronic opioid or cannabinoid exposure on both the MOR and CB1 receptor protein 
abundance.  The present study found important qualitative similarities of the tolerance that 
develops following chronic 7-day morphine exposure with that previously reported in both in 
vivo and in vitro exposure studies (Taylor et al., 1988; Basilico et al., 1999; Li et al., 2010). 
However, the qualitative nature of the change in sensitivity to a limited number of agents 
observed following chronic WIN-55,212-2 treatment appears to contrast with that previously 
observed in morphine tolerant animals which exhibit subsensitivity to a variety LM/MP 
inhibitory agents and increased responsiveness to excitatory agents like nicotine (Schulz and 
Goldstein, 1973; Johnson et al., 1978).  This difference in the character of the tolerance could 
have important implications for defining the potential mechanisms that underlie the development 
of the phenomenon in the guinea pig and could provide an avenue to explore the combinatorial 
use of these agents therapeutically. 
The development of heterologous tolerance following chronic in vivo exposure to 
morphine is consistent with previously reported data that have shown tolerance to develop 
between 1 and 4 days of exposure, become maximal by day 7 and remain for several days 
beyond that (Taylor et al., 1988; Li et al., 2010).  However, these are the first studies to examine 
the question of whether the heterologous subsensitivity observed following chronic in vivo 
opioid exposure extended to the cannabinoid receptor agonist, WIN-55,212-2, in the LM/MP 
model.  The observed subsensitivity to WIN-55,212-2 substantiates previous studies using the 
LM/MP that revealed similar heterologous tolerance following chronic in vitro exposure to 
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opioids (Basilico et al., 1999). However, the change in responsiveness was accompanied by a 
significant reduction in the maximum response suggesting that there may also be a change in 
efficacy (Stephenson, 1956).  Since opioids and cannabinoids employ comparable signaling 
pathways, shared components of these pathways offer some sites at which adaptive changes 
could occur.  However, the basis for the difference in efficacy could also reside in the receptor 
reserve that is present for each receptor family. As demonstrated in these studies, chronic 
morphine treatment did not alter the abundance of either MOR or CB1 receptor protein; this is 
consistent with the maintenance of the maximal inhibitory effect of DAMGO, and suggests that a 
non-receptor dependent adaptive mechanism is, at least in part, responsible for the development 
of tolerance.  Furthermore, the inability of chronic morphine exposure to reduce MOR protein or 
the maximal effect of DAMGO is consistent with previous studies showing that morphine has a 
low capacity to induce MOR internalization and downregulation (Johnson et al., 2006) and 
supports the fact that the mu-opioid receptor reserve approaches ~90 % the LM/MP (Chavkin 
and Goldstein, 1984). The lab has previously proposed that the non-receptor dependent changes 
underlying the heterologous tolerance involve a partial depolarization of the resting membrane 
potential (Meng et al., 1997) secondary to a reduction in the level of the functional alpha3 subunit 
of Na+/ K+-ATPase  (Kong et al., 1997; Biser et al., 2002; Li et al., 2010). The alteration in the 
membrane potential ultimately accounts for the reduced sensitivity to inhibitory agents (e.g. 
DAMGO, CADO and WIN-55,212-2) and the enhanced responsiveness to excitatory agents like 
nicotine. The reduction in WIN-55,212-2 maximal response could also have been caused by a 
non-receptor mediated change since the cannabinoid system in the LM/MP appears to have a low 
functional reserve susceptible to chronic drug exposure (Basilico et al., 1999; Guagnini et al., 
2006). The fact that CADO appears to inhibit neurogenic activity through a cellular mechanism 
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different from that of morphine (Meng et al., 1997) and WIN-55,212-2 (Coutts and Pertwee, 
1997) suggests that the adaptation events precipitated by chronic morphine exposure must 
involve some alteration in basic cellular function.   
In contrast to chronic opioid exposure, chronic in vivo cannabinoid exposure resulted in 
the development of homologous tolerance that was expressed as a loss of sensitivity to WIN-
55,212-2 only as evidenced by a 9.8-fold rightward shift of the concentration-response curve. 
Interestingly, the maximum responses to both WIN-55,212-2 and DAMGO but not CADO were 
also significantly decreased.  However, the reduction in maximal effect was significantly greater 
for WIN-55,212-2 than DAMGO and was associated with a selective reduction in the CB1 
receptor protein abundance that would account in part for the decrease in maxima. The fact that 
the percent reduction in CB1 receptor protein levels was relatively proportionate to the reduction 
in maximal effect of WIN-55,212-2 (32% vs. 25% respectively) further reinforces the idea that 
the CB1 receptor system in the LM/MP may possess a low functional receptor reserve as 
observed following in vitro exposure (Basilico et al., 1999; Guagnini et al., 2006). The reduction 
in CB1 receptor protein abundance is consistent with previous studies which demonstrated robust 
cannabinoid receptor downregulation that occurs through beta-arrestin mediated desensitization, 
internalization and ultimately degradation (Gonzalez et al., 2005). The tolerance induced by 
chronic in vivo cannabinoid exposure mediated by CB1 receptor activation may involve at least 
two components; one related exclusively to CB1 receptor downregulation (receptor-dependent 
and specific) and another possibly through dual internalization of CB1 receptors and MOR as 
heterodimers (receptor-dependent but non-specific). Studies have reported heterodimerization of 
MOR and CB1 receptors resulting in signaling through common G proteins (Hojo et al., 2008). 
Receptor heterodimerization has also been reported to result in co-internalization of MOR and 
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other G protein-coupled receptors (e.g. somatostatin receptors) and has also been reported to 
result in receptor desensitization (Pfeiffer et al., 2003). Internalization or uncoupling of 
MOR/CB1 receptor heterodimers following chronic CB1 receptor activation would also result in 
as small a reduction in the apparent functional efficacy of MOR as the heterodimers contributed 
to the total receptor population. The possibility also exists that the lack of correlation between 
the change in responsiveness and receptor protein abundance might not be physiologically 
relevant.   
The absence of increased responsiveness to the excitatory effect of nicotine after chronic 
cannabinoid exposure contrasts to the elevated responsiveness observed in morphine tolerant 
animals (Schulz and Goldstein, 1973; Johnson et al., 1978) and the enhanced maximum response 
observed in these studies.  Since opioid-induced supersensitivity is thought to be associated with 
a partial depolarization of the resting cell membrane potential (Meng et al., 1997), this could 
imply that chronic cannabinoid treatment does not alter the cell resting membrane potential of 
neurons in the LM/MP model. Furthermore, it could signify that cannabinoid exposure may not 
alter Na+/K+ ATPase isoform expression or function, a proposed key facet in the maintenance of 
the resting membrane potential, as observed following chronic opioid exposure (Biser et al., 
2002). Previous studies assessing the development of tolerance have reported conflicting data on 
the interactions between opioids and cannabinoids suggesting that the diverse interplay between 
the two receptor systems could be influenced by the cell/tissue/model system employed and the 
parameter(s) assessed. The differential results may be due to different levels of enzymes or 
isoforms involved in the adaptive desensitization; namely adenylyl cyclase, beta-arrestin, G 
protein-coupled receptor kinase (GRK), PKA, PKC and other kinases ((Bloom and Dewey, 
1978; Hine, 1985; Smith et al., 1994; Thorat and Bhargava, 1994)   
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It is concluded that the type and nature of tolerance exhibited in the guinea pig LM/MP 
model following chronic in vivo WIN-55,212-2 treatment is qualitatively and mechanistically 
different from that observed following chronic morphine exposure despite the large number of 
similarities between the two systems. The data presented in this study provide support for the 
concept that the development of tolerance is a function of several converging influences and is 
subject to considerable variation that may impact upon the cellular processes that are employed 
to elicit the adaptive response (Taylor and Fleming, 2001). The fact that cannabinoid treatment 
produces tolerance that is primarily homologous in nature compared to the heterologous form of 
tolerance associated with chronic opioid exposure provides an important foundation upon which 
to develop mechanistic studies.  Furthermore, the data raise the possibility that such differences 
in adaptive responses to these agents could be employed to lead to modification in the 
therapeutic management of patients with these agents. 
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Table 3.1 Schedule for morphine subcutaneous injection  
Dose escalation schedule for parenteral (subcutaneous) administration of morphine for 7 days.  
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Day Morphine dose (mg/kg body weight) 
 
10:00  a.m. 10:00 p.m. 
1 10 10 
2 20 20 
3 20 20 
4 40 40 
5 40 40 
6 40 40 
7 80 80 
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Table 3.2 Geometric mean IC50 and maximal efficacy values for the inhibitory effect of WIN-
55,212-2, DAMGO and CADO following 7-day treatment with morphine or 5-day treatment 
with WIN-55,212-2.  
The geometric mean IC50 values for agonists (the agonist concentration required to reduce the 
amplitude of the neurogenic twitch of the LM/MP to 50% of its initial value) are displayed as -
log M (± S.E.M.). The maximal efficacy depicts the % inhibition at the highest agonist 
concentration.  Statistically significant differences (p≤ 0.05) are identified by *.  The N values 
for the experimental sets are between 6 and 13. 
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Experimental 
Treatment 
Agonist 
WIN-55,212-2  DAMGO  CADO  
Control Test Mean 
Ratio of 
IC50 
Control Test Mean 
Ratio of 
IC50 
Control Test Mean 
Ratio of 
IC50 
Morphine vs. 
Control - IC50 
(-log M ± S.E.M.) 
8.23 
(±0.18) 
7.52 
(±0.2) 
5.16* 
(±2.0) 
7.51 
(±0.21) 
6.83 
(±0.2) 
4.8* 
(±4.1) 
7.12 
(±0.13) 
6.58 
(±0.1) 
3.5* 
(±0.9) 
Maximal efficacy 
(% Inhibition) 
97.32 
(±4.3) 
73.87* 
(±4.8)  
86.55 
(±5.6) 
76.06 
(±5.7)  
95.87 
(±2.7) 
88.17 
(±2.6)  
WIN-55,212 vs. 
Control - IC50 
(-log M ± S.E.M.) 
8.32 
(±0.18) 
7.33 
(±0.15) 
9.77* 
(+12.7) 
7.73 
(±0.08) 
7.67 
(±0.05) 
1.1 
(±0.41) 
7.29 
(±0.05) 
7.17 
(±0.05) 
1.3  
(±0.4) 
Maximal efficacy 
(% Inhibition) 
94.76 
(±2.3) 
70.37* 
(±3.7)  
95.13 
(±2.9) 
84.29* 
(±3.4)  
96.99 
(±3.0) 
95.76 
(±2.9)  
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Table 3.3 Geometric mean EC50 and maximum isometric tension values for nicotine following 
chronic treatment with either WIN-55,212-2 or morphine.  
The geometric mean EC50 values for nicotine (the agonist concentration required to elicit the 
amplitude of the neurogenic twitch of the LM/MP to 50% of its maximal value) are displayed as 
-log M (± S.E.M.).  Maximal efficacy depicts the maximum isometric tension attained in 
LM/MP. Statistically significant differences (p≤ 0.05) are identified by *. The N value for each 
experimental set is 4. 
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Experimental Treatment 
Nicotine  
Control Test Mean Ratio of EC50 
Morphine vs. Control - EC50 
(-log M ± S.E.M.) 
5.45 (±0.03) 5.32 (±0.1) 1.35 (±0.2) 
Maximal efficacy (g) 2.43 (±0.1) 3.66 (±0.4)*  
WIN-55,21-2 vs. Control - EC50 
(-log M ± S.E.M.) 
5.34 (±0.10) 4.98 (±0.25) 2.3 (±2.8) 
Maximal efficacy (g) 2.68 (±0.2) 2.73 (±0.3)  
 
. 
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Figure 3.1 Mean concentration-response curves for DAMGO (A), CADO (B) and WIN-55,212-2 
(C) in longitudinal muscle/myenteric plexus from control and guinea pigs chronically treated 
with WIN-55,212-2.  
A significant rightward shift of the curve was observed for WIN-55,212-2 only. No significant 
rightward shift observed for DAMGO and CADO.  Significant reduction in the maximum 
response was observed to both WIN-55,212-2 and DAMGO. Statistically significant differences 
(p≤ 0.05) are identified by *.  The N values for the experimental sets are between 6 and 13. 
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Figure 3.2 Mean concentration-response curves for DAMGO (A), CADO (B) and WIN-55,212-2 
(C) in longitudinal muscle/myenteric plexus from control and guinea pigs chronically treated 
with morphine.  
A significant rightward shift of the concentration-response curve was observed for DAMGO, 
CADO and WIN-55,212-2.  The maximum response obtained to WIN-55,212-2 was significantly 
reduced. Statistically significant differences (p≤ 0.05) are identified by *. The N value for each 
experimental set is 8.  
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Figure 3.3 Mean concentration-response curves for nicotine in longitudinal muscle/myenteric 
plexus preparations obtained from morphine or WIN-55,212-2 pretreated guinea pigs and their 
respective controls.  
No significant change in the EC50 values for nicotine was observed following chronic treatment 
with morphine (A) or WIN-55,212-2 (B). Fig. 3.3C shows a bar graph comparing the maximal 
tension values attained by nicotine stimulation in the control and test groups. A significant 
increase in nicotine maximal effect is observed in morphine-treated animals. Statistically 
significant differences (p≤ 0.05) are identified by *. The N value for each experimental set is 4.  
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Figure 3.4 Comparison of MOR and CB1 receptor protein levels following chronic morphine or 
WIN-55,212-2.  
Fig 3.4A illustrates the ratio of the CB1 receptor or MOR protein intensity to the GAPDH 
intensity from animals treated chronically with WIN-55,212-2. Fig. 3.4B illustrates the ratio of 
the MOR or CB1 receptor protein intensity to the GAPDH intensity from animals treated 
chronically with morphine. Respective prototypical images of the immunoblot membrane 
showing the density of the MOR and CB1 protein are shown below the bar graphs. p* < 0.05 
considered to be statistically significant. The N values for the experimental sets are between 4 
and 6. 
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CHAPTER FOUR: COMPARISON OF THE EXPRESSION OF TOLERANCE TO 
HYPOTHERMIA AND ANALGESIA IN THE GUINEA PIG FOLLOWING CHRONIC 
OPIOID VERSUS CANNABINOID EXPOSURE. 
I. Abstract 
The candidate previously reported that chronic in vivo treatment with morphine resulted 
in the development of heterologous tolerance in the guinea pig longitudinal muscle-myenteric 
plexus (LM/MP) whereas chronic WIN-55,212-2 exposure resulted in homologous tolerance. 
Few studies have compared tolerance that develops to the hypothermic and analgesic activity of 
opioids and cannabinoids with that observed in the guinea pig LM/MP model. Tolerance was 
induced by chronic morphine (7 days) or WIN-55,212-2 (5 days) exposure and assessed by 
determining the alteration in response to challenge doses of WIN-55,212-2 and morphine. 
Hypothermia was measured by a rectal thermometer while mechanical and thermal analgesia 
were assessed using the paw pressure and hot plate tests, respectively. The nature of tolerance 
observed in the hot plate test corresponds closely to that observed in the LM/MP studies 
(CHAPTER THREE) where morphine pretreatment produced heterologous tolerance and WIN-
55,212-2 pretreatment resulted in homologous tolerance. In contrast to the results in the LM/MP 
studies, WIN-55,212-2 pretreatment produced tolerance to the analgesic effect of morphine in 
the paw pressure model despite the fact that it did not produce analgesia in this model. Unlike 
chronic treatment with WIN-55,212-2, chronic morphine treatment did not induce tolerance to 
the hypothermic effect of WIN-55,212-2. However, since only a very modest hypothermia was 
observed in response to a morphine challenge, tolerance to this effect was difficult to assess and 
may not be biologically relevant.  The results suggest that the nature of tolerance that develops in 
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one model system cannot be inferred to another even in the same species since chronic morphine 
treatment produced heterologous tolerance in the hot plate test and homologous tolerance in the 
hypothermia model while chronic WIN-55,212-2 treatment elicited homologous tolerance in the 
LM/MP, hypothermia and hot plate models but heterologous tolerance in the paw pressure 
model. The present findings affirm the notion that the nature of tolerance depends on the model, 
drug, species, and regimen used. Our data also suggest that the analysis of tolerance using in vivo 
test systems involves complex neuronal interactions and that multiple cellular effects at various 
sites in the signal cascade may induce differential functional tolerance in different models. 
II. Introduction 
Common pharmacological effects observed with the use of opioid and cannabinoid 
agonists include the ability to induce hypothermia, sedation, hypotension, antinociception and 
inhibition of both intestinal motility and locomotor activity (Bloom and Dewey, 1978; Smith et 
al., 1994; Bass and Martin, 2000). These common effects are rooted in the similar cellular 
signaling events and comparable central and peripheral distribution of the opioid and 
cannabinoid receptors within the ileum, vas deferens, caudate-putamen, dorsal hippocampus, 
substantia nigra and hypothalamus (Rosow et al., 1980; Ross et al., 1998; Rawls et al., 2002). 
Common cellular signaling pathways between the two receptor systems include coupling through 
Gi/o proteins leading to inhibition of adenylyl cyclase (Howlett and Fleming, 1984); inactivation 
of N, P/Q, and R-type Ca2+ channel (Rhim and Miller, 1994; Howlett et al., 2002); activation of 
the MAPK pathway (Bouaboula et al., 1995); and activation of G protein-activated inwardly 
rectifying potassium (GIRK) channels (McAllister et al., 1999). Cellular co-localization of 
cannabinoid and opioid receptors in both the central nervous system and peripheral neurons  
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(Salio et al., 2001) may contribute to the closely related physiological and clinical effects 
(Manzanares et al., 1999) including the development of dependence and tolerance (Lichtman and 
Martin, 2005).  
Considerable numbers of the studies that have been undertaken to assess whether chronic 
opioid or cannabinoid exposure results in the development of tolerance to either agent have often 
reported conflicting and discordant results. The differential effects could be based on the fact that 
the analgesic effects of these agents follow from activation of their receptors in the one or more 
of the following brain areas associated with the pain pathway: periaquaductal gray, amygdala, 
raphe and the dorsal horn of the spinal cord (Tsou et al., 1998; Farquhar-Smith et al., 2000). 
Furthermore some studies have reported cellular co-localization of opioid and cannabinoid 
receptors in the superficial dorsal horn of the spinal cord and caudate-putamen (Hohmann et al., 
1999; Rodriguez et al., 2001; Salio et al., 2001). In one study, morphine tolerant animals were 
reported to be hypersensitive to ∆9-THC (Rubino et al., 1997)  whereas in a separate study, 
morphine dependent animals exhibited a decrease in the analgesic effect of ∆9-THC (Thorat and 
Bhargava, 1994). Furthermore, Cichewicz and Welch (2003) discovered that low doses of 
cannabinoids curtailed the development of morphine tolerance while preserving the levels of the 
three major opioid receptors. Though most behavioral studies have focused on analgesic 
tolerance, few studies have investigated the nature of tolerance that develops to the hypothermic 
effect of these agents (Rosow et al., 1980; Rawls et al., 2002). The basis for possible alteration in 
opioid and cannabinoid agonists’ hypothermic potency could be related to the reported presence 
of both MOR and CB1 receptors in the hypothalamus and the fact that activation of these of these 
receptors results in the regulation of body temperature. Furthermore, chronic cannabinoid 
exposure has been reported to regulate levels of MOR in the hypothalamus  (Corchero et al., 
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2004). Possible mechanisms that could be involved in development of tolerance include changes 
in receptor abundance or levels of the endogenous ligands. Previous studies assessing the effect 
of chronic drug administration on receptor abundance have often reported conflicting results; in 
one study chronic morphine exposure resulted in an increase in cannabinoid receptor density 
(Rubino et al., 1997) while in another the receptor density seemed not to be altered (Thorat and 
Bhargava, 1994). In addition, the change in cannabinoid receptor abundance following opioid 
exposure appears to be region dependent and varies amongst different species (Vigano et al., 
2003; Gonzalez et al., 2005). The effects of cannabinoid pretreatment on opioid receptors has 
been reported to involve a time dependent increase in MOR density that was observed in several 
brain regions including the amygdala, thalamus and hypothalamus (Corchero et al., 2004). The 
interaction between the cannabinoid and opioid systems as evidenced by the cross-regulation of 
their endogenous ligands may also play a critical role in the qualitative nature of tolerance 
observed with these agents. ∆9-THC and other endocannabinoids (except anandamide) have been 
shown to increase extracellular levels of dynorphin in the spinal cord thus enhancing KOR 
stimulation and analgesic (Mason et al., 1999; Welch and Eads, 1999). In contrast, the effect of 
opioid exposure on the endocannabinoid levels seems limited since chronic exposure to 
morphine did not affect the levels of anandamide or 2-AG in the striatum, cortex, hippocampus, 
limbic area or hypothalamus.  
The assessment of mechanisms involved in the development tolerance in an in vivo 
model is complicated since it is dependent on complex neuronal network interactions involving 
multiple synaptic connections that may have different receptor population distribution. Thus, 
most studies are conducted in vitro using isolated tissues or cell lines. Most in vivo studies 
performed have used mice and rats: The current study used the guinea pig model whose 
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advantages include the fact that it exhibits closer anatomical, physiological, neurological and 
developmental similarities to the human that is well established thus making it an appropriate 
model for studying gastro-intestinal, respiratory and opioid tolerance (Chavkin and Goldstein, 
1984; Hunter et al., 1997; Gray et al., 2001). Studies investigating the development tolerance to 
cannabinoids in the human and guinea pig ilea have reported comparable results thus further 
reinforcing the similarities between the two species and the utility of using the guinea pig as an 
animal model (Guagnini et al., 2006). 
There is a growing body of evidence pointing toward convergence and commonality of 
activity and cell signaling pathways between the two receptor systems that may act in concert to 
alter many of the pharmacological effects of each including the development of tolerance (Bass 
and Martin, 2000). The effect of chronic cannabinoid or opioid pretreatment on hypothermic or 
analgesic efficacy of opioid and cannabinoid agonists is hard to define as it seems to be 
dependent on complex neuronal networking activated by these agonists. The goal of the present 
study was to evaluate the effect of chronic in vivo cannabinoid or opioid exposure on the 
expression of tolerance to the hypothermic effects or analgesic effects of both agents. Based on 
these similarities in signal transduction pathways, and comparable anatomical distribution and 
co-localization of their respective receptors, it was hypothesized that chronic treatment with 
either agonist would lead to the development of heterologous tolerance to the hypothermic and 
analgesic effects of these agents. Furthermore the studies investigated how the qualitative nature 
of tolerance to the analgesic and hypothermic effect of opioids and cannabinoids compares with 
that observed in the guinea pig LM/MP following chronic in vivo treatment.  
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III. Experimental Protocol 
The present study investigated the development of tolerance to the analgesic and 
hypothermic effect of cannabinoid and opioid agents following chronic treatment with either 
agent. Drug pretreatment regimens employed were based on those previously used in other 
studies to induce tolerance or dependence (Mizutani et al., 2005; Spina et al., 1998) and by 
preliminary studies performed in the laboratory. The treatment regimens that were employed 
were identical those outlined previously (CHAPTER THREE) which were shown to induce the 
development of tolerance in the LM/MP model. Briefly, morphine was administered 
subcutaneously twice daily (10:00 a.m. and 10:00 p.m.) for 7 days in an escalating dose fashion 
whereas WIN-55,212-2 was administered intraperitoneally once daily (10:00 a.m.) for 5 days. 
Animals were tested between 9:00 and 10:00 am on the following day after administration of the 
last dose (12 h after the last dose of morphine and 24 hrs after the last dose of WIN-55,212-2).. 
1. Analgesia Assessment 
All animals were acclimated to the observation room for 1 h prior to the initiation of any 
assessment. Baseline mechanical (paw pressure) or thermal (hot plate) analgesia was measured 
prior to injecting the challenge drug. The Randall and Selitto test was used to assess mechanical 
nociception (Randall and Selitto, 1957). In this test, pressure was manually applied to the plantar 
surface of the hind paw using a cone-shaped pusher with a rounded tip. The force (measured in 
grams) at which the guinea pig withdrew its hind paw was defined as the paw pressure threshold. 
A cut-off was set at 600 g to prevent tissue damage. Mean response threshold was determined at 
the following time intervals after acute drug administration: 0 (baseline), 15, 30, 45, 60, 90 and 
120 min. Tolerance was defined as a reduction in the antinociceptive effect (increased threshold 
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for withdrawal) of the challenge dose of agonist such that the maximum amount of pressure 
required to elicit a paw withdrawal was decreased. Challenge doses employed (morphine 
10mg/kg or WIN-55,212-2 6mg/kg) were selected based on preliminary studies done to assess 
the optimum dose required to produce an adequate and quantifiable analgesic response.  
The hot plate analgesia procedure used was similar to that previously described (Bannon 
and Malmberg, 2007). The response to a thermal stimulus was measured using a hot plate 
analgesia meter (IITC Life Science, Woodland Hills, CA) set at a constant temperature of 50oC. 
Once an animal was placed on the hot plate, the timer was activated and the latency to respond 
with either a front paw lick or flick was determined. To prevent tissue damage, a 40 second cut-
off time period was used at which the animal was removed from the hot plate and a time of 40 
seconds recorded as the latency. Challenge doses (morphine 6mg/kg or WIN-55,212-2 3mg/kg) 
were determined based on preliminary studies done to assess the optimum dose required to 
produce an adequate and quantifiable analgesic response. The doses used in the hot plate test 
were lower than those used to assess mechanical analgesia since higher doses resulted in latency 
values beyond the 40 second cut off threshold. 
2. Hypothermia Assessment 
Assessment of body temperature using a rectal thermometer was performed in a quiet 
room at an ambient temperature of 25oC. After a 1 h acclimatization period in the test room, 
body temperature was measured with a digital rectal thermometer inserted to a constant depth of 
2.5 cm. Following thermometer insertion, a 15 sec equilibration period was allowed to lapse 
before the temperature was recorded. The rectal temperature was measured at the following time 
intervals post challenge drug administration: 0 (baseline), 15, 30, 45, 60, 90 and 120 min. 
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Baseline temperature was measured twice prior to drug challenge (morphine 10mg/kg or WIN-
55,212-2 6mg/kg) and the results expressed as the means + S.E.M of the oC change from 
baseline.  Baseline temperature was also recorded to determine whether chronic treatment with 
either agonist had any impact upon core body temperature. 
The Student’s t-test (unpaired) was used to analyze the maximum rectal temperature 
change or analgesia threshold for mechanical and thermal tests. Analysis was also done at each 
time point.  A p value ≤ 0.05 was considered to be statistically significantly different. 
IV. Results 
1. Assessment of acute analgesic response following chronic treatment 
A. Paw pressure test. The analgesic effect of morphine (10mg/kg body weight) was 
determined using the paw pressure assessment method in control (vehicle treated) vs. drug-
treated (7- day morphine or 5-day WIN-55,212-2 treated) guinea pigs.  The analgesic effect of 
morphine was evident within 15-30 min and persisted throughout the observation period with the 
highest values of pressure required to elicit retraction ranging from 400 to up to 600g (Fig. 
4.1.A). The maximum analgesic effect was observed between 45 and 60 min for both the vehicle 
and test groups.  As illustrated in Fig. 4.1.A and B, significantly lower pressure was required to 
elicit a paw withdrawal in the test animals chronically treated with either cannabinoids (318 g vs. 
557 g, p < 0.05) or opioids (217 g vs. 398 g, p < 0.05) compared to the vehicle groups following 
morphine challenge implying that tolerance had developed in response to the chronic treatment.  
Results presented in Fig. 4.2.A and B illustrate the absence of any analgesic response to 
acute challenge with WIN-55,212-2 (6 mg/kg) in either vehicle- or drug-treated groups.  In an 
effort to determine the basis for the lack of response, doses of WIN-55,212-2 up to 18mg/kg 
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were evaluated during the preliminary experiments without yielding any apparent analgesic 
effect. Therefore, the development of tolerance could not be assessed since no analgesic response 
to WIN-55,212-2 was observed even in naïve animals in this model of analgesia assessment. 
B. Hot Plate Analgesia Test. The analgesic effect of morphine (6mg/kg body weight) 
and WIN-55,212-2 (3mg/kg body weight) was determined by hot plate assessment in vehicle 
treated controls vs. test (7-day morphine or 5-day WIN-55,212-2 treated) animals.  The challenge 
doses of morphine and WIN-55,212-2 used were determined in preliminary experiments in 
which a dose dependent analgesic effect of both agents that occurred in the range of 1-10 mg/kg 
of morphine and 1-6 mg/kg of WIN-55,212-2 was observed. As illustrated in Fig. 4.3 and Fig. 
4.4, comparison of the latency to thermal response (sec) between the morphine- and vehicle-
treated groups shows the development of significant tolerance to the analgesic effect of morphine 
(9.0 vs. 23.5 seconds; p < 0.05) and WIN-55,212-2 (9.8 vs. 26.8 seconds; p < 0.05) as indicated 
by the substantial loss of latency to respond. Comparison of the latency to thermal response (sec) 
between WIN-55,212- and vehicle-treated groups shows the development of tolerance to the 
analgesic effect of WIN-55,212-2 (12 vs. 26.3 seconds; p < 0.05) but not to morphine challenge 
(22.3 vs. 36.0 seconds; p > 0.05). 
2. The effect of chronic treatment on the hypothermic response 
The hypothermic effect of morphine (10mg/kg body weight) and WIN-55,212-2 
(6mg/kg) was determined by rectal body temperature assessment in vehicle treated controls vs. 
drug-treated (7-day morphine or 5-day WIN-55,212-2 treated) guinea pigs. The challenge doses 
used were based on preliminary studies performed which show a dose dependent reduction in 
rectal temperature with both agents. Body temperature was assessed at baseline (0 min), 15, 30, 
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45, 60, 90 and 120 min after challenge drug administration. Following chronic treatment with 
either cannabinoids or opioids, challenge with morphine or WIN-55,212-2 resulted in steadily 
increasing hypothermia at an ambient temperature of 25oC that peaked around 90 min after acute 
exposure. The hypothermic effect of WIN-55,212-2 was considerably and statistically more 
pronounced than that observed with morphine (maximum change in temperature of 0.88 ± 0.23 
°C for morphine versus 3.81± 0.17°C for WIN-55,212-2; p < 0.05). 
As illustrated in Fig. 4.5A, comparison between morphine and vehicle treated animals 
shows the development of tolerance to the hypothermic effect of morphine (0.10 vs. -0.43°C; p < 
0.05). In contrast, comparison between WIN-55,212-2 and vehicle treated animals (Fig 4.5B) 
shows that no tolerance develops to after the hypothermic effect of morphine challenge (0.34 vs. 
1.3°C; p > 0.05). This lack of effect could have been influenced by the fact that morphine 
produced only modest hypothermia and/or by the wide variability in the hypothermia values. The 
hypothermic effect of morphine appears to develop slowly, and seemed to peak around 90 min 
for both groups. Fig. 4.6 illustrates the results of studies in which vehicle- and drug-treated 
animals were challenged with WIN-55,212-2.  Challenge with WIN-55,212-2 (6 mg/kg) in 
animals chronically treated with morphine did not reveal the development of tolerance to the 
hypothermic effect (vehicle: -4.2 vs. test -3.8°C p > 0.05). The maximum hypothermic effect 
peaked at 90 min for both groups and by 120 min the body temperature had not recovered to 
baseline levels. The studies further assessed the hypothermic effect of lower challenge doses of 
WIN-55,212-2 (1mg/kg and 3mg/kg) following chronic exposure with morphine. The results 
depicted in Fig. 4.7 indicate that the development of tolerance was not apparent with both 
challenge doses, thereby reinforcing the results observed with WIN-55,212-2 (6 mg/kg) and 
suggesting that the highest dose was not supramaximal. Fig. 4.8 shows a dose-response curve 
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constructed by determining the maximal hypothermic effect of WIN-55,212-2 using the 1mg/kg, 
3mg/kg and 6mg/kg challenge doses in control and morphine pretreated animals. The data 
indicate that the hypothermic effect of WIN-55,212-2 was dose-dependent and, furthermore, that 
no tolerance developed to that effect in animals treated chronically with morphine. In contrast, 
chronic WIN-55,212-2 treatment resulted in the development of tolerance to the acute 
hypothermic effect of WIN-55,212-2 (6 mg/kg) challenge (control: -3.79°C; test -2.49°C; p < 
0.05) as shown in Fig. 4.6B. The maximum hypothermic effect was observed at 90 min for both 
groups and extended to at least 120 min which was chosen as the time period to stop the 
experiment. Preliminary studies in the laboratory demonstrated that acute WIN-55,212-2 
exposure produces a long lasting hypothermic effect spanning up to 6 h.  
V. Discussion 
Complex interactions have been observed in the development of tolerance to the effects 
of opioids and cannabinoids especially in in vivo models where the complex neuronal network 
interactions are vast (Taylor and Fleming, 2001). It is for this reason that mechanistic studies on 
the development of tolerance are performed in vitro using isolated tissue or cell models (Johnson 
et al., 1978; Shapira et al., 2003; Li et al., 2006). The current study examined the development of 
tolerance using the in vivo approach cognizant of the complication presented by the complex 
neuronal network interaction in assessing and interpreting the development of tolerance to the 
effects of opioids and cannabinoids observed in the whole animal. Results from the present study 
clearly indicate that the interplay between the cannabinoid and opioid systems is very 
complicated and that development of tolerance to these effects may be dependent upon the model 
being assessed and the acute effects of the agonist in the model.  
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The current study reports the development of tolerance to the analgesic effect of 
morphine in the paw pressure model following pre-treatment with WIN-55,212-2 despite the fact 
that WIN-55,212-2 did not acutely induce analgesia in this model. This effect could have 
occurred through various pathways. One mechanism could involve an indirect intracellular 
interaction between the opioid and cannabinoid system whereby activation of CB1 receptors 
results in non-specific adaptive desensitization through sequestration of common G proteins and 
making them unavailable to couple to other receptors (Vasquez and Lewis, 1999). This activity 
would result in a reduced potency of agonists whose receptors use the same G proteins and thus 
would result in the development of heterologous tolerance; however, the development of this 
effect would be dependent on the co-localization/co-expression of MOR and CB1 receptors in the 
same neurons. Studies reporting co-localization of MOR and CB1 receptors in regions 
responsible for pain regulation (e.g. the superficial dorsal horn of the spinal cord (Hohmann et 
al., 1999; Salio et al., 2001) and caudate putamen (Rodriguez et al., 2001)) seem to support this 
notion. Another possible pathway could involve a network interaction between the two receptor 
systems whereby the cannabinoid receptor input resides on neurons or brain regions upstream of 
the neurons engaged in the response such that its down-regulation would result in the reduced 
activation of the downstream endogenous opioid system hence tolerance to the analgesic effect 
of agonists targeting the latter would be evident. In support of this proposal are reports that show 
the attenuation of ∆9-THC analgesia by the opioid antagonist, naloxone (Manzanares et al., 
1999), and the fact that ∆9-THC administration elevates pro-opiomelanocortin (POMC) levels in 
the hypothalamus, and increases the expression of preproenkephalin in the PAG, spinal cord and 
striatum (Corchero et al., 1997; Manzanares et al., 1998). Since cannabinoid receptor activation 
has been proposed to induce the release of enkephalins, hence performing a permissive or 
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synergistic role in opioid analgesia (Pugh et al., 1996; Pugh et al., 1997), the cannabinoid 
analgesic system may be perceived to be upstream of the opioid receptors such that 
downregulation of the system would negatively regulate the opioid system. Our results are 
consistent with this idea since chronic cannabinoid exposure results in the development of 
tolerance to opioid-induced analgesia in the paw pressure model (Thorat and Bhargava, 1994). It 
should be noted that WIN-55,212-2 did not elicit mechanical analgesia; this could imply that the 
paw pressure model may not be a sensitive enough model system to employ or that WIN-55,212-
2 does not produce analgesia in the model hence tolerance could not be assessed. Studies in 
humans have also reported absence of analgesia to cannabinoids in similar pain models (Naef et 
al., 2003). 
The development of tolerance to the thermal analgesic effect of WIN-55,212-2 following 
chronic morphine exposure appears to be related to the reduction in opioid signaling. Since 
cannabinoid analgesia is in part dependent on the release of enkephalins (Pugh et al., 1996; Pugh 
et al., 1997), it follows that opioid receptor desensitization (possibly due to receptor 
downregulation) following chronic morphine exposure may indirectly result in a decreased 
efficacy of cannabinoids (Manzanares et al., 1999). This would be consistent with the 
heterologous tolerance observed to the analgesic effect of WIN-55,212-2 following chronic 
opioid exposure and correlates with the tolerance observed in the LM/MP model. In contrast, 
chronic WIN-55,212-2 treatment did not result in tolerance to morphine challenge in the thermal 
analgesia model. The development of homologous tolerance in the thermal analgesia model 
following chronic WIN-55,212-2 pretreatment also supports the adaptive desensitization of the 
cannabinoid signaling and is consistent with WIN-55,212-2-induced CB1 receptor-mediated 
desensitization and downregulation observed in the LM/MP (CHAPTER 3). It is important to 
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note that other studies have reported contrasting results in the form of enhanced analgesia 
(Welch and Eads, 1999); however, it should also be considered that the drug regimens and 
animal models used in these studies significantly differ from those used in the present study. The 
ability of chronic cannabinoid exposure to elicit tolerance to the analgesic effect of opioids 
appears to be dose-dependent since exposure to low non-analgesic doses of cannabinoids has 
been shown to maintain or augment analgesic sensitivity to opioids (Thorat and Bhargava, 1994; 
Welch and Eads, 1999). The difference between the nature of tolerance observed in the paw 
pressure or hot plate analgesia models following WIN-55,212-2 pretreatment could be a function 
of variance in the spinal and supraspinal analgesia pathways and the relative distribution and 
interaction between the activated opioid (mu- and kappa-) and cannabinoid receptors involved in 
analgesia. Differences in the analgesic pathways engaged are derived from the fact that the hot 
plate test more closely resembles a supraspinal response involving higher centers of the 
ascending and descending pathways including the PAG, the thalamus, the hypothalamus and the 
cerebral cortex, whereas the paw pressure is mainly a reflex under spinal control (Mansour et al., 
1988; Kieffer, 1999). Differences in these pathways may have profound effects on the type of 
tolerance observed since the spinal response may only reflect interaction between receptors 
located on the first-order afferent fibers (A-delta or C type) and the dorsal root ganglia in the 
spinal cord whereas the supraspinal response additionally involves networks of nuclei in the 
higher centers (Almeida et al., 2004). The involvement of multiple nuclei in the expressed 
response to pain offers another level of complexity since such pathways frequently involve both 
excitatory and inhibitory pathways that may be differentially altered by the same agonist through 
the same receptor.  Furthermore, permutations of possible interactions between opioid and 
cannabinoid receptors may also be vastly different since both kappa- and mu- opioid receptors 
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are involved in morphine-induced analgesia, and have been reported to interact and co-localize 
with the CB1 receptors (Manzanares et al., 1999; Salio et al., 2001). The heterogeneity of first-
order afferent neurons activated (C-type fibers versus A-delta type fibers) by different noxious 
stimuli (thermal vs. mechanical) should also be considered (Almeida et al., 2004). The levels and 
activity of opioid (mu- or kappa-) and CB1 receptors may also vary between the afferent fibers. 
These factors may have a great influence on the input-output relationship to the spinal cord and 
could have profound impact on the type of tolerance observed in these two models. Tolerance to 
the acute analgesic effect of WIN-55,212-2 or morphine could have occurred through 
desensitization of signaling in the following brain areas where MOR and CB1 receptors are 
expressed: amygdala; hypothalamus; cortex; PAG; or dorsal horn of the spinal cord (Rosow et 
al., 1980; Rodriguez et al., 2001; Salio et al., 2001; Rawls et al., 2002). Electron microscopy 
studies in rats have demonstrated co-localization of MOR and CB1 receptors in the following 
areas involved in pain regulation: dorsal horn; and caudate-putamen (Rodriguez et al., 2001; 
Salio et al., 2001). Furthermore, studies in cells cotransfected with MOR and CB1 receptors have 
demonstrated heterodimerization of these receptors (Hojo et al., 2008) suggesting a much closer 
interaction between the convergent signaling pathways if the receptors are expressed in the same 
neurons.  
The development of tolerance to the hypothermic effect following chronic drug exposure 
appears to be a physiological adaptation dependent on whether an acute hypothermic effect is 
observed with the pretreatment agent. WIN-55,212-2 produced robust hypothermia supporting 
the well documented significant role for cannabinoid receptors in temperature regulation (Rawls 
et al., 2002). A desensitization of the CB1 receptor signaling in the hypothalamus, consistent with 
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robust downregulation of CB1 receptor-mediated effects (Oviedo et al., 1993; Rodriguez de 
Fonseca et al., 1994), could also result in the type of homologous tolerance as that which was 
observed in the current study. In contrast, the modest hypothermia observed in response to acute 
opioid treatment may be due to the fact that morphine activates both mu- and kappa- opioid 
receptors which produce opposing effects on core temperature with the latter producing 
hypothermia and the former hyperthermia (Rosow et al., 1980). The modest hypothermic effect 
produced by morphine may not have been sufficient to trigger a physiological adaptive response 
that would extend the reduced responsiveness to the hypothermic effect of WIN-55,212-2. This 
is consistent with previously published data that show that the use of minimally effective or sub-
effective doses of cannabinoids and opioids does not induce tolerance (Welch and Eads, 1999) 
and reinforces the idea that the development of tolerance is an adaptive response of cells and 
tissues that is dependent upon chronic agonist activation of receptors.  The candidate speculates 
that the absence of heterologous tolerance to WIN-55,212-2-induced hypothermia following 
chronic morphine exposure may be due to the fact that the slight reduction in body temperature 
may not facilitate a significant pharmacological stimulus to evoke adaptation responses in the 
temperature regulation pathway that possibly includes cannabinoid receptors (Rosow et al., 
1980). WIN-55,212-2 pretreatment produced a robust reduction in body temperature that resulted 
in the development of tolerance to the cannabinoid hypothermic effect; this type of selective 
adaptational response correlates with previously reported data in the LM/MP model (CHAPTER 
THREE). However, it could not be ascertained whether WIN-55,212-2 pretreatment produced 
heterologous tolerance since acute morphine challenge elicited a modest hypothermic effect with 
high variability. It should be noted that hypothermia results from a complex interplay between 
the CNS and peripheral processes.  Based upon the results obtained in this study, additional 
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studies would be required to isolate the specific pathways that may be involved in the 
development of tolerance. 
In light of the differences observed in the development of tolerance between opioids and 
cannabinoids, it is concluded that the analysis of the development of tolerance in intact animal 
models is complicated by the possible network interactions between the two receptor systems 
and their respective signaling pathways and the complex neural networks engaged in most 
outcomes being assessed at the level of the whole animal. Differences in the animal species can 
also make it difficult to interpret and compare results with those that have been obtained in other 
laboratories. Further studies are required to fully elucidate the receptor interactions and possible 
role that receptor co-localization between the endogenous opioid and cannabinoid networks may 
play in hypothermia and analgesia models that were employed as well as in the mechanism(s) 
responsible for the development of tolerance. In light of the results obtained in the hypothermia 
assessment, there is need to assess the distribution of the MOR and CB1 receptor distribution in 
the hypothalamus to determine whether the possible co-localization of both receptor systems that 
has been reported in the hypothalamus may serve as a site through which the alteration in 
responsiveness is developed. 
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Figure 4.1 Effect of morphine challenge on mechanical analgesia following 7-day morphine or 5-
day WIN-55,212-2 treatment 
The analgesic effect of morphine (10mg/kg body weight) was determined by assessing the 
pressure required for paw retraction. A: control vs. morphine (7 days) B: control vs. WIN-
55,212-2 (5 days) treated animals.  Analgesia was measured at baseline (0 min), 15, 30, 45, 60, 
90 and 120 min after challenge dose injection. Each point represents the mean ± S.E.M of 
measurements from at least 4 guinea pigs.   (●) Test (morphine or WIN-55,212-5 treated) group, 
(○) control (vehicle treated) group. *p ≤ 0.05 considered to be statistically significant. The N 
value for each experimental set is 4. 
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Figure 4.2 Effect of WIN-55,212-2 challenge on mechanical analgesia following 7-day morphine 
or 5-day WIN-55,212-2 treatment 
The analgesic effect of WIN-55,212-2 (6mg/kg body weight) was determined by measuring the 
pressure required to elicit paw retraction using the Randall-Selitto model system. A: control vs. 
morphine (7 days) B: control vs. WIN-55,212-2 (5 days) treated animals.  Analgesia was 
measured at baseline (0 min), 15, 30, 45, 60, 90 and 120 min after challenge dose injection. Each 
point represents the mean ± S.E.M of measurements from at least 4 guinea pigs. (●) Test 
(morphine or WIN-55,212-5 treated) group, (○) control (vehicle treated) group. *p ≤ 0.05 
considered to be statistically significant. The N value for each experimental set is 4. 
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Figure 4.3 Effect of morphine challenge on thermal analgesia following 7-day morphine or 5-day 
WIN-55,212-2 treatment 
Assessment of the thermal analgesic effect of morphine (6mg/kg body weight) determined using 
the hot plate test. Time to withdrawal was determined manually by visual inspection of the 
animal movements. A: control vs. morphine (7 days) B: control vs. WIN-55,212-2 (5 days) 
treated animals.  The level of analgesia was measured at baseline (0 min), 15, 30, 60, 90 and 120 
min after challenge dose injection. Each point represents the mean ± S.E.M of measurements 
from at least 4 guinea pigs. (●) Test (morphine or WIN-55,212-5 treated) group, (○) control 
(vehicle treated) group. *p ≤ 0.05 considered to be statistically significant. The N values for each 
experimental set ranges from 4 – 6. 
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Figure 4.4 Effect of WIN-55,212-2 challenge on thermal analgesia following 7-day morphine or 
5-day WIN-55,212-2 treatment 
Assessment of the thermal analgesic effect of WIN-55,212-2 (3mg/kg body weight) determined 
using the hot plate test. Time to withdrawal was determined manually by visual inspection of the 
animal movements. A: control vs. morphine (7 days) B: control vs. WIN-55,212-2 (5 days) 
treated animals.  Analgesia was measured at baseline (0 min), 15, 30, 60, 90 and 120 min after 
challenge dose injection. Each point represents the mean ± S.E.M of measurements from at least 
4 guinea pigs. (●)Test (morphine or WIN-55,212-5 treated) group, (○) control (vehicle treated) 
group. A *p value ≤ 0.05 considered to be statistically significant. The N value for each 
experimental set is 4. 
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Figure 4.5 Effect of morphine challenge on rectal body temperature following 7-day morphine or 
5-day WIN-55,212-2 treatment 
Assessment of the hypothermic effect of morphine (10mg/kg body weight) determined by rectal 
body temperature measurement. A: control vs. morphine (7 days) B: control vs. WIN-55,212-2 
(5 days) treated animals.  The change in core temperature was assessed at baseline (0 min), 15, 
30, 45, 60, 90 and 120 min after challenge dose injection. Each point represents the mean ± 
S.E.M of measurements from at least 4 guinea pigs. (●) Test (morphine or WIN-55,212-5 
treated) group, (○) control (vehicle treated) group. *p ≤ 0.05 considered to be statistically 
significant. The N value for each experimental set is 4. 
132 
 
 
 
  
A 
B 
133 
 
Figure 4.6 Effect of WIN-55,212-2 challenge on rectal body temperature following 7-day 
morphine or 5-day WIN-55,212-2 treatment 
Assessment of the hypothermic effect of WIN-55,212-2 (6mg/kg body weight) determined by 
rectal body temperature measurement. A: control vs. morphine (7 days) B: control vs. WIN-
55,212-2 (5 days) treated animals.  Hypothermia was assessed at baseline (0 min), 15, 30, 45, 60, 
90 and 120 min after challenge dose injection. Each point represents the mean ± S.E.M of 
measurements from at least 4 guinea pigs. (●) Test (morphine or WIN-55,212-5 treated) group, 
(○) control (vehicle treated) group. *p ≤ 0.05 considered to be statistically significant. The N 
value for each experimental set is 4. 
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Figure 4.7 Effect of 7-day morphine treatment on the hypothermic effects of different doses of 
WIN-55,212-2 challenge. 
Assessment of the hypothermic effect of WIN-55,212-2 (1mg/kg [A] or 3mg/kg [B] .body 
weight) determined by rectal body temperature measurement.  Hypothermia was assessed at 
baseline (0 min), 15, 30, 45, 60, 90 and 120 min after challenge dose injection. Each point 
represents the mean ± S.E.M. (●) Test (morphine treated) group, (○) control (vehicle treated) 
group. *p ≤ 0.05 considered to be statistically significant. The N value for each experimental set 
ranges from 7 - 8. 
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Figure 4.8 Dose response curve of the maximal WIN-55,212-2 hypothermic effect following 7-
day morphine treatment. 
Comparison of the maximal hypothermic effect of WIN-55,212-2 challenge (1mg/kg, 3mg/kg 
and 6mg/kg) following 7-day morphine or vehicle treatment. Hypothermia was assessed at 
baseline (0 min), 15, 30, 45, 60, 90 and 120 min after challenge dose injection. Each point 
represents the mean ± S.E.M of measurements from at least 4 guinea pigs. (●) Test (morphine 
treated) group, (○) control (vehicle treated) group. *p ≤ 0.05 considered to be statistically 
significant. The N value for each experimental set ranges form 4 - 8. 
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CHAPTER FIVE: ASSESSMENT OF MOR AND CB1 RECEPTOR DISTRIBUTION IN 
THE LM/MP AND HYPOTHALAMUS FOLLOWING CHRONIC IN VIVO EXPOSURE 
TO OPIOID OR CANNABINOID RECEPTOR AGONISTS. 
I. Abstract 
Cellular co-localization or co-expression of receptors is considered to be one of the pre-
requisites for intracellular interaction of signaling systems. Few studies to date have assessed the 
relative distribution and/or possible co-localization of CB1 cannabinoid receptor and mu-opioid 
receptor (MOR) in either the LM/MP or hypothalamus and whether or not this characteristic 
could be related with the qualitative nature of the tolerance to the hypothermic or gastrointestinal 
inhibitory effects that are observed following chronic opioid or cannabinoid exposure. The 
candidate previously reported that chronic administration of morphine resulted in the 
development heterologous tolerance in the LM/MP model while chronic WIN-55,212-2 
treatment not only evoked homologous tolerance associated with a 32% reduction in CB1 
receptor protein. Based on these data and the closely related gastrointestinal inhibitory effects 
observed with both opioids and cannabinoids, the candidate hypothesized that there is substantial 
co-localization of MOR and CB1 receptors in the LM/MP. Furthermore since the hypothalamus 
is a common locus for the regulation of body temperature through region specific MOR and CB1 
receptor activation, also it was predicted that there would be extensive co-expression of these 
receptors in the hypothalamus. The present study used multiple-labeling immunofluorescence to 
examine the expression of MOR and CB1 receptors in the LM/MP as well as the preoptic 
hypothalamic area, a key region responsible for regulation of body temperature. Results from the 
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study revealed a comparable distribution of MOR and CB1 receptors in both myenteric and 
preoptic anterior hypothalamic neurons. In addition, the results demonstrated extensive co-
localization of the receptors in both tissues. Up to 50% of the neurons expressing MOR or CB1 
receptor protein in the LM/MP co-expressed both receptors whereas up to 89% of hypothalamic 
neurons co-expressed MOR and CB1 receptors. The receptor co-localization suggests that the 
two receptor systems share a number of sites for convergence of action that could serve as the 
cellular basis of tolerance which include receptor-dependent and/or receptor-independent but 
signaling pathway-dependent components.   
II. Introduction 
There is a growing body of evidence pointing toward convergence and commonality of 
activity between the MOR and the CB1 receptor systems that may alter the cellular signaling 
pathways involved in producing many of the effects including the development of tolerance. 
There is also evidence for a similar neuroanatomical distribution of cannabinoid and opioid 
receptors within the ileum, vas deferens, caudate-putamen, dorsal hippocampus, substantia nigra 
and hypothalamus (Rosow et al., 1980; Ross et al., 1998; Rawls et al., 2002) that correlates with 
common pharmacological effects, namely hypothermia, hypomotility, catalepsy and decreased 
gastrointestinal motility. Furthermore, some studies have reported co-localization of these 
receptors in the superficial dorsal horn of the spinal cord (Hohmann et al., 1999; Salio et al., 
2001) and caudate putamen (Rodriguez et al., 2001). 
Our previous studies using the LM/MP model (CHAPTER THREE) revealed the 
development of heterologous tolerance following chronic opioid exposure that contrasted 
distinctly with the receptor-specific alteration in responsiveness and reduction in CB1 receptor 
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protein levels following chronic cannabinoid exposure. Furthermore, previous studies assessing 
the development of tolerance to the hypothermic effects of opioids and cannabinoids (CHAPTER 
FOUR) seem to point to a possible interaction between the two systems since chronic WIN-
55,212-2 treatment appears to induce the development of heterologous tolerance to the 
hypothermic effect of morphine, though chronic morphine treatment does not seem to affect the 
hypothermic potency of WIN-55,212-2. Based on these data and the reported correlation of 
neuroanatomical distribution and physiological effects between CB1 and opioid receptors in the 
LM/MP and hypothalamus, it was hypothesized that there is significant co-localization of both 
receptor populations in LM/MP neurons that provides a common site of cellular interaction 
between the opioid and cannabinoid receptor system (Rawls et al., 2002). Cellular co-
localization of cannabinoid and opioid receptors in the central nervous system and peripheral 
neurons (Salio et al., 2001) is suggested to contribute to the closely related physiological and 
clinical effects (Manzanares et al., 1999) including analgesia, hypothermia, gastrointestinal 
inhibitory activity and the development of dependence and tolerance (Lichtman and Martin, 
2005). Both cannabinoid and opioid receptor agonists reduce intestinal peristaltic activity via 
cannabinoid (CB1) and opioid (kappa- and mu-) receptor activation, respectively.  Studies have 
shown that activation of these  receptors results in the inhibition of release of acetylcholine from 
myenteric ‘S’ neurons that are the motor neurons to the longitudinal muscle resulting in 
decreased peristaltic activity (Coutts and Pertwee, 1997). MOR and CB1 receptors are located on 
the soma and reduce transmitter release by hyperpolarization by opening GIRK channels while 
kappa opioid receptors are “presynaptic” on the axon terminals and decrease acetylcholine 
release by inhibiting calcium influx necessary for transmitter release (Kojima et al., 1994; Coutts 
and Pertwee, 1997). Approximately 15% of the myenteric ‘S’ motor neurons (Dogiel type I) are 
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reported to be cholinergic neurons and over 98% of these cholinergic neurons in the guinea pig 
have been reported to express CB1 receptors (Coutts et al., 2002).  In contrast, only 43% (mostly 
Dogiel type 1) of the cholinergic neurons express MOR (Ho et al., 2003). It is therefore 
reasonable to assume that co-localization of MOR and CB1 receptors within the same neurons is 
likely to exist though the extent of co-localization is unknown. 
The hypothermic effect of these agents is, at least in part, mediated via the hypothalamus 
(preoptic anterior hypothalamic area). Previous studies using mice and rats have shown the 
expression of MOR and CB1 receptors within the anterior hypothalamic area (Rosow et al., 1980; 
Rawls et al., 2002; Zheng et al., 2005). Furthermore, direct microinjection of the CB1 receptor 
agonist WIN-55,212-2 into the preoptic hypothalamic area of the rat has been associated with 
acute hypothermia that can be abolished by the cannabinoid receptor antagonist rimonabant 
(Rawls et al., 2002). Stimulation of opioid receptors has been shown to result in receptor-
dependent regulation of body temperature; MOR selective agonists appear to induce 
hyperthermia whereas KOR agonists produce hypothermia (Adler and Geller, 1987; Spencer et 
al., 1988). 
In the current study the candidate assess MOR and CB1 receptor distribution in the 
LM/MP and the preoptic anterior hypothalamic area. The advantages of the guinea pig model 
include the fact that it exhibits closer anatomical, physiological, neurological and developmental 
similarities to the human which makes it an appropriate model for studying gastro-intestinal, 
respiratory and opioid tolerance (Chavkin and Goldstein, 1984; Hunter et al., 1997; Gray et al., 
2001). In addition, the guinea pig does not exhibit an excitatory action to opioids and the 
distribution of opioid receptors in regions of the CNS more closely resembles that of human than 
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that observed in the rat (Mansour et al., 1988; Bot et al., 1992). However, one major drawback to 
using the guinea pig as a model for CNS studies is the lack of comprehensive information 
outlining specific anatomical co-ordinates for different regions of the brain. Only a handful of 
atlases have delineated specific regions of the guinea pig brain; most are too general and predate 
the current standards of comprehensive outlining of specific brain regions (Rapisarda and 
Bacchelli, 1977). The absence of specific stereotaxic co-ordinates has hampered its favorability 
as a model for assessing CNS effects; however, some studies have mapped co-ordinates for 
specific areas of the brain including the hypothalamus, brainstem, forebrain and midbrain 
(Luparello et al., 1964; Tindal, 1965; Voitenko and Marlinsky, 1993). Another drawback is that 
it is difficult to infer neuronal CNS projections in the guinea pig from those described for other 
species since inter-species variability between neurons of the same type has been observed 
(Livneh and Mizrahi, 2010). 
In light of our previous studies that show a 32% reduction in CB1 receptor protein 
following WIN-55,212-2 treatment (CHAPTER THREE), it was important to characterize the 
possible changes in distribution and localization of MOR and CB1 receptor expression and 
investigate the possible presence and extent of co-localization of the receptor populations. This 
information will be critical in delineating the possible interactions between the two receptor 
systems in the regulation of body temperature and gastrointestinal motility. Based on our 
previous assessments in which WIN-55,212-2 pretreatment appears to induce tolerance to the 
hypothermic effect of morphine (CHAPTER FOUR) and the studies which have shown 
expression of MOR and CB1 receptors in the hypothalamus (Gulledge et al., 2000; Zheng et al., 
2005) and the fact that ∆9-THC administration elevates pre-opiomelanocortin (POMC) levels in 
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the hypothalamus, (Corchero et al., 1997; Manzanares et al., 1998), it was also hypothesize 
extensive co-localization of these receptor populations will be evident in this region.  The 
experimental plan was based upon the following specific aims: 1) To identify the distribution of 
MOR and CB1 receptors in the LM/MP and in the pre-optic anterior hypothalamus (POAH) and 
evaluate the presence and extent of co-localization of these receptors in neurons in these 
regions. 2) To determine whether chronic drug exposure would modify the abundance and/or 
distribution of MOR and CB1 receptor positive neurons in the terminal LM/MP and 
hypothalamus, and to assess whether the extent of receptor co-localization was altered.  
The unavailability of reliable stereotaxic coordinates made it imperative for us to devise a 
method for determining the location of the preoptic anterior hypothalamus. The current study 
employed antibodies targeting gonadotropin releasing hormone (GnRH), a hormone primarily 
expressed in the GnRH-secreting neurons mostly found in the preoptic anterior hypothalamus 
(POAH), to identify this region in coronal sections of the guinea pig brain. A previously 
published article outlining the stereotaxic co-ordinates of the hypothalamus was used as a basis 
to confirm and locate the preoptic anterior hypothalamus (POAH) (Luparello et al., 1964). The 
current study demonstrates the presence of robust co-localization of MOR and CB1 receptors in 
both the LM/MP and POAH thereby providing further correlative evidence for the possible 
functional interaction between the MOR and CB1 receptor systems that may relate to the 
mechanism by which tolerance develops. 
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III. Experimental Protocol 
1. LM/MP Preparation 
The LM/MP whole mount preparation was prepared as outlined earlier (CHAPTER 2) by 
obtaining segments of ileum that were flushed free of intestinal contents and opened along it 
mesenteric border, stretched and pinned in a chamber made of plexiglass containing Sylgard® to 
which the segments were pinned for dissection.  The whole mounts were then fixed in 4% 
paraformaldehyde overnight prior to immunofluorescence probing with primary and secondary 
antibodies.  Preliminary tests were performed to optimize the concentration of primary and 
secondary antibodies to be employed (APPENDIX D). The CB1 receptor was localized using a 
rabbit primary polyclonal antibody directed against the C-terminus (1:50 – Cayman, Ann Arbor, 
MI) and the secondary antibody used was a donkey anti-rabbit FITC-conjugate (1:100 – Jackson 
Immunoresearch, West Grove, PA). MOR was detected using a goat primary polyclonal 
antibody directed against the C-terminus (1:50 – Santa Cruz Biotechnology, Santa Cruz, CA) 
and the secondary antibody used was a donkey anti-goat Cy5-conjugate (1:100 - Jackson 
Immunoresearch, West Grove, PA). LM/MP sections were incubated in 0.1% Triton X-100 in 
PBS for 25 min followed by three 10 min washes with PBS. Prior to primary antibody 
incubation, the LM/MP tissues were blocked with donkey serum (10%) for 45 min and rinsed 
using PBS. Thereafter, the tissues were incubated overnight in a cocktail of anti-CB1 and anti-
MOR primary antibodies in 2% BSA in PBS at 4°C. Following the overnight incubation, the 
tissues were washed with PBS and then incubated for 4 h in a mixture containing both Cy5- and 
FITC-conjugated secondary antibodies targeting MOR and CB1 receptors, respectively. Negative 
control experiments excluded the primary antibodies and these revealed negligible faint labeling 
due to non-specific binding of the secondary antibodies (Fig. 2.2). Following incubation with the 
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respective secondary antibodies, the LM/MP tissues were mounted on slides, allowed to dry in 
total darkness, then cover slipped and retained until viewing.  
2. Preparation of Brain Sections 
Animals were anesthetized and transcardially perfused as outlined in CHAPTER TWO. 
In brief, animals were first anesthetized using Ketamine (85 mg/ml)/Xyalazine (15 mg/ml) 
administered via intraperitoneal injection (0.10 ml/100 g body weight) followed by opening of 
the chest cavity to expose the heart, Initial transcardial perfusion was performed using PBS until 
perfusate was clear and thereafter 4% paraformaldehyde was perfused until the animal 
extremities became stiff. Brains were then removed, postfixed in 4% paraformaldehyde for 24 h 
and later immersed in PBS solution containing 25% sucrose prior to sectioning. The preparation 
of brain slices and incubation of antibodies was performed as outlined in CHAPTER TWO. 
Sectioning of the brain was executed using the Leica VT1000S vibratome brain slicer (Leica 
Microsystems, Bannockburn, IL) with the brain fully immersed in cold PBS. The resulting 
sections of approximately 40 µm thickness were immersed and stored in cold PBS containing 
0.1% sodium azide at 4oC prior to immunofluorescence probing. Initial studies involved 
attempting to outline and visualize the anatomical landmark structures in 13 coronal sections of 
the cerebrum (Fig. 5.4). This was accomplished by tagging CB1 receptor and MOR proteins with 
near-infrared secondary antibodies as outlined in CHAPTER 2. Near infra-red imaging of these 
slices was performed using the Odyssey imaging system (Li-Cor Biosciences. Lincoln, NE) in an 
effort to define the regions of greatest receptor density.  
The first step in quantitative immunofluorescence imaging involved identifying the brain 
sections expressing GnRH, the preoptic anterior hypothalamic area marker. For these initial 
147 
 
studies, sections (7, 8, 9, 10, 11 and 12) were used since these were anatomically relevant 
sections where the hypothalamus is located based on the gross structure of the cerebrum. For 
subsequent experiments, only the brain slices that displayed GnRH immunofluorescence were 
used for triple labeling studies targeting the GnRH, CB1 receptor and MOR proteins. The 
concentrations of primary and secondary antibodies used for CB1 and MOR are identical to those 
used for the LM/MP (see APPENDIX F). In addition, GnRH was used as a marker protein for 
the preoptic anterior hypothalamic neurons where the hormone is exclusively expressed. 
GnRH was localized using a mouse primary polyclonal antibody directed against the C-terminus 
(1:500 Santa Cruz Biotechnology, Santa Cruz, CA) and the secondary antibody used was a 
donkey anti-mouse Cy3-conjugate (1:500 – Jackson Immunoresearch, West Grove, PA). 
3. Confocal Imaging 
A Zeiss® LSM 510 laser scanning confocal imaging system and microscope were used 
for image acquisition and processing of immunopositive neurons tagged by the FITC- (CB1), 
Cy5- (MOR) and Cy3-conjugated secondary antibodies. In LM/MP dual-labeling experiments, a 
composite image targeting the FITC- and Cy5-conjugates was scanned simultaneously that could 
be merged or separated and analyzed offline. For triple labeling experiments (using FITC-, Cy3- 
and Cy5-conjugates), an initial scan was performed targeting the Cy3-GnRH fluorophore so as to 
identify the preoptic anterior hypothalamic area. Thereafter, a composite image targeting the 
FITC- and Cy5-conjugates was scanned simultaneously. All images from slides were captured 
using identical parameters for laser intensity, detector gain, pin hole size and amplifier offset. 
Co-localization in the brain tissues was only examined in brain areas where GnRH-positive 
neurons were detected. 
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4. Assessment of MOR and CB1-Immunopositive neurons 
A qualitative analysis of the scanned images was used to determine the distribution 
pattern and the extent of co-localization of MOR and CB1 receptor-immunopositive neurons. 
Cells were considered to be immunopositive if they expressed visually detectable fluorescent 
labeling. Immunopositive neurons with bright to faint labeling were analyzed, because the faint 
labeling may represent low protein expression in positively labeled cells. The Zeiss® LSM 
software was used to analyze the distribution and co-localization of MOR and CB1 receptor-
immunopositive neurons and Image J® software was used to quantify the density of the neurons 
per defined unit area. The relative expression of co-localized was expressed as a percentage of 
the total population of neurons possessing both receptor proteins versus those neurons expressing 
either MOR or CB1 receptor proteins only. 
The density of immunopositive neurons was assessed by counting the number of 
immunopositive neurons in a manually circumscribed region of the myenteric ganglia (i.e. 
number of neurons/area of circumscribed region). The area of the circumscribed region was 
computed using Image J® software whereas the number of visually detectable immunopositive 
neurons was counted manually.  Neurons expressing both receptor proteins were counted 
individually and converted to a density based upon the circumscribed area evaluated.  The 
relative expression of co-localized was expressed as a percentage of the total population of 
neurons possessing both receptor proteins versus those neurons expressing either MOR or CB1 
receptor proteins only. 
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IV. Results 
1. Assessment of MOR and CB1 Receptor Protein Expressing Neurons in the LM/MP  
Representative images from whole mounts of the guinea pig LM/MP showing 
CB1 receptor and MOR-immunopositive neurons in the myenteric plexus are provided in Fig 5.1. 
The red immunofluorescence (Fig 5.1A) indicates MOR-expressing neurons while the green 
immunofluorescence (Fig 5.1B) depicts CB1 receptor-expressing neurons. Neurons expressing 
both receptor populations appear orange-yellow (Fig 5.1C) in color. There are a number of 
important characteristics observed from these tissues.  As indicated in Fig 5.1A and Fig 5.1B 
which depict MOR and CB1 receptor-immunopositive-neurons, respectively, it appears that a 
significant proportion of myenteric neurons actually express both receptor populations 
simultaneously.  It is also interesting to note that neurons exclusively expressing MOR protein 
seem to reside predominately in the periphery of the myenteric ganglion whereas neurons that 
exclusively express CB1 receptors appear to congregate in the central part of the ganglion; this 
distribution pattern was consistent in drug-naïve, vehicle-treated, WIN-55,212-2- or morphine-
treated animals. Finally, there appears to be some degree of co-localization as indicated by the 
high intensity of the orange-yellow color in Fig 5.1C. The co-localization observed (Fig 5.1C) 
between the MOR and CB1 receptor positive neurons further suggests that the two receptors are 
co-expressed in some but not all myenteric neurons. The results in Fig 5.1D show a similar 
relative density of neurons expressing MOR or CB1 receptors in the LM/MP as assessed using 
Image J® software (16.7 vs. 14.3 neurons/µm2, respectively; p > 0.05). The density of neurons 
co-expressing both CB1 and MOR receptors in drug-naïve animals was 2.9 neurons/µm2 which 
translates to 17% and 20% of the total MOR or CB1 receptor populations, respectively. 
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Comparison of vehicle or WIN-55,212-2 treated groups (Fig 5.2A) shows no statistically 
significant difference in the density of MOR-immunopositive (p > 0.05), CB1-immunopositive 
neurons (p > 0.05) or neurons co-expressing both receptors. Similarly, chronic morphine 
treatment did not alter the relative density of MOR, CB1-immunopositive neurons or neurons co-
expressing both receptors. In tissues obtained from animals chronically treated with morphine 
(Fig 5.2A) or WIN-55,212-2 (Fig 5.2B) or respective drug-free vehicle solutions, the relative 
density of neurons expressing either CB1 receptors (F (4, 3) = 1.05, p = 0.45) or MOR (F (4, 3) = 
1.43, p = 0.33) was similar in magnitude to that observed in naïve animals (Fig 5.1D).  
Interestingly, in the preparations from vehicle and drug-treated animals, the relative percentage 
of neurons co-expressing both families of receptors appears to slightly increase from the 20% 
level seen in naïve animals to around 50% in the preparations from treated animals. Negative 
controls showed faintly labeled neurons, possibly due to non-specific binding, but the signal was 
not nearly as intense as that observed in the non-control test groups.  
2. Assessment of MOR and CB1 Receptors in Hypothalamus 
Following slicing of guinea pig coronal brain slices at the outlined coronal co-ordinates 
(Table 5.1) the investigator incubated the slices with near-infrared antibodies targeting the MOR 
and CB1 receptors. Qualitative analysis of these images show generalized distribution of the 
regions positive for the receptors. Anatomical outlines of major regions of the brain could be 
visualized including the cortex, hippocampus and ventricles; these were used as reference 
markers for other regions of the brain including the hypothalamus. 
The first step in quantitative immunofluorescence imaging involved identifying the brain 
sections expressing GnRH, the preoptic anterior hypothalamic area marker. For these initial 
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studies, sections (7, 8, 9, 10, 11 and 12) were used since these were anatomically relevant 
sections where the hypothalamus is located based on the gross structure of the cerebrum. Initial 
assessment of the coronal brain sections 7, 8, 9 10 and 11 (Fig 5.3) of the cerebrum revealed that 
the expression of GnRH was only detected in coronal sections 9, 10 and 11 (Fig 5.5). The 
expression of GnRH was sparse in these regions with the greatest immunofluorescence observed 
in Coronal section 11 located -7.5 mm from bregma. Fig 5.5 shows extensive co-localization of 
the MOR and CB1 receptors in the preoptic hypothalamic area in coronal section 11. Assessment 
of the hypothalamic area expressing GnRH revealed the presence of robust immunoreactivity or 
expression of MOR and CB1 receptor protein (Fig 5.5). The area where GnRH was expressed 
correlates with the location of the hypothalamus that has been reported in previous atlases 
(Luparello et al., 1964). These data are consistent with previously reported data which reported 
extensive CB1 receptor expression in the POAH (Rawls et al., 2002). Immunofluorescence 
images of the cortex show no expression of the GnRH; however, expression of the MOR and 
CB1 receptors can be seen in this region (Fig 5.6).  
As indicated in Fig 5.5B and Fig 5.5C which depict MOR and CB1 receptor-
immunopositive-neurons, respectively, there appears to be a significant degree of co-localization 
in the POAH as indicated by the high intensity of the orange-yellow color in Fig 5.5D. 
Comparison of vehicle or WIN-55,212-2 treated groups (Fig 5.7B) shows no statistically 
significant difference the density of MOR-immunopositive (4.9 vs. 3.9; p > 0.05), CB1-
immunopositive neurons (4.1 vs. 3.9; p > 0.05) or neurons co-expressing both receptors (2.6 vs. 
2.9; p > 0.05). Similarly, chronic morphine treatment did not alter the relative density of MOR 
(3.9 vs. 3.2; p > 0.05), CB1-immunopositive neurons (4.2 vs. 4.0; p > 0.05) or neurons co-
expressing both receptors (2.5 vs. 2.9; p > 0.05). Up to 89% of neurons in the POAH co-
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expressed MOR and CB1 receptors suggesting that there is substantial co-localization of these 
receptor populations in this region. 
V. Discussion 
The rapid development of subsensitivity to pharmacological effects of opioid and 
cannabinoid agonists like analgesia, hypomotility, hypothermia and inhibition of gastrointestinal 
motility following the chronic use of opioids and cannabinoids is well documented (Martin et al., 
2004; Bailey and Connor, 2005). There is increasing emphasis on the common anatomical 
distribution and shared cell signaling pathways between opioid and cannabinoid receptor systems 
as potential overlapping sites for producing the pharmacological effects of each. Common 
cellular effects include inhibition of adenylyl cyclase (Howlett and Fleming, 1984), inactivation 
of Ca2+ channels (Rhim and Miller, 1994; Howlett et al., 2002), activation of the MAPK pathway 
(Bouaboula et al., 1995), and activation of G protein-activated inwardly rectifying potassium 
(GIRK) channels (McAllister et al., 1999). Similar distribution of opioid and cannabinoid 
receptors in the central nervous system (Rosow et al., 1980; Ross et al., 1998; Rawls et al., 2002) 
and their cellular co-localization (Salio et al., 2001) may also contribute to the comparable 
physiological and clinical effects (Manzanares et al., 1999) including dependence and tolerance 
(Lichtman and Martin, 2005). Cellular co-localization of cannabinoid and opioid receptors in 
central neurons (e.g. the superficial dorsal horn of the spinal cord and the caudate-putamen) has 
also been reported (Hohmann et al., 1999; Rodriguez et al., 2001; Salio et al., 2001). In this study 
the candidate attempted to determine the distribution of neurons expressing MOR in relation to 
those expressing CB1 receptors in the LM/MP and preoptic anterior hypothalamic area (POAH) 
in an effort to determine whether any distribution or alteration in receptor properties might be 
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associated with the development of tolerance that was observed in the previous studies 
(CHAPTER THREE and FOUR). 
Our immunofluorescence data support the possibility of substantial co-localization of 
MOR and CB1 receptors since up to 50% of CB1 receptor-immunopositive neurons also 
expressed MOR in LM/MP preparations from treated animals and even greater percentages of 
neurons expressed both receptor populations in the POAH. However further studies would need 
to be performed to verify whether the co-localization reflected mere direct physical presence and 
interaction in the same neurons or whether the cellular co-expression represented the presence of 
heterodimerization between the receptor populations. The observed reduction in CB1 receptor 
protein following chronic WIN-55-212-2 treatment does not seem to alter the relative 
distribution of CB1-, MOR- or CB1/MOR co-expressing neurons and is further reinforced by the 
similar pattern of distribution that was observed in drug-naïve, vehicle- and morphine-treated 
groups. The absence of changes in density of neurons expressing CB1 receptors following WIN-
55,212-2 treatment in the presence of a significant reduction in total CB1 receptor protein 
observed in western blot studies could be due to a modest but uniform reduction in total CB1 
receptor protein that does not substantially eliminate the receptor from individual neurons and, 
therefore, would not alter the density of CB1-expressing neurons. Further studies would be 
required to determine whether the mean integrated CB1 receptor immunofluorescence intensity 
levels per neuron was decreased and whether it corresponds to the observed reduction in CB1 
receptor protein levels. While the fact that the expression of both receptors on the same neuron 
does not automatically translate into heterodimers, the observed CB1/MOR co-localization 
suggests a common neuronal expression that may facilitate convergence of the two receptor 
signaling pathways involved in regulating acetylcholine release. Approximately 15% of the 
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myenteric ‘S’ motor neurons (Dogiel type I) are reported to be cholinergic neurons; over 98% of 
these cholinergic neurons in the guinea pig have been reported to express CB1 receptors (Coutts 
et al., 2002) whereas 43% (mostly Dogiel type 1) express MOR (Ho et al., 2003). It is therefore 
reasonable to assume that co-localization of MOR and CB1 receptors in the LM/MP is likely as 
demonstrated by these studies which show up to 50% of the MOR and CB1 neurons co-
expressing both receptors in the LM/MP. The larger relative density of co-localized neurons in 
vehicle and drug-treated animals compared to drug-naïve animals could represent the impact of 
treatment or could reflect the mere fact that different samples or different areas of evaluation of 
the stretch preparations were employed. 
Assessment of the hypothalamic area expressing GnRH revealed the presence of robust 
immunoreactivity or expression of MOR and CB1 receptor protein (Fig 5.5). The area where 
GnRH was expressed correlates with the location of the hypothalamus that has been reported in 
previous atlases (Luparello et al., 1964). These data are also consistent with previously reported 
data which reported extensive CB1 receptor expression in the POAH (Rawls et al., 2002). The 
presence of MOR and CB1 receptor positive neurons in the preoptic anterior hypothalamus 
(POAH) is consistent with effect of agents targeting these receptors in this brain region on 
temperature regulation (Rosow et al., 1980; Rawls et al., 2002) and is consistent with the opioid-
induced analgesia and modulation of hormone release (Rang et al. 2007). The observed co-
localization of MOR and CB1 receptors points to a complex interplay between the two receptor 
populations in the regulation of body temperature since MOR activation has been shown to 
induce hyperthermia while CB1 receptor activation results in hypothermia (Rosow et al., 1980; 
Adler and Geller, 1987; Rawls et al., 2002). Our results outlined in CHAPTER FOUR show that 
chronic WIN-55,212-2 treatment appears to induce the development of tolerance to the 
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hypothermic effect of morphine therefore suggests that there is an interaction between the two 
receptor systems in this particular pharmacological response. In contrast, morphine pretreatment 
does not appear to affect the potency of WIN-55,212-2 to produce hypothermia. This 
asymmetrical development of tolerance suggests the possibility of downstream-upstream 
interactions between the two receptor systems. Cannabinoid receptor agonists also interact with 
the hypothalamic–pituitary-adrenal axis which regulates body temperature through a number of 
hormonal processes (for review see Murphy 2002).  
The interaction of co-localized receptors may involve heterodimerization; studies in co-
transfected cells have reported heterodimerization of MOR and CB1 receptors (Hojo et al., 2008) 
but no reports have been made using animal tissues. Heterodimerization of GPCRs, in general, 
has been shown to stimulate complex novel signaling pathways that are foreign to each of the 
individual receptors that can alter the potency of agonists targeting these receptors or instigate 
several other effects including co-internalization (Pfeiffer et al., 2003; Milligan et al., 2006). 
Internalization of MOR with other G protein-coupled receptors as heterodimers has also been 
reported to result in receptor desensitization (Pfeiffer et al., 2003). The previously reported 
heterodimerization of the MOR and CB1 receptors (Hojo et al., 2008) in baby hamster kidney 
(BHK) cells co-expressing both receptors  may provide a locus whose activation could result in 
internalization or uncoupling of CB1/MOR heterodimers as an adaptive response following 
chronic agonist exposure which could have a significant impact on the nature of the tolerance 
that develops. This possibility is especially important when considering the fact that both 
systems have comparable physiological and pharmacological effects and the fact that their 
respective receptors have been identified to be co-localized in the same neurons. However, there 
is need to perform further studies to ascertain whether the interaction between the MOR and CB1 
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receptors is actually heterodimeric. Possible experimental techniques that can be employed to 
evaluate this possibility include co-immunoprecipitation, fluorescence resonance energy transfer 
(FRET) or high resolution electron microscopy.  
In summary, the presence of MOR and CB1 receptors in the LM/MP and hypothalamus in 
high abundance demonstrate the importance of endocannabinoid and opioid systems in these 
tissues. The substantial MOR and CB1 receptor co-localization analysis in the LM/MP and 
hypothalamus suggests that the two receptor systems share a number of sites including cellular 
localization where convergence of action could serve as the cellular basis of tolerance for both 
the receptor-dependent and/or receptor independent cell signaling pathway-dependent 
components.  The fact that the two receptor populations exist separately as well as together 
potentially as heterodimers suggests that the expression of tolerance may reflect the additive 
effect of receptor-dependent and –independent components and that the relative ability of the 
agonist to activate specific intracellular adaptive processes may involve the ability to interact 
distinctly with heterodimeric receptors versus homomeric co-localized receptors. 
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Figure 5.1 Representative images from whole mounts of the guinea pig ileum showing 
immunofluorescence in neurons expressing MOR and CB1 receptors in myenteric ganglia.  
Fig. 5.1A shows MOR-immunopositive neurons (red) only whereas Fig. 5.1B illustrates CB1 
receptor-immunopositive neurons (green) only. Fig. 5.1C shows a merged image depicting 
neurons in the myenteric plexus that are immunopositive for both MOR and CB1 receptors. The 
graph displayed in Fig. 5.1D shows a comparison of the density of MOR and CB1 receptor-
immunopositive neurons (number of immunopositive neurons per unit area) in the myenteric 
plexus of drug-naïve animals. The graph also illustrates the density of neurons co-expressing 
MOR and CB1 receptors. Each bar represents the mean + S.E.M of measurement of tissue 
sections obtained from 3 guinea pigs. p* < 0.05 considered to be statistically significant. 
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Figure 5.2 Comparison of the density of MOR and CB1 receptor-immunopositive neurons in the 
myenteric plexus in vehicle- and drug-treated animals.  
Fig 5.2A shows a comparison of the density of neurons expressing MOR or CB1 receptors, and 
the density of neurons co-expressing both MOR and CB1 receptors in the myenteric plexus 
samples from vehicle and morphine treated animals. Fig 5.2B compares the same parameters 
between tissues obtained from vehicle- and WIN-55,212-2-treated animals. Each bar represents 
the mean + S.E.M of measurement in tissues obtained from 3 guinea pigs. p* < 0.05 considered 
to be statistically significant. 
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Figure 5.3 Picture of the guinea pig brain. 
The guinea pig brain in preparation for serial coronal sectioning to identify areas of interest for 
evaluation of receptor localization and distribution.  Sections were obtained and numbered 
sequentially from rostral to caudal. 
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Figure 5.4 Coronal sections of the cerebrum 
Representative coronal sections representing serial sections 1 - 13 of the guinea pig brain 
following incubation with infra-red antibodies targeting MOR and CB1 receptors. Sections were 
obtained and numbered sequentially from rostral to caudal. 
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Table 5.1 Stereotaxic co-ordinates of coronal sections relative to bregma. 
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Coronal section Position Relative To Bregma 
 
Section 1 +5 
Section 2 +4 
Section 3 +3 
Section 4 +2.5 
Section 5 +1 
Section 6   0 
Section 7 -2 
Section 8 -3 
Section 9 -4.5 
Section 10 -6 
Section 11 -7.5 
Section 12 -9 
Section 13 -11 
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Figure 5.5 Representative images of guinea pig brain sections (serial sections 9, 10 and 11) 
showing immunofluorescence in neurons expressing MOR, CB1 receptors and GnRH presumed 
to be in the hypothalamus.  
A: GnRH-immunopositive neurons (blue). B: MOR-immunopositive neurons (red). C CB1 
receptor-immunopositive neurons (green). D: merged image depicting both CB1 receptor and 
MOR-immunopositive neurons illustrating the significant co-localization between the two 
immunofluorescence markers. E: merged image depicting immunopositive neurons expressing 
MOR, CB1 receptors and GnRH simultaneously.  
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Figure 5.6 Representative images from brain sections showing immunofluorescence in neurons 
expressing MOR, CB1 receptors and GnRH in the outer cerebral cortex.  
A: MOR-immunopositive neurons (red). B: CB1 receptor-immunopositive neurons (green). C: 
GnRH-immunopositive neurons (blue). D: merged image depicting both CB1 receptor and MOR-
immunopositive neurons.  Note the significant co-localization between the two 
immunofluorescence markers and the absence of any reactive product for GnRH-
immunopositive cells in the cerebral cortex. 
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Figure 5.7 Comparison of the density of MOR and CB1 receptor-immunopositive neurons in the 
preoptic anterior hypothalamus of vehicle and drug-treated animals.  
Fig 5.7A shows a comparison of the density of neurons expressing MOR or CB1 receptors, and 
the density of neurons co-expressing both MOR and CB1 receptors in the preoptic anterior 
hypothalamus in vehicle and morphine treated animals. Fig 5.7B compares the same parameters 
between vehicle and WIN-55,212-2 treated animals. Each bar represents the mean + S.E.M of 
measurement in tissues obtained from 3 guinea pigs. A *p value < 0.05 considered to be 
statistically significant. 
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CHAPTER SIX: CONCLUSIONS AND FUTURE DIRECTIONS 
The development of tolerance following chronic treatment with drugs is a common 
consequence of a number of drugs from several different classes.  The nature of tolerance, 
whether homologous or heterologous, can be an important component of the expression of the 
altered phenotype that can be characterized by determining the nature of the specificity of 
changes in responsiveness. The character of the tolerance that develops also provides important 
information regarding the most likely cellular and molecular adaptive changes that occur to 
account for the altered responsiveness.  Homologous tolerance, which generally occurs within 
min/hours, is mainly associated with receptor-dependent modifications such as functional 
uncoupling of the agonist-occupied receptor from G proteins, receptor downregulation through 
internalization and degradation, or changes in the cellular components specific to the signaling 
pathway that is activated. In contrast, heterologous tolerance develops over much longer time 
periods (days/weeks) and is often characterized by non-receptor dependent modifications in 
global cell function (Taylor and Fleming, 2001). Chronic exposure to opioids and cannabinoids 
has been shown to result in adaptive changes in responsiveness that have been attributed to 
alterations in adenylyl cyclase and/or the coupling of the enzyme to the cognate G proteins (Gi/o 
proteins) which are responsible for mediating the action of the activated receptor(s) (Nestler, 
1993; Rhee et al., 2000; Gintzler and Chakrabarti, 2008). Cannabinoid tolerance has been 
suggested to be dependent on changes in protein kinase A (PKA), Src kinase (Lee et al., 2003) 
and also nitric oxide (Spina et al., 1998) whereas development of opioid tolerance appears to be 
dependent on changes in protein kinase A (Nestler, 2001; Gintzler and Chakrabarti, 2008), 
protein kinase C, or the level of the alpha3 subunit of the sodium pump (Taylor and Fleming, 
2001). Beta-arrestin mediated downregulation of opioid or cannabinoid receptors following 
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prolonged exposure to the respective agonists has also been proposed as a key facet in the 
development of tolerance though changes in receptor abundance are usually associated with the 
rapidly developing form of tolerance. The development of tolerance to cannabinoids and opioids 
is particularly intriguing because of the speed with which it manifests. 
The remarkable similarities between the neuroanatomical distribution of the MOR and 
CB1 receptor systems and the comparable physiological and cellular signaling pathways, 
suspected to manifest in synergism of action or heterologous desensitization depending on the 
model of drug exposure, has led us to propose the possibility of a significant interaction between 
agonists targeting the two receptor systems with respect to the development of tolerance. The 
development of heterologous tolerance to these agents would prompt the need to use higher 
doses to achieve the same pharmacological effect, hence potentially resulting in the expression of 
a complex myriad of adverse events especially in terminally ill patients (e.g. cancer patients 
using morphine for pain and dronabinol for nausea). This is especially apparent for biological 
effects where tolerance is not observed e.g. constipating and miotic effects of opioids. Several 
methods have been proposed to combat the development of tolerance including the use of low 
sub-effective doses of synergistic drugs targeting different pathways (Welch and Eads, 1999) or 
instituting drug holidays to allow upregulation of receptors to regain pretreatment levels. Clinical 
studies evaluating tolerance to the analgesic effect of opioids have reported attenuation of 
tolerance upon concurrent use of agents like calcium channel blockers and cholecystokinin 
antagonists (Santillan et al., 1994; McCleane, 2003). In animal studies, the phosphodiesterase 
inhibitor ibudilast (Ledeboer et al., 2007), or  the intrathecal administration of magnesium and 
zinc (McCarthy et al., 1998; Larson et al., 2000) have also been reported as promising remedies 
for overcoming opioid tolerance (McCarthy et al., 1998; Larson et al., 2000). 
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Research on the possible mechanisms of tolerance associated with sequential or 
concurrent use of cannabinoids and opioids is important to establish possible drug interactions 
that may be involved with chronic use of these drugs. Based on the similarities between opioid 
and cannabinoid distribution and signaling systems, and previous in vitro drug exposure studies 
using the LM/MP model that have reported bidirectional heterologous tolerance (Basilico et al., 
1999) it was hypothesized: 1) that in vivo drug exposure would also result in bidirectional 
heterologous tolerance; 2) that the qualitative characteristics of the tolerance expressed could 
be used to define the cellular mechanisms most appropriate to explore mechanistically; 3) that if 
homologous tolerance was displayed, it would employ a mechanism that involved receptor 
regulation; 4) that co-localization of opioid and cannabinoid receptors to the same neurons 
could provide a basis for some cross-tolerance between agonists; and 5) that the mechanisms 
that underlie the development of tolerance need not be the same for every tissue, drug or model 
system studied.  
Complex interactions have been observed in tissue or cell models used for assessing the 
development of tolerance to the effects of opioids and cannabinoids (Shapira et al., 2003; 
Johnson et al., 2006). The task of dissecting the cellular pathways involved is more challenging 
in in vivo models where complex neuronal interactions are vast and may contribute to the 
concurrent development of both receptor-dependent and –independent forms of tolerance (Taylor 
and Fleming, 2001). The fact that in vivo systems may involve multiple sequential sites at which 
the same receptor may exert an action provides even greater complexity when considered within 
the context of the question of whether the development of tolerance at one site in a signaling 
cascade would modify the development of tolerance at another site in the same cascade that uses 
the same receptor.  The current studies assessed the development of tolerance after chronic in 
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vivo treatment cognizant of the intricate neuronal interactions that exist and may be altered 
especially in the hypothermia and analgesia models. Though previous studies have used in vitro 
drug exposure models (Basilico et al., 1999; Guagnini et al., 2006), the current study employed 
in vivo exposure regimens which are more physiologically relevant as they account for the 
complex interaction between the peripheral and central nervous systems in regulating the 
physiological effects assessed namely hypothermia, analgesia and gastrointestinal inhibition. The 
in vivo drug exposure is also clinically relevant since it mimics the therapeutic administration of 
these agents. In these studies the guinea pig was chosen as a model on the basis of a number of 
advantages that the animal model system offers. These include the fact that this species exhibits 
closer anatomical, physiological, neurological and developmental similarities to the human thus 
making it an appropriate model system for studying gastrointestinal, respiratory and opioid 
tolerance (Chavkin and Goldstein, 1984; Hunter et al., 1997; Gray et al., 2001). In addition, the 
guinea pig does not exhibit an excitatory action to opioids and the distribution of opioid 
receptors in regions of the CNS more closely resembles that of the human than that observed in 
the rat (Mansour et al., 1988; Bot et al., 1992). Use of the LM/MP isolated nerve-smooth muscle 
model also provides a model system that has been used for decades to assess the development of 
tolerance in an in vitro system following in vivo treatment.  Furthermore, this particular model 
may be able to provide greater insight into possible neuronal interactions in the CNS since 
similar neurotransmitters are found in both the enteric and central nervous systems (Rang et al. 
2007).  
Data generated from studies investigating the characteristics and mechanisms of the 
development of opioid and cannabinoid tolerance have often been contradictory and ambiguous. 
This confusion may be due, in part, to differences in the species and models used for analysis, 
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the dosage regimen employed to induce the change in responsiveness, and/or whether drug 
exposure is accomplished in vivo or in vitro. Heterologous tolerance, as evidenced by reduced 
responsiveness to the analgesic effect of ∆9-THC, was observed in morphine tolerant mice 
(Thorat and Bhargava, 1994). On the other hand, studies using rats observed an opposite effect 
(i.e. analgesic hypersensitivity) to ∆9-THC in morphine tolerant animals (Rubino et al., 1997). 
Furthermore, the effect of chronic opioid exposure on the cannabinoid receptor population has 
also provided varying results with decreases in CB1 receptor levels observed in the rat 
hippocampus (Vigano et al., 2003) and an increase in receptor levels in the caudate putamen and 
limbic structures (Gonzalez et al., 2005). Therefore, in spite of the extensive investigation that 
has been done, the precise nature and mechanism of the interactions between the opioid and 
cannabinoid systems and how those interactions impact upon the modifications in responsiveness 
following chronic treatment remains elusive. Relatively few studies have compared the 
development of tolerance to the hypothermic, antinociceptive and the inhibitory effects of 
cannabinoids and opioids on ileum longitudinal muscle in the guinea pig. Furthermore, no 
studies have explored possible opioid and cannabinoid receptor downregulation or co-
localization of MOR and CB1 receptors in the LM/MP and how such receptor localization may 
impact upon the nature of tolerance observed in this animal model. In light of the controversies, 
conflicts and limited data comparing the development of tolerance following chronic in vivo 
opioid or cannabinoid exposure, an experimental plan was developed to address the hypothesis 
that tolerance would appear similar between opioids and cannabinoids.  The experimental plan 
was based upon the following specific aims: (1) To determine whether chronic in vivo exposure 
to opioids or cannabinoids would result in the development of heterologous tolerance that 
extended to both agents; (2) To compare and contrast the effect of chronic in vivo cannabinoid 
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or opioid exposure on the sensitivity of the LM/MP to excitatory agents like nicotine as a 
possible clue towards cellular mechanisms; (3) To determine if chronic cannabinoid/opioid  
exposure results in changes in the MOR and CB1 receptor population; 4) To evaluate the 
anatomical distribution of MOR and CB1 receptor-positive neurons in the terminal LM/MP and 
hypothalamus, and to assess possible receptor co-localization; 5)To evaluate the effect of 
chronic drug exposure on the development of tolerance to the analgesic and hypothermic effects 
of opioids and cannabinoids. Results from the present study clearly indicate that the interaction 
between the endocannabinoid system and the opioid system is complex and shows the 
importance of the neural context in which receptor activation occurs. The nature of tolerance 
induced by chronic treatment appears to be dependent on the model being employed as well as 
the model being assessed.  
The first section of the current study (CHAPTER THREE) evaluated the development of 
tolerance in an in vitro LM/MP model whereas the second part focused on the phenomenon as it 
developed in in vivo assessment models (hypothermia and analgesia). The impact of chronic in 
vivo opioid or cannabinoid pretreatment on the sensitivity of the LM/MP to inhibitory and 
excitatory agents was evaluated. In addition, the effect of agonist exposure on MOR and CB1 
receptor protein abundance and possible co-localization MOR and CB1 receptors was also 
determined. Behavioral assessment of the development of tolerance compared the effect of 
chronic agonist exposure on the development of tolerance to the analgesic and hypothermic 
effect of challenge doses of morphine and WIN-55,212-2. As an extension of the in vivo 
assessment, the studies evaluated the distribution of MOR and CB1 receptors in the preoptic 
anterior hypothalamus (POAH), a key area involved in the regulation of body temperature. 
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The in vitro LM/MP model was employed determine whether prolonged parenteral 
treatment with either opioids or cannabinoids results in the development of tolerance that is 
qualitatively similar. Chronic drug exposure involved 7 twice daily injections of morphine or 5 
daily injections of the cannabinoid receptor agonist, WIN-55,212-2, and tolerance was examined 
and confirmed by comparing the ability of DAMGO, 2-chloroadenosine (CADO) and WIN-
55,212-2 to inhibit neurogenic contractions of the longitudinal muscle/myenteric plexus 
preparation (LM/MP). To investigate the potential cellular mechanisms involved in the 
development of tolerance, the studies assessed the sensitivity of the LM/MP to the 
neuroexcitatory substance, nicotine, and also evaluated the impact of cannabinoid or opioid 
pretreatment on MOR or CB1 receptor abundance. Chronic morphine treatment resulted in the 
development of heterologous tolerance that extended to inhibitory agonists working through 
activation of cannabinoid, opioid and adenosine receptors and increased the responsiveness of 
the LM/MP to the neuroexcitatory effect of nicotine. In contrast, chronic WIN-55,212-2 
treatment resulted in subsensitivity only to WIN-55,212-2 and a reduction in maximum response 
to both WIN-55,212-2 and DAMGO without any change in responsiveness to CADO. As 
demonstrated in these studies, chronic morphine treatment did not alter the abundance of either 
MOR or CB1 receptor protein; this observation is consistent with the maintenance of the 
maximal inhibitory effect of DAMGO, and suggests that a non-receptor dependent adaptive 
mechanism is, at least in part, responsible for the development of tolerance after chronic 
morphine exposure.  The fact that CADO appears to inhibit neurogenic activity through a 
receptor-mediated effect with a cellular mechanism different from that of morphine (Meng et al., 
1997) suggests that the adaptation events induced by chronic morphine exposure must involve 
some alteration in basic cellular function. The laboratory has proposed that the non-receptor 
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dependent changes underlying the heterologous tolerance involve a partial depolarization of the 
resting membrane potential (Meng et al., 1997) secondary to a reduction in the level of the 
functional alpha3 subunit of Na+/ K+-ATPase (Kong et al., 1997; Biser et al., 2002; Maguma et 
al., 2010) which accounts for the reduced sensitivity to inhibitory agents (e.g. DAMGO, CADO 
and WIN-55,212-2) and the enhanced responsiveness to excitatory agents such as nicotine (see 
Fig 6.1 for proposed pathways of opioid tolerance in the LM/MP). The reduction in WIN-
55,212-2 maximal response could also have been caused by a non-receptor mediated change 
since the cannabinoid system in the LM/MP appears to have a low functional reserve that may be 
susceptible to chronic drug exposure (Basilico et al., 1999; Guagnini et al., 2006). Since chronic 
WIN-55,212-2 pretreatment resulted in a reduction in CB1 receptor protein that was relatively 
proportionate to the reduction in the maximal effect of WIN-55,212-2, it can be proposed that the 
mechanism by which tolerance is induced by WIN-55-212-2 is receptor-dependent and that the 
CB1 receptor system in the LM/MP may possess a low functional receptor reserve as was 
suggested following in vitro exposure (Basilico et al., 1999; Guagnini et al., 2006). The 
reduction in CB1 receptor levels is also consistent with previous studies which demonstrated 
robust cannabinoid receptor downregulation that occurs through beta-arrestin mediated 
desensitization, internalization and ultimately degradation (Gonzalez et al., 2005) (see Fig 6.2 for 
proposed pathways of cannabinoid tolerance in the LM/MP). The WIN-55,212-2-induced CB1 
receptor downregulation may involve at least two components; one related exclusively to CB1 
receptor downregulation that would be receptor-dependent and specific to cannabinoid agonists 
and the second one due to dual internalization of CB1 receptors that are also coupled to MOR as 
heterodimers that would be receptor-dependent but not specific to cannabinoid receptor agonist 
(Pfeiffer et al., 2003; Hojo et al., 2008). The fact that chronic cannabinoid treatment produces 
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tolerance that is primarily homologous in nature compared to the heterologous form of tolerance 
associated with chronic opioid exposure provided an important foundation upon which to 
develop mechanistic studies. The MOR and CB1 receptor co-localization analysis in the LM/MP 
suggests that the two receptor systems share a number of sites for convergence of action that 
could serve as the common cellular basis of tolerance which include receptor-dependent and/or 
signaling pathway-dependent components.  The fact that the two receptor populations exist 
separately as well as together potentially as heterodimers suggests that the expression of 
tolerance may reflect the additive effect of receptor-dependent and –independent components 
and the relative ability of the agonist to activate specific intracellular adaptive processes.  
In the in vivo behavioral experiments, the development of tolerance to the analgesic and 
hypothermic effects of opioids or cannabinoids was investigated following chronic in vivo drug 
exposure. Since these studies were performed after the LM/MP studies, one of the specific aims 
was to assess whether the results would corroborate and correlate with those observed in the 
LM/MP model. These studies presented several unanticipated challenges as the experimental 
results began to accumulate.  While chronic morphine treatment produced heterologous tolerance 
to the analgesic effects of morphine and WIN-55,212-2 in the hot plate analgesia tests, it could 
not be assessed whether morphine pretreatment produced heterologous tolerance in the paw 
pressure model since no analgesia was observed following WIN-55,212-2 challenge. In contrast, 
chronic WIN-55,212-2 pretreatment resulted in the development of apparent homologous 
tolerance in the thermal analgesia test since morphine challenge did not show a significant 
difference between the control and test groups. Interestingly, chronic WIN-55,212-2 
pretreatment also produced tolerance to morphine-induced mechanical analgesia despite the fact 
that WIN-55,212-2 did not produce analgesia in this model. The development of heterologous 
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tolerance to the analgesic effect (thermal) of morphine or WIN-55,212-2 following pre-treatment 
with an opioid could have occurred through a variety of mechanisms. One involves a direct 
intracellular interaction whereby activation of either MOR or CB1 receptors results in a non-
specific adaptive desensitization through sequestration of Gi/o proteins thereby making them 
unavailable to couple to any other receptors using the common pool of Gi/o proteins (Vasquez 
and Lewis, 1999) (Vasquez and Lewis, 1999).  Thus, deactivation of both MOR and CB1 
receptor-mediated downstream signaling leads to the development of heterologous tolerance (i.e. 
reduced responsiveness to agents utilizing different receptor populations but similar signaling 
pathways).  For this mechanism to be operative, however, it would be dependent on the co-
localization of MOR and CB1 receptors in the same neurons. Co-localization of CB1 receptors 
and MOR reported in regions responsible for pain regulation such as the superficial dorsal horn 
of the spinal cord (Hohmann et al., 1999; Salio et al., 2001) and caudate putamen (Rodriguez et 
al., 2001) seem to support this notion. Another possible scenario involves a network interaction 
between the two receptor systems whereby the cannabinoid input mediating the response resides 
upstream of the site of action of opioid receptor activation such that down-regulation of CB1 
receptors results in the reduced activation of the downstream opioid system thereby leading to 
the development of tolerance to the mechanical analgesic effect of morphine. In support of this 
idea are reports that show the attenuation of ∆9-THC analgesia by the selective opioid antagonist, 
naloxone (Manzanares et al., 1999) and the fact that ∆9-THC administration elevates pre-
opiomelanocortin (POMC) levels in the hypothalamus (Corchero et al., 1997; Manzanares et al., 
1998), and increases the expression of preproenkephalin in the PAG, spinal cord and striatum.  
Unlike chronic WIN-55,212-2 treatment, chronic morphine treatment did not induce 
tolerance to the hypothermic effect of WIN-55,212-2. However, the magnitude of the 
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hypothermic effect of morphine in the guinea pig was not very robust making clear interpretation 
of the development of tolerance to the response somewhat difficult.  Confocal 
immunofluorescence evaluation of the densities of neurons expressing MOR and CB1 receptors 
in the preoptic anterior hypothalamus (POAH), a key area responsible for the regulation of body 
temperature, revealed extensive co-localization of the two receptor populations suggesting 
possible convergence and interaction between the two receptor systems which establishes a 
platform for receptor-dependent and/or receptor-independent but signaling pathway-dependent 
interactions in the regulation of body temperature. The modest hypothermic effect produced by 
morphine may not have been sufficient to trigger a pharmacological adaptive response that 
would extend the reduced responsiveness to the hypothermic effect of WIN-55,212-2. This is 
consistent with previously published data that show that the use of minimally effective or sub-
effective doses of cannabinoids and opioids does not induce tolerance (Welch and Eads, 1999) 
and reinforces the idea that the development of tolerance is an adaptive response of cells and 
tissues to chronic agonist activation of receptors.  In addition, the lack of tolerance to the 
hypothermic response to WIN-55,212-2 could be due to the ability of morphine to act at multiple 
sites to modulate body temperature in both hypo- and hyperthermic fashions.  Acute morphine 
administration is associated with either hypothermic or hyperthermic responses depending on the 
ambient temperature or receptor subtype activated. This suggests that the action of morphine 
may be mediated through multiple sites which may or may not involve only the hypothalamus. 
In summary, comparison of our behavioral findings with the LM/MP data, show that 
nature of tolerance in one model cannot be inferred to another even in the same species as 
evidenced by the observation that morphine pretreatment produces heterologous tolerance in the 
hot plate and LM/MP models and homologous tolerance in the hypothermic model while chronic 
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WIN-55,212-2 treatment elicits homologous tolerance in the LM/MP and hot plate but 
heterologous tolerance in the paw pressure model. The in vitro LM/MP data are most 
qualitatively explained by the production of modification of cell excitability following chronic 
morphine treatment (Taylor and Fleming, 2001; Li et al., 2010) and receptor downregulation 
following chronic cannabinoid receptor agonist treatment (CHAPTER 3). In contrast, the data 
obtained using in vivo analysis suggests that the development of the phenomenon of tolerance 
involves complex neuronal interactions and multiple cellular effects that may induce differential 
functional tolerance in different models. Other studies have also reported the development of 
both symmetrical (Hine, 1985; Thorat and Bhargava, 1994; Shapira et al., 2003) and 
asymmetrical (Bloom and Dewey, 1978; Smith et al., 1994) interactions between opioids and 
cannabinoids suggesting that the diverse interplay between the two receptor systems might be 
influenced by the cell/tissue/model system being employed and the parameter(s) being assessed. 
Such an interaction is particularly dependent upon the ability of the agonists to adequately 
activate the receptors in appropriate regions to promote the stimulation of the cellular processes 
that are responsible for the development of tolerance.  The differential results may be due to 
different levels of enzymes or enzyme isoforms involved in the adaptive desensitization process; 
namely beta-arrestin, G protein-coupled receptor kinase (GRK), PKA, PKC and other kinases 
(Bloom and Dewey, 1978; Hine, 1985; Smith et al., 1994; Shapira et al., 2003). A number of 
investigators have suggested various components of the cell signaling pathways as candidates for 
the cellular locus of tolerance, including the protein kinases, adenylyl cyclases, transcription 
factors and tyrosine kinases (Shapira et al., 1998; Shapira et al., 2003).   
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I. Future Directions 
In light of the differences observed in the development of tolerance between opioids and 
cannabinoids in the various models, it can be concluded that the development of tolerance in 
intact animal models is challenging to interpret because it is complicated by the possibility of 
intracellular or neuronal network interactions between the two receptor systems at multiple sites 
and levels. These interactions could occur separately, in sequence or in tandem creating intricate 
interactions in vivo.  Hence, it is important to consider the neural context in which receptor 
activation occurs in the interpretation of the results obtained. Differences in the animal species 
also make it difficult to compare results that have been compiled in other laboratories. In 
addition, the inability to observe an alteration in responsiveness empirically depends upon the 
ability of an agonist to acutely produce a response through the same network that is employed by 
the agonist used for chronic treatment. 
The development of heterologous tolerance in the analgesia model points toward possible 
interactions of the opioid and cannabinoid systems in the different regions responsible for 
regulation of pain namely the PAG, dorsal horn of the spinal cord, raphe and the hypothalamus 
(Tsou et al., 1998; Farquhar-Smith et al., 2000). Since studies have demonstrated the existence of 
both receptor families in these regions, it would be worthwhile to conduct a series of experiments 
to ascertain whether co-localization and/or heterodimerization of opioid and cannabinoid 
receptors can be observed in these regions. Such information would be critical in evaluating the 
possible cellular interactions between these systems since the presence of heterodimers could 
produce changes in responsiveness that appear to be non-selective. The assessment of analgesia 
and hypothermia used a non specific agonist (morphine) which targets both MOR and KOR. The 
fact that both of these receptors are involved in the regulation of pain and body temperature 
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(Rosow et al., 1980)  makes it challenging to interpret the interaction between the CB1 and the 
two opioid receptors. This is particularly significant with respect to the temperature responses 
since MOR and KOR produce opposing changes on body temperature.  A closer examination 
using selective agonists targeting the MOR (e.g. DAMGO) or KOR (e.g. niravoline, U50,488H) 
as part of the treatment regimens and/or acute challenge drugs could potentially delineate 
specific effects of the targeted receptor subtypes and how they interact with the cannabinoid 
system. It would also be important to establish the ambient temperature at which a significant 
and consistent hypothermic response is obtained. Subcutaneous and intraperitoneal drug 
administration used in the study did not target specific regions or tissues hence the in vivo results 
were due to activation of a combination of both peripheral and central inputs. In order to 
determine the specific regions of the CNS involved in the development of tolerance to the 
hypothermic or analgesic effects, there may be need to consider stereotaxic microinjection into 
specific regions of the brain; however, prior to those types of studies in the guinea pig, there is a 
more important need to develop a comprehensive guinea pig stereotaxic co-ordinates for the 
relevant areas. 
In our previous discussion (CHAPTER THREE), the candidate speculated that since 
cannabinoid treatment does not change the sensitivity of the LM/MP to nicotine, then it might 
not alter the resting membrane potential as has been observed with chronic morphine treatment. 
It may be worthwhile to pursue electrophysiological studies to explore this notion. Such studies 
would clarify the involvement of a change in membrane potential on the development of 
tolerance. To investigate potential cellular pathways involved in the development of tolerance, it 
may be important to explore the impact of other key players (e.g. kinases) proposed to be 
involved; in vitro exposure studies using opioid or cannabinoid agonists in the presence of 
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inhibitors of PKA, PKC, PKG or Src kinases could be vital in ascertaining the involvement of 
kinases in the development of tolerance in the LM/MP model. 
The effect of chronic in vivo cannabinoid treatment on CB1 receptor protein levels in the 
LM/MP preparation was considerably different from that observed following chronic morphine 
exposure. These differences might be due to subtle variability in the signaling or coupling 
pathways that are involved, as has been shown to occur with ligands that employ similar 
signaling pathways (e.g. DAMGO induces greater MOR internalization and the ensuing 
desensitization is GRK2-dependent whereas morphine confers negligible internalization and 
desensitization is PKC dependent (Johnson et al., 2006)). It has been proposed that this 
difference in spectrum of actions could be due to differences in the receptor configuration 
attained upon receptor activation, which determines the differential downstream effects (Violin 
and Lefkowitz, 2007). It can be speculated that this could occur between the MOR and CB1 
receptor systems investigated as demonstrated in previous studies (Swaminath et al., 2004; 
Rochais et al., 2007). The role of beta-arrestin in internalization efficacy, development tolerance 
and downstream signaling efficacy could also be affected by the phenomenon known as ligand-
dependent signaling bias. Different receptor conformations may induce differential assembly of 
adaptor and scaffolding protein entities that determine the nature and mechanism of the tolerance 
that is expressed. The configuration attained by the CB1 receptor following WIN-55,212-2 
activation might only be conducive to triggering selective signaling events that precipitate CB1 
receptor-targeted homologous tolerance like receptor phosphorylation, internalization and 
degradation, whereas that conformation induced by morphine-induced activation of MOR 
induces differential pathways that result in heterologous tolerance like differential protein 
expression (e.g. reduction in alpha3 subunit levels of the Na+/K+ ATPase) or a change in 
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membrane potential which alters cell excitability. The ligand residence time at the receptor might 
also contribute to the difference. WIN-55,212-2 is a highly lipophilic compound that is known to 
have a high receptor residence or occupancy time whereas the residence time for morphine at the 
MOR is considerably shorter and thus may modify different intracellular processes which will 
result in different characteristics of tolerance.  
The data presented in this study provide support for the concept that the development of 
tolerance is a function of several converging influences and is subject to considerable variation 
that may impact upon the cellular processes that are employed to elicit the adaptive response. 
Delineation of specific mechanisms involved in the interaction between cannabinoid and opioid 
systems will represent an important advance in the knowledge of the functional interaction in 
these two systems. Furthermore, the data raise the possibility that such differences in adaptive 
responses to these agents could potentially be employed to lead to modification in the therapeutic 
management of patients with these agents. 
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Figure 6.1 Proposed mechanisms involved in the development of tolerance in the longitudinal 
muscle/myenteric plexus following cannabinoid exposure 
Proposed mechanism of cannabinoid induced homologous tolerance in the guinea pig LM/MP 
following chronic exposure to WIN-55,212-2. Treatment results in receptor dependent adaptive 
changes in the form of exclusive CB1 receptor downregulation and CB1/MOR heterodimer 
internalization. 
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Figure 6.2 Proposed pathways for the development of opioid tolerance in the longitudinal 
muscle/myenteric plexus 
Proposed mechanism of opioid induced heterologous tolerance in the guinea pig LM/MP 
following chronic exposure to morphine. Treatment elicits global non- receptor dependent 
adaptive changes (e.g. attenuation of sodium pump activity) that results in decreased sensitivity 
to inhibitory agonists e.g. DAMGO and WIN-55,212-2and increased sensitivity to excitatory 
agent like nicotine. A negligible reduction in MOR is expected since morphine exhibits a low 
MOR internalization efficacy. 
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APPENDIX A: ANIMAL CARE AND USE COMMITTEE APPROVAL LETTER 
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APPENDIX B: PROTEASE INHIBITOR BUFFER 
Protease Inhibitor buffer (PIB) 
 
PMSF (Phenylmethyl Sulfonyl Fluoride) 
35.6 mg into 1 ml of isopropanol (concentration = 204mM), this is more 
concentrated than Sigma recommends but it will get into solution by heating it at 
55oC for 5 min. 
 
Bacitracin 
50mg added to 500µl of dH2O then add an additional 500µl to of dH2O to bring it 
to 1ml; this can be heated at 55oC for 10-15 min. Store the remainder at <0oC 
 
4-Aminobenzamide 
50.4mg into 1ml of dH2O (concentration = 242 mM) 
 
EDTA 
46.53g into 500ml of dH2O for a concentration of 250mM, pH to 8.0 
 
Working solution (make up daily for use) 
 
0.5ml PMSF for a final concentration of 4.08mM 
500µl Bacitracin for a final concentration of 1mg/ml 
100µl 4-Aminobenzamide for a final concentration of 1mM 
2.14g Sucrose for a final concentration of 0.25M 
1ml EDTA for a final concentration of 10mM 
Bring up to 25ml with dH2O 
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APPENDIX C: WESTERN BLOT BUFFER SOLUTIONS 
Western Blot Buffer solutions 
10X Running buffer 
30.28 Tris-Base 
150.14g Glycine 
10.00g Sodium Dodecyl Sulfate (SDS) 
pH to 8.6 and adjust volume to 1000ml 
Dilute 1:10 in dH2O for working solution 
 
Transfer Buffer 
2.9 Glycine 
5.8Tris-Base 
0.37 g SDS 
200 ml Methanol 
pH to 8.3 and adjust volume to 1000ml. 
 
10X Phosphate Buffered Saline (PBS) 
80.00g  NaCl 
2.00g K Cl 
14.40g Na2HPO4 
2.40g KH2PO4 
pH to 7.4 and adjust volume to 1000ml 
 
Phosphate Buffered Saline – 0.1% Tween 20 (PBS-T) 
100ml 10X PBS 
1.0ml Tween 20 
Bring to 1000ml with dH2O 
 
Sample buffer (Laemmli, 1970) 
295.5mg Tris-HCl (pH 6.8) 
0.6g SDS 
3.0g Glycerol 
0.0003g Bromophenol Blue 
Bring to 28.5ml – this is a stock solution 
 
Working solution: 
950µl of Sample Buffer Stock 
50µl of β-mercaptoethanol (βME) 
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APPENDIX D: IMMUNOFLUORESCENCE BUFFER SOLUTIONS 
Immunofluorescence buffer solutions 
Solutions for  
10X Phosphate Buffered Saline (PBS) 
80.00g  NaCl 
2.00g K Cl 
14.40g Na2HPO4 
2.40g KH2PO4 
pH to 7.4 and adjust volume to 1000ml 
 
4% Para-formaldehyde in 1X PBS (Fixative solution) 
100ml 10X PBS (heated to 45 - 60oC) 
40g Para-formaldehyde 
Bring to 1000ml with dH2O 
 
Phosphate Buffered Saline – 0.1% Sodium Azide 
100ml 10X PBS 
1.0g Sodium Azide 
Bring to 1000ml with dH2O 
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APPENDIX E: ANTIBODIES USED FOR WESTERN IMMUNOBLOTTING 
 
Antibodies used for Western Immunoblotting 
 
Primary Antibodies 
 
Protein of Interest:  Cannabinoid receptor subtype 1 (Cat. # 10006590) 
Host    Rabbit 
Dilution   1:200 
Antibody Source   Cayman, Ann Arbor, MI (Cat. # 10006590) 
 
Protein of Interest:  mu-Opioid Receptor (MOR) (Cat # AB5511) 
Host    Rabbit 
Dilution   1:2000 
Antibody Source   Millipore, Burlington, MA  
 
Protein of Interest:  GAPDH (Cat. # MAB 374) 
Host    Mouse 
Dilution   1:60 000 
Antibody Source   Millipore, Burlington, MA   
 
 
Secondary Antibodies 
Secondary Antibody:  Donkey anti-rabbit IRDye 800 
Dilution   1:20 000 (for CB1 receptor) 
Antibody Source   Li-Cor Biosciences (Lincoln, NE) 
 
Secondary Antibody:  Donkey anti-rabbit IRDye 800 
Dilution   1:60 000 (for MOR) 
Antibody Source   Li-Cor Biosciences (Lincoln, NE) 
 
Secondary Antibody:  Donkey anti-mouse IRDye 800 
Dilution   1:60 000 (for GAPDH) 
Antibody Source   Li-Cor Biosciences (Lincoln, NE) 
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APPENDIX F: ANTIBODIES USED FOR IMMUNOFLUORESCENCE 
Antibodies used for Immunofluorescence 
Primary Antibodies 
Protein of Interest:  Cannabinoid receptor subtype 1 (Cat. # 10006590) 
Host    Rabbit 
Dilution   1:50 
Antibody Source   Cayman (Ann Arbor, MI) 
 
Protein of Interest:  mu-Opioid Receptor (Cat. # Sc-7488) 
Host    Goat 
Dilution   1:50 
Antibody Source   Santa Cruz Biotechnology (Santa Cruz, CA) 
 
Protein of Interest:  Gonadotropin Releasing Hormone (Cat # sc-32292) 
Host    Mouse 
Dilution   1:500 
Antibody Source   Santa Cruz Biotechnology (Santa Cruz, CA) 
 
Secondary Antibodies 
Secondary Antibody:  Donkey anti-rabbit FITC-conjugate (Cat. #711-095-152) 
Dilution   1:100 (for CB1 receptor) 
Antibody Source   Jackson Immunoresearch (West Grove, PA)  
 
Secondary Antibody:  Donkey anti-goat Cy5-conjugate (7Cat. # 705-175-003) 
Dilution   1:100 (for MOR) 
Antibody Source   Jackson Immunoresearch (West Grove, PA)  
 
Secondary Antibody:  Donkey anti-mouse Cy3-conjugate (Cat. # 715-165-150) 
Dilution   1:500 (for GnRH) 
Antibody Source   Jackson Immunoresearch (West Grove, PA) 
 
 
 
 
